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Omega-3 fatty acids are vital for brain development and have been associated with positive 
health outcomes. However, there is yet no clear understanding about the cognitive effects of 
supplementation in youths. Furthermore, a research deficit exists concerning associations of 
omega-3 fatty acids and cognitive functioning in psychiatric disorders, especially in youths. 
This thesis broadens current knowledge about the aforementioned issues. A meta-analysis deal-
ing with the effects of omega-3 fatty acid supplementation in youths revealed no overall bene-
ficial effect of supplementation, however small beneficial effects were found for eicosapentae-
noic acid (EPA)-rich but not docosahexaeonic acid (DHA)-rich formulations. A tendency to-
wards stronger effects in clinical rather than healthy populations presented. The second study 
investigated associations between blood omega-3 fatty acid status and verbal memory perfor-
mance in depressed youths. Similar results to the ones reported in the meta-analysis presented, 
where EPA but not DHA status was positively associated with short-term verbal memory per-
formance. Both studies hence suggested that EPA rather than DHA might be positively related 
to cognitive test performance in youths. They also both suggested associations in clinical pop-
ulations. Future studies should further evaluate potential cognitive supplementation effects of 
EPA and DHA separately, in order to establish specific recommendations for supplementation 




Omega-3 Fettsäuren sind für die Gehirnentwicklung unerlässlich und werden mit positiven 
Gesundheitsfolgen in Verbindung gebracht. Der genaue Einfluss von Omega-3 Supplementie-
rung auf die Kognition bei Kindern und Jugendlichen ist jedoch zum heutigen Zeitpunkt noch 
nicht abschliessend untersucht. Ausserdem besteht eine Forschungslücke, was den Zusammen-
hang zwischen Omega-3 Fettsäuren und kognitiven Funktionen bei psychischen Erkrankungen 
betrifft, dies vor allem bei Kindern und Jugendlichen. Die vorliegende Dissertation erweitert 
den aktuellen Wissensstand zu dieser Thematik. Eine Meta-Analyse zum Einfluss von Omega-
3 Supplementierung auf die kognitive Testleistung von Kindern und Jugendlichen konnte kei-
nen generellen positiven Effekt von Omega-3 Supplementierung feststellen, hingegen konnten 
kleine positive Effekte von Eicosapentaensäure (EPA)-reichen, nicht aber von Docosahexaen-
säure (DHA)-reichen Präparaten festgestellt werden. Es konnte eine Tendenz zu positiven Ef-
fekten in klinischen Stichproben im Vergleich zu gesunden Stichproben aufgezeigt werden. 
Die zweite Studie befasste sich mit dem Zusammenhang zwischen dem Omega-3 Status im 
Blut und verbaler Gedächtnisleistung bei depressiven Kindern und Jugendlichen. Hier gingen 
die Ergebnisse in dieselbe Richtung, da für den EPA Status, nicht aber für den DHA Status ein 
positiver Zusammenhang mit der verbalen Gedächtnisleistung gefunden werden konnte. Beide 
Studien weisen somit darauf hin, dass eher EPA und nicht DHA mit der kognitiven Testleistung 
bei Kindern und Jugendlichen in Verbindung steht. Ausserdem weisen beiden Studien auf Zu-
sammenhänge in klinischen Stichproben hin. Zukünftige Studien sollten Supplementierungs-
effekte von EPA und DHA gesondert untersuchen, um spezifische Supplementierungsempfeh-
lungen für Kinder und Jugendliche entwickeln zu können.  
 III 
List of Figures 
 
Figure 1 Synthesis cascade of n-3 and n-6 PUFAs. ................................................................... 4 
Figure 2 Simplistic model depicting the impact of chronic stress on structural and functional 
changes to the brain. ........................................................................................................ 30 
Figure 3 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flow diagram (Moher, Liberati, Tetzlaff, & Altman, 2009) ............................................. 50 
Figure 4 Main treatment effect of n-3 PUFA supplementation on long-term memory (recall) 
and subgroup analysis for the studies supplementing either more DHA or more EPA. . 61 
Figure 5 Main treatment effect of n-3 PUFA supplementation on working memory and 
subgroup analysis for the studies supplementing either more DHA or more EPA. ........ 62 
Figure 6 Main treatment effect of n-3 PUFA supplementation on problem solving and 
visuospatial cognition and subgroup analysis for the studies supplementing either more 
DHA or more EPA. .......................................................................................................... 63 
Figure 7 Main treatment effect of n-3 PUFA supplementation on working memory and 
subgroup analysis for studies supplementing either non-clinical or clinical study 
populations. ...................................................................................................................... 64 
Figure 8 Main treatment effect of n-3 PUFA supplementation on shifting and flexibility and 
subgroup analysis for studies supplementing either non-clinical or clinical study 
populations. ...................................................................................................................... 65 
Figure 9 Main treatment effect of n-3 PUFA supplementation on problem solving and 
visuospatial cognition and subgroup analysis for studies supplementing either non-
clinical or clinical study populations. .............................................................................. 66 
Figure 10 Main treatment effect of n-3 PUFA supplementation on long-term memory (recall) 
and subgroup analysis for studies supplementing either non-clinical or clinical study 
populations. ...................................................................................................................... 67 




List of Tables 
 
Table 1 Summary of objective test procedures to measure memory performance .................. 17 
Table 2 Diagnostic criteria for depression defined by the DSM-5 .......................................... 23 
Table 3 Additional diagnostic criteria for differentiation between depression and other 
psychiatric disorders with similar symptoms ................................................................... 24 
Table 4 Effects of chronic stress on selected brain areas, the HPA axis and cognitive 
functioning ....................................................................................................................... 31 
Table 5 Summary of baseline characteristics of included studies ........................................... 51 
Table 6 Baseline characteristics of all included studies and those excluded due to missing 
data. ................................................................................................................................. 52 
Table 7 Main treatment effect for all cognitive domains. ........................................................ 60 
Table 8.  Descriptive statistics for sociodemographic information, biological parameters, IQ, 
psychopathology ............................................................................................................ 111 
Table 9 Fatty acid status for moderately and severely depressed patients ........................... 113 
Table 10 MANCOVA and ANCOVA results for VLMT and digit span parameters. EPA status 
and depression severity entered as factors and gender as a covariate. ........................ 115 




List of Abbreviations 
 
AA       arachidonic acid 
ADHD     Attention Deficit      
     Hyperactivity Disorder 
ALA      alpha-linolenic acid 




AVLT Auditory Verbal Learning 
Test 
BDNF   brain-derived neurotrophic 
  factor 
BMI   body mass index 
CDR      Cognitive Drug Research  
      Battery 
CDRS-R Children’s Depression Rat-
ing Scale revised 
CPT-IP The Continuous Perfor-
mance Test, Identical Pairs 
Version 
CRP       C-reactive protein 
CVLT California Verbal Learning 
Test  
DALY     disability-adjusted life   
    years 
DHA      docosahexaeonic acid 
DPA n-3    docosapentaenoic acid  
DSM-5 Diagnostic and Statistical 
Manual of Mental Disor-
ders – Fifth Edition 
ENI Evaluación Neuropsico-
lógica Infantil 
EPA       eicosapentaenoic acid 
FFQ food frequency question-
naire 
FIQ       full scale IQ 
FO        fish oil 
GIX       global intelligence index 
HAWIK-IV Hamburg-Wechsler-Intelli-
genztest für Kinder 
HPA axis    hypothalamic-pituitary-  
     adrenal axis 
HVLT-R  Hopkins Verbal Learning 
 Test–Revised 
ICD-10 International Classification 
of Diseases, Tenth Revi-
sion 
IL        interleukin 
IQ        intelligence quotient 
KABC-II Kaufman Assessment Bat-
tery for Children – Second 
Edition 
(Ki)TAP    (Kinder)-Testbatterie zur  
       Aufmerksamkeitsprüfung 
K-SADS Kiddie Schedule for Affec-
tive Disorders and Schizo-
phrenia 
LA        linoleic acid 
LC-PUFAs   long-chain polyunsaturated 
       fatty acids 
LTD       long-term depression 
LTP       long-term potentiation 
M        mean 
 VI 
MANCOVA multivariate analyses of 
covariance 
MCI       mild cognitive impairment 
MDD      major depressive disorders 
MDI       mental development index 
NAPLAN National Assessment Pro-
gram - Literacy and Nu-
meracy 
NIX nonverbal intelligence in-
dex 
N-3        omega-3 
N-6       omega-6 
N-9       omega-9 
PFC       prefrontal cortex 
PIQ     performance intelligence  
    quotient 
pMDD     pediatric major depressive 
      disorder 
PUFAs     polyunsaturated fatty acids 
Q-Q plot    Quantile-Quantile plot 
RAVLT Rey Auditory Verbal 
Learning Test 
RBC       red blood cell 
RCT       randomized controlled trial 
RIAS Reynolds Intellectual As-
sessment Scales and 
Screening 
SC-PUFAs   short-chain          
       polyunsaturated fatty acids 
SD        standard deviation 
SE        standard error 
SMD      standardized mead     
       difference 
TEA-ch Test of Everyday Attention 
for Children 
TMT A/B Trail Making Test Part 
A/B 
TNF       tumour necrosis factor 
TOVA Test of Variables of Atten-
tion 
VIQ       verbal intelligence quotient 
VIX       verbal intelligence index 
VLMT Verbaler Lern- und Merk-
fähigkeitstest 
WHO      world health organization 
WIAT-II Wechsler Individual 
Achievement Test – Sec-
ond Edition 
WISC-III/IV Wechsler Intelligence 
Scale for Children, 
Third/Fourth Edition 
WMTB-C    Working Memory Test   
        Battery for Children 
WORD     Wechsler Objective     
       Reading Dimensions 
WPPSI-III Wechsler Preschool and 
Primary Scale of Intelli-
gence 
WRAT4     Wide Range Achievement 
       Test, Fourth Edition 




1 General Introduction 
Nutritional patterns have changed dramatically since the industrial revolution, with main health 
concerns related to the dramatic increase in intake of omega-6 fatty acids compared to omega-
3 fatty acids (Simopoulos, 2002, 2011a). Among other adverse health outcomes discussed, 
these changes have been associated with potential adverse outcomes concerning cognitive de-
velopment and functioning (Simopoulos, 2011a, 2011b). Because omega-3 fatty acids are part 
of the lipid bilayer of the brain and have been shown to be involved in many core elements of 
cognitive development (J. Baumgartner, 2016; Bazinet & Layé, 2014; Innis, 2008; Koletzko et 
al., 2008; Lauritzen et al., 2016; Sun et al., 2018), concerns have arisen related to a potential 
deficiency of omega-3 fatty acids. Consequently, research investigating the association be-
tween omega-3 fatty acids and cognitive development and potential beneficial effects of 
omega-3 fatty acid supplementation on cognitive functioning has increased.  
Cognitive functions like memory and attention influence all aspects of everyday functioning 
and deficits can hence have detrimental effects on all aspects of life. Because the human brain 
develops until the age of about 25 (Arain et al., 2013; S. B. Johnson, Blum, & Giedd, 2009; 
Sowell et al., 2003; Thompson et al., 2000), youths constitute an especially vulnerable sub-
group when it comes to the disruption of cognitive development and functioning. In some psy-
chiatric diseases, for example, cognitive complaints constitute key symptoms, which might 
have detrimental effects for later life in this vulnerable population. In depressed youths, cogni-
tive complaints have been negatively associated with vocational, social and independent func-
tioning and educational attainment (Fletcher, 2008; Morey-Nase et al., 2019). Improving defi-
cits concerning cognitive functioning or even improving healthy cognition by means of omega-
3 supplementation has hence been discussed within several research fields. Especially in young 
and clinical populations, improving cognitive deficits might prove essential in order to improve 
quality of life. This dissertation introduces omega-3 fatty acids as a potential natural nutritional 
supplement for improvement of cognitive test performance. The current dissertation will tackle 
the following general research questions: 1) Does previous research suggest a beneficial effect 
of omega-3 fatty acid supplementation on cognitive test performance in children and adoles-
cents? 2) If so, are there differences depending on the type of omega-3 fatty acid ingested? 3) 
Do specific populations, like for example clinical subgroups compared to healthy subgroups, 
benefit differently from supplementation? 4) Is the omega-3 blood status related to cognitive 
test performance in children and adolescents with major depressive disorder? 5) If so, are there 
differences concerning the type of omega-3 fatty acid ingested? The following chapters give 
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an introductory overview over basic concepts and current research related to these questions. 
More specific research questions related to the research papers included in this dissertation, are 
given at the end of the respective introductory sections.  
This dissertation was written as part of “The Omega-3-pMDD trial”, a multi-center placebo-
controlled trial investigating the efficacy of omega-3 fatty acid supplementation in depressed 
youths aged 8-17 years. The trial is funded by the Swiss National Foundation. The clinical trial 
has been registered on www.ClinicalTrials.gov protocol no. NCT03167307. 
 
1.1 Omega-3 fatty acids 
Omega-3 fatty acids are one of two classes of polyunsaturated fatty acids (PUFAs) that play an 
essential role in human nutrition (Jones & Rideout, 2012) and are considered to influence nu-
merous health outcomes (Simopoulos, 2002, 2008). In this chapter, omega-3 PUFAs are intro-
duced concerning their chemical structure and synthesis, potential health outcomes and meth-
ods of measurement.  
 
1.1.1 Chemistry 
PUFAs are fatty acids that contain more than one carbon double bond (Jones & Rideout, 2012). 
They can be classified into two groups, namely short-chain polyunsaturated fatty acids (SC-
PUFAs) and long-chain polyunsaturated fatty acids (LC-PUFA), based on the number of car-
bon atoms in their backbone (Buckley et al., 2017; Jones & Rideout, 2012). Furthermore, they 
can also be grouped into omega-3 (n-3) and omega-6 (n-6) fatty acids, based on the location of 
the carbon double bond in relation to the terminal methyl group (Jones & Rideout, 2012). The 
precursors of long-chain n-3 PUFAs and long-chain n-6 PUFAs are alpha-linolenic acid (ALA) 
and linoleic acid (LA) respectively. Both are essential fatty acids, which means that the human 
body is unable to synthesize these fatty acids and hence relies on the intake through nutrition 
(J. Baumgartner, 2016; Bazinet & Layé, 2014; Simopoulos, 2011a; Weiser, Butt, & Mohajeri, 
2016). ALA can be found in a number of seeds and their derived oils like walnuts, chia seeds 
or linseeds and LA is abundantly found in for example safflower and corn (Jones & Rideout, 
2012). In the liver, ALA and LA are desaturated by adding a carbon bond, resulting in the 
synthesis of LC-PUFAs (Bazinet & Layé, 2014). However, this process is considered not to be 
very efficient (approx. < 5%) (Brenna, 2002). The enzyme Δ6 desaturase plays an important 
role in the desaturation process and is hence considered to limit the rate of desaturation (Bazinet 
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& Layé, 2014). It is currently believed that n-3 and n-6 PUFAs compete for elongation because 
they share the same enzymes responsible for desaturation (Bazinet & Layé, 2014). Also, inges-
tion of n-6 PUFAs is an important determinant of n-3 PUFA incorporation into membranes, 
where high levels of n-6 PUFAs inhibit n-3 PUFA incorporation (Simopoulos, 2008). Further-
more, animal studies have suggested that n-3 PUFA deficiency is often compensated with the 
nearest equivalent n-6 PUFAs (Carrié, Clément, De Javel, Francès, & Bourre, 2000; Neuringer, 
Connor, Lin, Barstad, & Luck, 1986). The nutritionally most important LC-PUFAs are eicosa-
pentaenoic acid (EPA) and docosahexaeonic acid (DHA) which are n-3 PUFAs, and arachi-
donic acid (AA), which is an n-6 PUFA (Layé, Nadjar, Joffre, & Bazinet, 2018). EPA and 
DHA can mostly be found in fatty fish, whereas AA is abundantly found in all sorts of meat (J. 
Baumgartner, 2016). The synthesis cascade starting from the parent fatty acids ALA and LA 





Synthesis cascade of n-3 and n-6 PUFAs. 
Note. n-3 generally have anti-inflammatory properties, whereas n-6 promote inflammation. 
Conversely, 𝛾-linolenic acid (GLA) has been shown to attenuate inflammatory processes 
(Sergeant, Rahbar, & Chilton, 2016). 
 
1.1.2 Health benefits 
Since the industrial revolution, PUFA intake in Western populations has shifted dramatically, 
from a balanced n-6:n-3 PUFA ratio to a ratio of about 15-25:1 (Simopoulos, 2011a). Because 
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been accompanied by balancing genetic changes, leading to inequalities between human ge-
netic constitution and nutritional habits (Grosso, Galvano, et al., 2014). These dramatic nutri-
tional changes have been linked to several diseases of civilization like cancer and cardiovascu-
lar diseases but also psychiatric disorders (Simopoulos, 2011). Lower n-3 PUFA intake has for 
example been associated with an increased risk of developing depression (Appleton, Rogers, 
& Ness, 2010). On the other hand, n-3 PUFA consumption has been associated with a de-
creased risk of, and beneficial effects on several diseases like cancer (Anderson & Ma, 2009; 
S. Lee et al., 2018; Vaughan, Hassing, & Lewandowski, 2013), diabetes (Anderson & Ma, 
2009; Natto, Yaghmoor, Alshaeri, & Van Dyke, 2019) and cardiovascular diseases (Anderson 
& Ma, 2009; Din, Newby, & Flapan, 2004; J. H. Lee, O’Keefe, Lavie, & Harris, 2009; 
Lovegrove et al., 2004; Massaro, Scoditti, Carluccio, & De Caterina, 2008; Natto et al., 2019; 
Psota, Gebauer, & Kris-Etherton, 2006). However, a recent Cochrane review now concluded 
that, against common belief, n-3 PUFA consumption had little or no effect on cardiovascular 
health (Abdelhamid et al., 2018). In general, meta-analytic evidence concerning n-3 PUFA 
health benefits has proven rather heterogenous (Fang, Li, Qian, Zeng, & Ye, 2017; Hanson et 
al., 2020). The association between dietary changes and the development of diseases of civili-
zation is thought to mainly be driven by the proinflammatory and pro-thrombotic properties of 
n-6 PUFAs (Simopoulos, 2008). n-3 PUFAs, on the other hand, have anti-inflammatory prop-
erties, as they give rise to important anti-inflammatory and pro-resolving mediators, reducing 
inflammation (Bazinet & Layé, 2014; Layé et al., 2018; K. Li, Huang, Zheng, Wu, & Li, 2014). 
Consequently, higher n-3 PUFA intake has also been associated with a decreased risk of de-
veloping certain neurological disorders that have been shown to be closely related to inflam-
matory processes (e.g. Alzheimer’s disease) (Layé, 2010). Because a number of studies have 
postulated an inverse relationship between DHA intake and the risk of developing certain neu-
rological disorders like Alzheimer’s disease (AD) (Cole & Frautschy, 2010), the anti-inflam-
matory properties of n-3 PUFA have been thought to benefit brain function and cognition 
(Layé, 2010). This might also apply to other psychiatric diseases like major depressive disorder 
(MDD), where inflammation has been discussed to play a significant role (A. H. Miller & 
Raison, 2016) and cognitive complaints are a main symptom. In depression, emotional symp-
toms as well as symptoms related to cognition might hence benefit from n-3 PUFA supplemen-
tation (Layé, 2010). The role of n-3 PUFAs in relation to MDD will be discussed in detail in 
chapter 1.6. Because n-3 PUFAs are part of the cell membrane and are amply found within the 
human brain, they have also been thought to impact cognitive developmental processes 
(Bazinet & Layé, 2014; Innis, 2008; Koletzko et al., 2008; Lauritzen & Carlson, 2011). The 
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role of n-3 PUFAs in the brain and potential implications for cognitive development and func-
tioning will be discussed in depth in chapter 1.2. 
 
1.1.3 Measuring n-3 PUFA levels 
Specific food frequency questionnaires (FFQ) have been developed in order to measure n-3 
PUFA intake (Herter-Aeberli et al., 2019; Rahmawaty, Charlton, Lyons-Wall, & Meyer, 2017; 
Sublette, Segal-Isaacson, et al., 2011). Along with common shortcomings of self-report ques-
tionnaire procedures such as response bias, lack of motivation or comprehension difficulties, 
the lack of an individual’s memory concerning his or her daily consumption of different kinds 
of foods, constitutes a serious drawback. Monitoring and remembering one’s own food con-
sumption can be difficult and self-report questionnaire results are hence unlikely to validly 
measure n-3 PUFA intake, especially in younger individuals. Furthermore, results are calcu-
lated using separate details concerning nutritional components for each food. This constitutes 
a further drawback, as the n-3 PUFA content, for example in fish, has changed significantly 
over the past few years and nutritional information might hence be outdated (von Schacky, 
2016). Even more, the large inter-individual differences in n-3 PUFA absorption rates may 
further bias results (Köhler, Bittner, Löw, & Von Schacky, 2010). Hence, n-3 PUFA supple-
mentation trials often rely on n-3 PUFA levels measured in human blood. Here, the omega-3 
index is often used to measure n-3 PUFA levels in erythrocytes. This index reflects the sum of 
total EPA and DHA levels expressed as a percentage of total fatty acids measured in red blood 
cell membranes (Harris, von Schacky, & Park, 2013). Current evidence suggests that this index 
should ideally lie between 8-11% (Von Schacky, 2015), with a minimum of 2% and a maxi-
mum of 20% (von Schacky, 2019b). In Western populations where fish intake is rather low, 
the omega-3 index has been found to typically lie between 3-5% (Harris, 2010). Although de-
termining this biomarker is a standardized procedure and can be validly used to, for example, 
measure compliance with study medication in randomized controlled trials (RCTs), little is 
known about the actual absorption and utilization of n-3 PUFAs in the brain. Also, our current 
understanding of the influence of genes, the microbiome or interactions with other substances 
and nutrients remains rather poor. Even more, the influence of the nutritional status on specific 




1.2 n-3 PUFAs in the developing brain and their influence on cognition 
In this chapter, the role of n-3 PUFAs in the developing brain is delineated. Current knowledge 
about the effects of n-3 PUFA supplementation on cognitive functioning in youths is explored 
in the second part of this chapter and the last part deals with research on the associations be-
tween n-3 PUFAs and memory in particular.  
 
1.2.1 n-3 PUFAs and neurodevelopment 
In the brain, lipids account for about 50-60% of its dry weight, of which about 35% are LC-
PUFAs (Hamilton, Hillard, Spector, & Watkins, 2007). LC-PUFAs are very important for 
nerve cell structure and function (for a review see Bazinet & Layé, 2014). Especially DHA and 
AA are abundantly found in the human brain, with DHA accounting for about 10-20% of total 
brain fatty acids (Bazinet & Layé, 2014; McNamara & Carlson, 2006; Weiser et al., 2016). 
Within the brain, DHA and AA are unequally distributed, with larger amounts of DHA in gray 
matter and larger amounts of AA in white matter (Bazinet & Layé, 2014; Weiser et al., 2016). 
EPA on the other hand only makes up for < 1% of total brain fatty acids (Bazinet & Layé, 
2014; McNamara & Carlson, 2006; Weiser et al., 2016). EPA concentration is around 200-500 
times lower than DHA concentration although EPA and DHA both enter the brain at a very 
similar rate (Bazinet & Layé, 2014). This is mainly a result of the fast catabolization of EPA 
to docosapentaenoic acid (DPA n-3) and DHA (Bazinet & Layé, 2014).  
PUFAs have diverse effects on various bodily systems. The bioactive roles of EPA and DHA 
and their bioactive mediators have been extensively reviewed in Dyall (2015), Layé et al. 
(2018) and Weiser et al. (2016). Most importantly, PUFAs form an essential part of the lipid 
bilayer of the cytoplasmic membrane and hence have a large impact on membrane fluidity and 
other membrane dynamics (for a review see Gawrisch, Eldho, & Holte, 2003; Salem, Litman, 
Kim, & Gawrisch, 2001; Shaikh & Teague, 2012). Changes in the fluidity of the membrane 
lead to alterations in the rotation and diffusion of proteins and other molecules. Transmission, 
for example, is facilitated in more fluid membranes (Weiser et al., 2016). These alterations in 
turn highly affect molecule functioning which might have large implications in neuropsychiat-
ric disorders (Guixà-González et al., 2016). An important underlying mechanism by which 
PUFAs can influence brain function is by their ability to modulate the endocannabinoid system 
(Bazinet & Layé, 2014). These have been shown to regulate synaptic function by suppressing 
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neurotransmitter release (Bazinet & Layé, 2014) and they are also involved in synaptic plastic-
ity (Castillo, Younts, Chávez, & Hashimotodani, 2012).  
Because DHA concentrations in the brain are so high (Bazinet & Layé, 2014; McNamara & 
Carlson, 2006; Weiser et al., 2016), a large proportion of research on PUFA actions in the brain 
has focused on DHA rather than EPA (Dyall, 2015). In animal studies, DHA has been shown 
to impact a series of mechanisms underlying normal neurological functioning, like for example, 
neurotransmission (Able et al., 2014), neurogenesis (Calderon & Kim, 2004; Coti Bertrand, 
O’Kusky, & Innis, 2006; Kawakita, Hashimoto, & Shido, 2006), cell survival (H. Y. Kim, 
Akbar, Lau, & Edsall, 2000), myelination (Haubner et al., 2007), synaptic plasticity (Bazinet 
& Layé, 2014) and neuroinflammation (Orr & Bazinet, 2008). Deficiency of DHA, on the other 
hand, has been associated with compromised neurodevelopment. Igarashi, Santos and Cohen-
Cory (2015), for example, observed morphologically simpler tectal neurons with fewer dend-
rite branches in tadpoles from n-3 PUFA deficient frogs. This process was partially reversed 
by later feeding them n-3 PUFAs. Depending on the location of these processes within the 
brain, n-3 PUFA deficiency could affect specific cognitive domains like memory or executive 
functions. DHA has further been thought to play an essential role in learning and memory, 
however underlying mechanisms have mainly been studied in animals and are to date not well 
understood (Fedorova & Salem, 2006). DHA might improve learning and memory by easing 
the formation of pre- and postsynaptic proteins that are responsible for synaptic transmission 
and long-term potentiation (Cao et al., 2009).  
To date, no unique role of EPA compared to DHA in the brain has been identified, however a 
series of shared effects with DHA have been described (Dyall, 2015). In rats, DHA and EPA 
have for example both been associated with increased neurite outgrowth (Robson, Dyall, 
Sidloff, & Michael-Titus, 2010) and in vitro neurogenesis (Katakura et al., 2013). Similarly, 
rodent studies have reported associations between both dietary DHA (McGahon, Martin, 
Horrobin, & Lynch, 1999) and EPA (Martin et al., 2002) intake and benefits to age-related 
decrease in long-term potentiation (LTP). Furthermore, in terms of anti-inflammatory effects 
of EPA and DHA seem to be comparable, however, differences concerning their effects in 
relation to different cytokine ratios exist (Serini et al., 2012). In humans, Borsini, Stangl, 
Jeffries, Pariante and Thuret (2020) were now able to provide the first evidence that EPA and 
DHA treatment could prevent cortisol-induced reduction in human hippocampal neurogenesis. 
These results suggest potential treatment effects of n-3 PUFAs for cognitive complaints in de-
pression, which will be discussed in depth in chapter 1.6. 
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Adequate intake of n-3 PUFAs, especially DHA, is crucial for normal brain development (J. 
Baumgartner, 2016; Lauritzen et al., 2016; Sun et al., 2018) and plays an important role during 
gestation (Bazinet & Layé, 2014; Innis, 2008; Koletzko et al., 2008; Lauritzen & Carlson, 
2011), during which the fetus relies on the mother’s intake of PUFAs (Hanebutt, Demmelmair, 
Schiessl, Larqué, & Koletzko, 2008). Especially in late stages of gestation, large amounts of 
DHA are accumulated in the brain (Kuipers et al., 2012; Lauritzen et al., 2016). Consequently, 
some maternal supplementation meta-analyses have reported benefits of maternal n-3 PUFA 
supplementation on child growth and development during pregnancy (Middleton et al., 2019), 
whereas others reported inconclusive results (Gould, Smithers, & Makrides, 2013). After a 
child is born, n-3 PUFAs are provided through breast milk or formula, of which many nowa-
days are supplemented with n-3 PUFAs after research confirmed their vital role in brain devel-
opment (Qawasmi, Landeros-Weisenberger, Leckman, & Bloch, 2012). The accumulation pro-
cess of DHA continues at very high rates until the age of about two years (Lauritzen et al., 
2016). Evidence, however, remains inconclusive concerning any developmental effects of n-3 
PUFA supplementation in infants (Eilander, Hundscheid, Osendarp, Transler, & Zock, 2007; 
Jiao et al., 2014; Qawasmi et al., 2012; Shulkin et al., 2018; Simmer, 1998). Most robust find-
ings have been reported for effects on visual acuity (European Food Safety Authority, 2009). 
PUFA metabolism regulation is also crucial for human pubertal brain development due to their 
involvement in many core elements like myelination or pruning (McNamara & Carlson, 2006; 
McNamara, Vannest, & Valentine, 2015). Congruently, post-mortem studies have shown that 
DHA levels in the brain continue to rise during adolescence and reach their maximum at the 
age of about 20 (Joffre, Nadjar, Lebbadi, Calon, & Laye, 2014). During adolescence, DHA 
levels have been shown to increase in the frontal cortex (Carver, Benford, Han, & Cantor, 
2001). The prefrontal cortex (PFC) is one of the latest brain areas to fully develop, undergoing 
vast developmental changes during puberty (Kolb et al., 2012). It is also known to be involved 
in a number of complex cognitive functions like attention, memory, planning and problem 
solving and is in sum responsible for cognitive control (E. K. Miller & Cohen, 2001). However, 
it has also been deemed to be especially vulnerable to external factors during development like 
for example stress, making it especially susceptible to abnormal development (Kolb et al., 
2012). The importance of n-3 PUFAs in relation to the PFC and associated cognitive functions 
has hence been studied in a number of supplementation trials. McNamara and colleagues 
(2010), for example, found increased functional activation in the dorsolateral prefrontal cortex 
of healthy children during the performance of a sustained-attention task in the DHA supple-
mented group compared to the placebo group (McNamara et al., 2010).  
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As key elements of both structural and functional components of the brain, n-3 PUFAs are 
essential for normal brain development (J. Baumgartner, 2016; Bazinet & Layé, 2014; Innis, 
2008; Koletzko et al., 2008; Lauritzen et al., 2016; Sun et al., 2018). Because brain develop-
ment continues until the mid 20s (Arain et al., 2013; S. B. Johnson et al., 2009; Sowell et al., 
2003; Thompson et al., 2000), children and adolescents might constitute an especially vulner-
able group for n-3 PUFA deficiency. n-3 PUFA deficiency might hence have detrimental ef-
fects on brain development and might contribute to the emergence of cognitive complaints.  
 
1.2.2 n-3 PUFAs and cognition in youths 
Due to their vital role in brain development, n-3 PUFAs have received great attention concern-
ing their potential to benefit cognitive functioning. As has been mentioned earlier, brain devel-
opment continues until the age of about 25 (Arain et al., 2013; S. B. Johnson et al., 2009; 
Sowell et al., 2003; Thompson et al., 2000), making youths an especially vulnerable subgroup 
for n-3 PUFA deficiency. Additionally, cognitive deficits in youths could have long-lasting 
consequences associated with personal life and educational attainment. At the same time, the 
developing brain might be more susceptible to change, making supplementation effects of n-3 
PUFAs more plausible. The investigation of potential associations between n-3 PUFAs and 
cognitive functioning in youths has hence gained importance over the last few years. Potential 
benefits have been studied by the means of associations between n-3 PUFA blood status and 
cognitive test performance or using supplementation RCTs. In a representative sample of 493 
British schoolchildren aged 7-9 years, Montgomery, Burton, Sewell, Spreckelsen and 
Richardson (2013) were able to identify positive associations between n-3 PUFA status and 
reading ability as well as working memory. Furthermore, a review by Ramakrishnan, Imhoff-
Kunsch and Digirolamo (2009), who studied scientific publications from 1966 to 2008, found 
that observational studies supported a direct association between low n-3 PUFA levels in chil-
dren and an increased risk of developing Attention Deficit Hyperactivity Disorder (ADHD), 
where cognitive complaints are key symptoms. However, evidence from intervention trials 
only marginally supported this finding (Ramakrishnan et al., 2009). 
Conflicting evidence regarding supplementation effects in infants exists. Brew, Toelle, Webb, 
Almqvist and Marks (2015), for example, found no beneficial effect of about 4.5 years supple-
mentation of n-3 PUFAs starting at the age of about 6 months, on literacy or numeracy in third, 
fifth, seventh or ninth grade. However, plasma n-3 PUFA levels at the age of 8 years were 
positively associated with cognitive test scores. Drover, Hoffman, Castañeda, Morale and Birch 
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(2009), however, reported improved means-end problem solving after n-3 PUFA supplemen-
tation when intervention was started early (a few days after birth). 
Meta-analytic evidence for supplementation in childhood and adolescence is heterogenous. 
Jiao and colleagues (2014) who investigated supplementation effects throughout the lifespan, 
were only able to establish benefits in infants and no other age group. Chang, Su, Mondelli and 
Pariante (2018), however, reported improved cognitive performances in youths with ADHD 
after n-3 PUFA supplementation. Conversely, Cooper, Tye, Kuntsi, Vassos, & Asherson 
(2015) found no beneficial effects of n-3 PUFAs on cognitive performance measures in healthy 
youths and adults or individuals with ADHD. Short-term memory was, however, improved in 
individuals with especially low n-3 PUFA status at baseline. A systematic review by Kuratko, 
Barrett, Nelson and Salem (2013) who investigated DHA supplementation effects in healthy 
school-aged children, found heterogenous treatment effects, with half of the studies supporting 
beneficial effects in this population. Van der Wurff, Meyer and de Groot (2020) concluded that 
efficacy was most probable when more than 450mg of EPA and DHA daily was administered 
and subjects showed an increase to more than 6% in the omega-3 index. The question remains, 
whether the specific kind of n-3 PUFA administered and baseline n-3 PUFA levels might play 
a significant role concerning efficacy of supplementation. In their recent study, Chang and 
colleagues (2019) for example, reported that especially youths with ADHD with low baseline 
EPA status achieved higher scores on a continuous performance task after supplementation 
with high-dose EPA. 
Whereas various studies have confirmed the essentiality of n-3 PUFAs in normal brain devel-
opment, effects of n-3 PUFA supplementation on cognitive functioning in youths have yet to 
be fully confirmed and understood. Importantly, factors like baseline n-3 PUFA status and 
effects of select n-3 PUFAs on select cognitive domains might influence supplementation re-
sults and are currently subject to extensive investigation. Furthermore, n-3 PUFAs and n-6 
PUFAs compete for their position in the membrane, meaning that an excess in either PUFA 
means that the other can be incorporated only to a lesser extent (Bazinet & Layé, 2014). How-
ever, studies eliminating n-6 PUFAs from study formulations or meta-analyses focusing on n-
3 PUFA supplementation only are lacking. In sum, beneficial effects of n-3 PUFA supplemen-
tation seem most plausible in populations with a poor nutritional status or cognitive complaints 
compared to healthy populations. However, no meta-analysis so far has investigated differen-
tial efficacy between clinical and healthy populations, distinguished between effects of EPA 
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and DHA and specifically eliminated studies also administering n-6 PUFAs in their study for-
mulations. Based on these research deficits, study 1 was designed. The rationale for study 1 
will be discussed in detail in chapter 1.4.  
 
1.2.3 n-3 PUFAs and memory 
The previous chapter introduced current knowledge about the effects of n-3 PUFAs on general 
cognition. Although associations between n-3 PUFAs and many different cognitive domains 
have been discussed, particularly neuroprotective effects of n-3 PUFAs concerning memory 
have been suggested. In elderly, memory complaints frequently become evident and can neg-
atively impact quality of life (Alice et al., 2016). However, also at a younger age, memory 
complaints can emerge, particularly related to psychiatric disorders (Trivedi, 2006). 
Current evidence of cognitive decline and Alzheimer’s disease was systematically reviewed by 
Fotuhi, Mohassel and Yaffe (2009) who concluded that observational trials suggested that n-3 
PUFA consumption might slow down cognitive decline in elderly individuals but that there 
was no evidence for the prevention or treatment of dementia or AD in clinical trials. In general, 
evidence for positive associations between n-3 PUFA status or supplementation and memory 
in AD has not been proven unequivocally (Itua & Naderali, 2010). However, EPA but not DHA 
has been negatively associated with grey matter atrophy of the right hippocampal and parahip-
pocampal area and the right amygdala (Samieri et al., 2012). Higher atrophy in the right amyg-
dala was in turn associated with decline in semantic memory performance. In subjects with 
mild cognitive impairment (MCI), L. K. Lee, Shahar, Chin and Yusoff (2013) reported bene-
ficial effects of 12 months fish oil supplementation on short-term memory,  working memory, 
immediate verbal memory and delayed recall capability. A meta-analysis on healthy adults 
with or without mild memory complaints (MMC) found that more than one gram per day of 
DHA and EPA supplementation improved episodic memory regardless of the cognitive status 
at baseline (Yurko-Mauro, Alexander, & Van Elswyk, 2015). Observational studies supported 
these findings by providing evidence for positive associations between DHA and EPA intake 
as well as blood status and memory function (Yurko-Mauro et al., 2015).  
Evidence in younger individuals has also proven to be rather inconsistent. Concerning cogni-
tive development, a study investigating perinatal DHA cord status, reported positive associa-
tions with memory performance in later childhood (Boucher et al., 2011). As has been men-
tioned in the previous chapter, n-3 PUFA status has also been positively associated with 
memory performance in youths (Montgomery et al., 2013), whereas supplementation studies 
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in young populations have often reported no positive effect of n-3 PUFAs on objective 
measures of memory performance (J. Baumgartner et al., 2012; Karr, Grindstaff, & Alexander, 
2012; Kirby, Woodward, Jackson, Wang, & Crawford, 2010). In their meta-analysis, Jiao and 
colleagues (2014) reported that there was no evidence for a beneficial effect of n-3 PUFAs on 
memory performance in youths. The question however remains, whether perinatal supplemen-
tation or supplementation at a young age might have long-term neuroprotective effects in later 
life and whether n-3 PUFAs are associated with memory complaints in relation to psychiatric 
disorders. While the results reported by Borsini and colleagues (2020) suggest that both EPA 
and DHA might prevent glucocorticoid-induced reduction in human hippocampal neurogenesis 
and increase in apoptosis, neuroprotective or direct supplementation effects of n-3 PUFAs in 
depressed youths have yet to be confirmed. Based on the previously described research deficits, 
study 2 was designed. The rationale for study 2 will be discussed in detail in chapter 1.7. 
 
1.3 Challenges for cognitive outcome assessment in meta-analyses 
In the previous chapters, research on the role of n-3 PUFAs in the brain and associations with 
cognitive functioning have been discussed. Although cognitive effects as a whole have been 
suggested, select effects associated with different cognitive domains seem plausible, because 
effects of n-3 PUFAs might affect select underlying mechanisms of action. Investigating do-
main-specific associations between n-3 PUFAs and cognitive functioning is, however, associ-
ated with certain obstacles that will be delineated in the following chapters. The importance 
but also the difficulty of the categorization of cognitive domains and associated outcome 
measures, especially for meta-analyses, are explained and stressed in the following chapters. 
 
1.3.1 Cognitive domains 
Cognition as a whole refers to a large set of different, often very specific functions which work 
together and subserve each other in order to enable an individual to perform certain tasks. The 
performance levels of the specific functions then add up to produce a certain general level of 
functioning in an individual. These functions can be grouped together and are then called cog-
nitive domains with the specific functions referred to as subdomains of the larger construct.  
Cognitive domains are often hierarchically organized with more basic perceptual functions sit-
uated at the bottom, increasing in complexity to domains at the top, like for example cognitive 
control (Harvey, 2019). The first conceptual question that hence arises for the meta-analytic 
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evaluation of n-3 PUFA supplementation effects on cognitive test performance is, whether to 
assess general cognitive functioning as opposed to domain-specific effects. Although supple-
mentation effects of n-3 PUFAs on general cognitive functioning have been suggested, specific 
effects on select cognitive domains could hint at underlying mechanisms of action and espe-
cially affected anatomical regions. Because the developmental course of the brain and the ac-
cumulation of n-3 PUFAs during brain development differs between anatomical structures, 
specific effects related to specific brain areas seem plausible. As has already been mentioned 
before, an example of a potentially especially affected brain area in youths is the PFC. Hence, 
investigating domain-specific effects of n-3 PUFA supplementation could prove important in 
order to capture potentially select effects related to human brain development. Furthermore, 
clinical trials usually report results for several cognitive functions, however in meta-analyses, 
several results from a single study cannot be pooled within one analysis. Consequently, inves-
tigating effects on general cognitive functioning would lead to the constraint of having to 
choose which result reported by the specific study to include in the quantitative analysis, giving 
rise to concern about potential bias related to this selection process. It was therefore decided to 
investigate domain-specific effects of n-3 PUFA supplementation on cognitive test perfor-
mance in this dissertation. In order to achieve this, supplementation effects related to specific 
cognitive functions assessed within clinical trials have to be separated and analyzed using sep-
arate meta-analyses. However, separating domain-specific effects is related to some conceptual 
difficulties. Although the basic concepts of cognitive domains are usually agreed upon, the 
categorization of the specific functions into cognitive domains and their labelling are not well 
defined and are often subject to debate. This can lead to diverging concepts in both neuropsy-
chological practice and research, which in turn can largely impact comparability of individual 
work within the field. For example, divergent classifications in relation to a domain’s hierar-
chical position often occur and sometimes certain domains are also involved in processes re-
lated to other domains, which impedes the separation into distinct domains. Attention for ex-
ample can be classified as an executive function, however attention also plays a key role in 
many other processes associated with diverse tasks, hence attention is also involved in many 
other cognitive functions. Remembering a list of words for example, strongly relies on a per-
son’s memory capacity but can at the same time not be done without focusing one’s attention 
to the list of words. Whereas executive functions conceptually represent single cognitive do-
main, they comprise a set of vastly different subdomains including attention but also for exam-
ple working memory. However, as the name already suggests, working memory is also part of 
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general memory. This overlap between (theoretically) conceptually different cognitive do-
mains hinders the sharp distinction between them and impedes domain-specific outcome as-
sessment, especially in meta-analyses. Most importantly, it can lead to difficulties in the inter-
pretation and the evaluation of outcome assessments of neuropsychological research, hamper-
ing the comparability of study results. Hence, while studies claim the investigation of specific 
domains, concepts can differ greatly between studies and hence so can results, which leads to 
decreased comparability. As has been mentioned before, this is especially problematic in meta-
analyses where conceptualization and comparability of outcome assessments used by different 
studies is crucial. For the meta-analysis written as part of this dissertation, the aforementioned 
difficulties with domain categorization constituted a main obstacle for data analysis. Included 
studies had to be screened for the exact outcome assessment used and these again had to be 
categorized within a cognitive domain. Although some outcome measures were clearly associ-
ated with the assessment of a certain cognitive domain, others engaged several domains. In 
order to account for this, specific outcome variables of the same assessment tool were placed 
in separate cognitive domains. When cognitive domains were assessed using several outcome 
measures, a decision had to be made which results to include in the quantitative analysis. It was 
decided to base this decision on the similarity of the assessment tool to the tools from the other 
trials placed within the domain-specific meta-analysis, in order to increase comparability be-
tween results.  
In sum, two major obstacles for the investigation of the effects of n-3 PUFA supplementation 
on cognitive functioning had to be considered for this dissertation. Firstly, a decision had to be 
made, whether to assess effects on general cognitive functioning or domain-specific effects. 
Secondly, the categorization process for domain-specific assessment in the meta-analysis was 
based on some conceptual difficulties related to cognitive functions in neuropsychology, which 
were carefully considered. The aforementioned difficulties in domain taxonomy are associated 
with difficulties in outcome assessment using specific measurement tools. Assessing isolated 
cognitive domains using specific outcome measures is all but trivial and will be discussed in 
the next chapter. 
 
1.3.2 Measuring cognitive functioning 
Although structural and functional neuroimaging has certainly contributed to the understanding 
of the brain, cognitive functioning and deficits associated with neuropsychiatric diseases can-
not be captured fully using imaging only (Fields, Ferman, Boeve, & Smith, 2011).  In order to 
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measure cognitive functioning and cognitive deficits, self-rating questionnaires and objective 
tests have been used in clinical and scientific settings. Self-rating questionnaires primarily fo-
cus on deficits concerning cognitive functioning and tend to assess cognitive complaints that 
occur in everyday life. As mentioned before, rating scales often include questions concerning 
abilities relevant in everyday life and hence results obtained through these scales have been 
shown to be closely linked to for example academic performance (Baars, Nije Bijvank, 
Tonnaer, & Jolles, 2015). However, these rating scales rely on self-reported information and 
have been deemed prone to bias, relevant to all forms of self-report scales (Althubaiti, 2016) 
and validity of assessment can strongly depend on factors like educational status (Spitzer, 
Weber, & Lutz, 2019) and language proficiency. Also, due to the fact that these cognitive rating 
scales are strongly deficit orientated, differentiation between average and above average cog-
nitive functioning is often impossible. Even more, difficulties can arise in the assessment of 
young children, for which the complex language used might be unsuitable and their ability of 
self-reflection might not be fully developed. Furthermore, age-appropriate self-report measures 
might not always be available. Based on the aforementioned bias constraints, the young popu-
lation investigated, and the rather small cognitive deficits expected within this population, this 
dissertation focused on the investigation of cognitive test performance rather that subjective 
cognitive complaints. 
Objective testing procedures on the other hand, tend to focus less on deficits but capture a 
broader spectrum of performance. A number of tests have been developed in order to measure 
global cognitive ability, like for example intelligence tests. These were designed to measure an 
individuals’ general intelligence compared to the average intelligence of the world’s popula-
tion, which is represented using an intelligence quotient (IQ). These objective testing proce-
dures usually comprise a verbal part where skills like general knowledge are assessed and a 
non-verbal part where skills are assessed which do not directly require verbal information com-
prehension or production (e.g. problem solving). Especially the verbal part (often referred to 
as verbal IQ (VIQ)) has been criticized as being confounded by other factors, such as the socio-
economic status of the assessed individual (Dolean & Cãlugãr, 2020). Therefore, it may not 
reflect fundamental cognitive functioning but rather skills associated with the availability of 
education and standards of living (von Stumm & Plomin, 2015). Hence, domain-specific 
measures have gained importance in the assessment of cognitive functioning. For example, in 
order to measure short-, long-term and working memory, a number of standard tests exist, 






Summary of objective test procedures to measure memory performance 
Domain Name Description 
Short-term 
memory 
Digits forward (e.g. 
WISC-IV) 
A sequence of digits is read out loud and the individ-
ual is asked to remember it and repeat it back. The 
number of digits increases in every second round. 
 HVLT-R, RAVLT 
(VLMT, German version) 
A list of nouns is learned over the course of several 
trials.   
Working 
memory 
Digits backwards (e.g. 
WISC-IV) 
A sequence of digits is read out loud and the individ-
ual is asked to remember it and repeat it back in re-
versed order. The number of digits increases in every 
second round. 
 Letter-number sequencing 
(WISC-IV) 
A sequence of letters and numbers is read out loud 
and the individual is asked to repeat the numbers in 





(VLMT, German version) 
A list of nouns is learned over the course of several 
trials. The examinee is asked to recall them after a 
specific amount of time. 
Note. WISC-IV (Wechsler Intelligence Scale for Children, Fourth Edition) (Wechsler, 2003), 
HVLT-R (Hopkins Verbal Learning Test–Revised) (Benedict, Schretlen, Groninger, & Brandt, 
1998), RAVLT (Rey Auditory Verbal Learning Test) (Schmidt, 1996b), VLMT (Helmstaedter 
& Durwen, 1990) 
Compared to subjective ratings of cognitive functioning, objective tests are not prone to the 
same biases. However, factors like motivation can play an equally large role as in subjective 
ratings. Also, objective cognitive tests for specific domains are usually biased by global intel-
ligence and hence otherwise evident deficits might be masked by an individual’s general cog-
nitive ability. Furthermore, objective tests usually have a large average range and primarily 
differentiate between average and below or above average scores. Especially in studies with 
healthy individuals and studies where only small cognitive effects might be expected, this could 
lead to an underestimation of effects. This is especially true when testing recognition memory, 
where ceiling effects are very common (Krishnan, Watkins, & Bishop, 2017; Sunderland, 
Harris, & Baddeley, 1983). Furthermore, testing situations for objective cognitive tests are very 
artificial. Hence, deficits might well be compensated in the specific test situation, whereas they 
might become relevant in everyday life. For example, problems concentrating might become 
evident in a school environment which is busy and loud, whereas these deficits might not be 
GENERAL INTRODUCTION 
 18 
captured in a quiet examination room without any external distractions. However, objective 
cognitive tests have often been reported to accurately reflect pathological processes within the 
brain and strongly predict functional impairment (Fields et al., 2011).  
An important issue that has to be kept in mind when using objective test measures of cognitive 
functioning is construct validity, hence whether the specific test administered actually 
measures the cognitive outcome it was designed to measure. Categorization of cognitive tests 
into a specific cognitive domain is not always straight forward because tests often engage sev-
eral different cognitive domains at the same time. As has already been mentioned in the previ-
ous chapter, for example attention processes play an important role in many different test situ-
ations. This issue of interconnectivity between cognitive domains can be well illustrated when 
considering studies in psychiatric patients, that show poor performance in different cognitive 
tests, which were originally developed in order to measure conceptually different domains 
(Harvey et al., 2016). Depressed patients for example might show deficits in a short-term 
memory and attention task, whereas the underlying cause could well be general problems con-
centrating. Disentangling the proportion of cognitive deficit attributable to memory or attention 
deficits might hence prove difficult. Further inconsistencies in test reports can arise from defi-
nition problems mentioned earlier, where authors claim to have measured for example atten-
tion, whereas another researcher might categorize the specific test used into another cognitive 
domain. This could prove especially detrimental when summarizing study results in meta-anal-
yses, where results wrongly categorized into a specific domain might cancel out results from 
other studies accurately reporting the cognitive domain tested. The thorough and correct do-
main categorization of assessment tools was hence made a priority for the meta-analysis written 
as part of this dissertation. 
Another important factor to consider with objective cognitive testing is the establishment of 
norms for the evaluation of individual test performance. The consideration of an expected “nor-
mal” level of functioning related to external individual factors is paramount in order to enable 
comparability of test results. Evidence for the need of such evaluations was long ago estab-
lished (Babcoc, 1931). Norms are especially relevant when investigating clinical populations 
without a healthy control group for comparison. In study 2, this was one of the main reasons 
for using the VLMT as the outcome measure for verbal memory performance. Although the 
California Verbal Learning Test (CVLT) (Delis, Kramer, Kaplan, & Ober, 2000) offers many 
advantages over the VLMT, like for example the evaluation of learning strategies employed, 
no norms for youths exist for the German version. Another reason constituted the fact that 
multiple assessments are done over the supplementation period of “the Omega-3 pMDD trial” 
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and the VLMT offers several parallel versions that can be used to avoid training effects. The 
VLMT was hence chosen as an objective measure for study 2 in order to assess certain subcat-
egories of verbal memory performance like immediate recall, delayed recall and recognition. 
In conclusion, it is safe to say that subjective and objective measures of cognition do not meas-
ure the same concepts of cognitive functioning and that they are prone to different kinds of 
biases. With this in mind, one can argue that an examinee might for example report cognitive 
complaints in a questionnaire, without any evident deficits in an objective cognitive test meas-
ure, for example due to negative self-perception. Especially in the cognitive assessment of clin-
ical populations, like for example patients suffering from MDD, this might pose a serious prob-
lem. The assessment of children and adolescents using subjective rating scales might prove 
even more difficult, because age-appropriate instruments are not always available, and the 
complex language used in questionnaires might not be fully understood. Also, the ability of 
self-reflection might be limited in younger children. At the same time, parent-rated question-
naires, especially in clinical populations, might not prove a valid alternative, as has been 
demonstrated for interviews used for depression severity rating in youths (N. Baumgartner et 
al., 2020). Furthermore, evaluation of distinct cognitive domains and the consideration of the 
construct validity as well as demographically corrected norms for the specific test used is par-
amount. Studies should carefully consider which kind of outcome measure to use in order to 
assess a specific function and hence be able to draw conclusions considering potentially asso-
ciated anatomical or functional brain mechanisms involved. Results should hence always be 
interpreted in relation to the specific measure used. The herein discussed issues of domain-
specific outcome assessment were carefully considered when designing both study 1 and 2 and 
will be further discussed in the following chapter and chapter 1.7 respectively.  
 
1.4 Rationale study 1: n-3 PUFAs and cognitive test performance in youths 
The previously discussed research findings and deficits are briefly summarized in the following 
chapter. Specific research questions for study 1 are described in a second step. 
 
1.4.1 Summary 
n-3 PUFAs are part of the lipid bilayer of the brain and have been shown to play an important 
role during gestation (Bazinet & Layé, 2014; Innis, 2008; Koletzko et al., 2008; Lauritzen & 
Carlson, 2011) and normal brain development (J. Baumgartner, 2016; Lauritzen et al., 2016) 
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and are involved in processes related to pubertal brain development (McNamara & Carlson, 
2006; McNamara et al., 2015). Due to their crucial role in the brain, associations between n-3 
PUFAs and cognitive functioning have been suggested. Because brain development is still on-
going until the mid 20s (Arain et al., 2013; S. B. Johnson et al., 2009; Sowell et al., 2003; 
Thompson et al., 2000), beneficial n-3 PUFA supplementation effects in youths seem most 
probable. Also, youths constitute an especially vulnerable subgroup considering cognitive def-
icits, as they could have detrimental long-lasting effects on educational attainment and every-
day functioning. However, both evidence for developmental effects of n-3 PUFA supplemen-
tation in infants (Eilander et al., 2007; Jiao et al., 2014; Shulkin et al., 2018; Simmer, 1998) 
and meta-analytic evidence concerning supplementation in youths seems rather heterogenous 
(Bloch & Qawasmi, 2011; Chang et al., 2018; Cooper et al., 2015; Jiao et al., 2014). One reason 
for this might be that supplementation trials often use both n-3 PUFAs as well as n-6 PUFAs 
in their study formulations (Almaas et al., 2016; Devlin et al., 2017; Stevens et al., 2003), 
although neurochemical mechanisms differ greatly and it has been shown that incorporation of 
DHA depends on n-6 PUFA consumption (Simopoulos, 2008). This issue has only been spe-
cifically addressed in one previous meta-analysis (Jiao et al., 2014), while others included trials 
with mixed supplements (Bloch & Qawasmi, 2011; Chang et al., 2018; Cooper et al., 2015). 
General study heterogeneity concerning n-3 PUFA doses and duration of intervention might 
have further contributed to the conflicting results, although Jiao and colleagues (2014) reported 
no association between treatment effect and supplementation dosage. Furthermore, although 
there are two nutritionally especially important n-3 PUFAs, with large concentration differ-
ences within the brain (Bazinet & Layé, 2014; McNamara & Carlson, 2006; Weiser et al., 
2016), most meta-analyses to date have reported overall supplementation effects of n-3 PUFAs, 
disregarding potential efficacy differences (Chang et al., 2018; Jiao et al., 2014). Only Bloch 
an Qawasmi (2011) suggested that higher doses of EPA were associated with increased effi-
cacy in treating ADHD symptoms and Cooper and colleagues (2015) found that small treatment 
effects emerged for working memory in studies that supplemented with an adequate amount of 
EPA. Although beneficial supplementation effects seem most plausible for example in popu-
lations with low n-3 PUFA levels (Cooper et al., 2015) or cognitive complaints, most meta-
analyses have yet failed to report results in order to compare healthy with clinical populations 
(Bloch & Qawasmi, 2011; Chang et al., 2018; Jiao et al., 2014). The aim of the first study was 
to tackle some of the aforementioned research deficits concerning the association between n-3 
PUFA and cognitive functioning in youths.  
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1.4.2 Research questions study 1 
In the last few years, research on potential cognitive supplementation benefits of n-3 PUFAs 
after birth has gained importance. As the number of studies on this matter has exploded, grasp-
ing the overall picture has become increasingly difficult. Several meta-analyses have aimed at 
summarizing results (Bloch & Qawasmi, 2011; Chang et al., 2018; Cooper et al., 2015; Jiao et 
al., 2014), however coming to heterogenous conclusions. This heterogeneity seems to have 
arisen from a number of heterogeneities and important shortcomings in study design. These 
include: 1) Separation of age groups using of an artificial (e.g. legally defined) cut-off of, for 
example, 18 years of age for adulthood (Cooper et al., 2015) instead of  a cut-off based on the 
developmental course of the brain, 2) Lack of thorough and hence sometimes inaccurate clas-
sification of cognitive tests used within cognitive domains (Jiao et al., 2014), 3) Vast differ-
ences in study formulations concerning n-3 PUFA dosage, 4) study formulations with both n-
3 and n-6 PUFAs (Bloch & Qawasmi, 2011; Chang et al., 2018; Cooper et al., 2015), 5) No 
comparison between effects in healthy an clinical population within the same study (Bloch & 
Qawasmi, 2011; Chang et al., 2018; Jiao et al., 2014), 6) No efficacy differentiation between 
EPA and DHA supplementation (Chang et al., 2018; Jiao et al., 2014), 7) Cognitive assess-
ments based on subjective rating scales (Abdullah, Jowett, Whittaker, & Patterson, 2019; Bloch 
& Qawasmi, 2011) as opposed to cognitive test performance (Chang et al., 2018; Cooper et al., 
2015; Jiao et al., 2014). 
The aim of the first research article was to perform a meta-analysis of n-3 PUFA supplemen-
tation effects in youths up to the age of 25, using a developmental cut-off for adulthood. It was 
decided to only investigate cognitive test performance rather than subjective cognitive com-
plaints based on previously discussed concerns about potential bias, hence all studies using 
questionnaire measures were excluded from analysis. Most importantly, specific effects related 
to separate cognitive domains were evaluated. A major obstacle to this goal, was a problem 
mentioned earlier in the introductory section, where studies sometimes claim to have investi-
gated effects concerning a certain cognitive domain, but the specific test used might actually 
measure cognitive functions more accurately attributed to another cognitive domain. Hence, 
every single article included in the quantitative analysis was screened for the exact test used 
and this test was then categorized into a specific cognitive domain. When multiple tests were 
used in order to measure performance attributable to the same domain, the most similar test to 
the tests used in other studies was selected in order to maximize comparability. All studies with 
formulations containing more n-6 PUFAs in the intervention compared to the control group 
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were excluded. Effects within clinical and healthy subgroups were investigated separately. Fur-
ther subgroup analyses were performed concerning EPA and DHA supplementation. Espe-
cially the categorization into subgroups with EPA-rich and DHA-rich formulations proved ra-
ther difficult, because not only n-3 PUFA kind but also concentration varied substantially be-
tween study formulations. To our knowledge, no other meta-analysis on the current subject has 
implemented the same criteria for analysis.  
Based on the findings described in the previous chapters, the following research questions for 
study 1 were developed.  
1) Does n-3 PUFA supplementation benefit cognitive test performance in youths? 
2) Are there efficacy differences between EPA and DHA supplementation? 
3) Are there efficacy differences in clinical versus healthy individuals? 
4) Which cognitive domains benefit from n-3 PUFA supplementation? 
 
1.5 Depression 
In this chapter, the psychiatric disorder depression is introduced. In a first step, diagnostic con-
cepts and epidemiological data are presented. In a second step, symptoms related to cognitive 
functioning and current research data on this subject are summarized.  
 
1.5.1 Symptoms and epidemiology 
Depression is a common psychiatric disorder that is part of a group of disorders called affective 
disorders or mood disorders. The main affective disorders are bipolar disorder and depression. 
Depression is characterized by a set of different symptoms that vary in number and extent 
throughout affected individuals. To meet the diagnostic criteria for Major Depressive Disorder 
(MDD) according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition), at least five symptoms must have been present for at least two weeks (American 
Psychiatric Association, 2013). These five symptoms must either include depressed mood or 
anhedonia (American Psychiatric Association, 2013). For children and adolescents, these key 
symptoms also include irritable mood (American Psychiatric Association, 2013). DSM-5 de-






Diagnostic criteria for depression defined by the DSM-5 
Symptom Frequency/persistency Further specifications 
Depressed mood Most of the day, 
nearly every day 
May be subjective (e.g. 
feels sad, empty, hopeless) 
or observed by others (e.g. 
appears tearful); can be ir-
ritable mood in children or 
adolescents. 
 
Markedly diminished interest or 
pleasure in all, or almost all, activi-
ties 
 
Most of the day, 
nearly every day; 
May be subjective or ob-
served by others 
 
Significant weight loss (when not di-
eting) or weight gain (+/- >5% body 
weight in a month) or decrease or in-
crease in appetite 
 
Nearly every day Can be failure to gain 
weight as expected in chil-
dren. 
Insomnia or hypersomnia Nearly every day 
 
 
Psychomotor agitation or retardation 
(a slowing down of thought and a re-
duction of physical movement) 
Nearly every day Observable by others, not 
merely subjective feelings 
of restlessness or being 
slowed down. 
 




Feelings of worthlessness or exces-
sive or inappropriate guilt 
Nearly every day Guilt may be delusional; 
not merely self-reproach or 
guilt about being sick 
 
Diminished ability to think or con-
centrate, or indecisiveness 
Nearly every day May be subjective or ob-
served by others. 
Recurrent thoughts of death (not just 
fear of dying), recurrent suicidal ide-
ation without a specific plan, or a 
suicide attempt or a specific plan for 
committing suicide. 
  
Adapted from American Psychiatric Association (2013) 
 
Furthermore, it is paramount to be able to differentiate between depression and other psychiat-






Additional diagnostic criteria for differentiation between depression and other psychiatric 
disorders with similar symptoms 
Further criteria 
 Symptoms should cause clinically significant distress or impairment in social, occupa-
tional, or other important areas of functioning 
 The episode should not be attributable to physiological effects of a substance or an-
other medical condition 
 The episode should not be better explained by schizoaffective disorder, schizophrenia, 
schizophreniform disorder, delusional disorder, or other specified and unspecified 
schizophrenia spectrum and other psychotic disorders 
 There should also be no history of manic or hypomanic episode; exclusion does not 
apply if all manic-like or hypomanic-like episodes are substance-induced or are at-
tributable to physiological effects of another medical condition 
Note. Adapted from American Psychiatric Association (2013) 
 
These additional requirements serve as an important mean to separate MDD from other psy-
chiatric diseases that may include similar symptoms. For example, bipolar disorder is also char-
acterized by periods of depressed mood, however with manic phases in between. It is also 
important to rule out depressed symptoms that arise from underlying organic causes or the use 
of psychotropic substances, in which case MDD is not diagnosed. The same diagnostic criteria 
are used when diagnosing pediatric major depressive disorder (pMDD) (Thapar, Collishaw, 
Potter, & Thapar, 2010), however adding irritable mood as one of the key criteria as has been 
mentioned earlier in the text. Also, children and adolescents can show different signs of de-
pression related to their level of development (Groen & Petermann, 2013). These include fre-
quent somatic symptoms, social isolation, separation anxiety or feelings of boredom (Groen & 
Petermann, 2013).  
Depending on the diagnostic manual used, differences in diagnostic criteria can lead to differ-
ential diagnostic outcomes. Both the International Classification of Diseases, Eleventh Revi-
sion (ICD-11) (World Health Organization, 2018) and the DSM-5 (American Psychiatric 
Association, 2013) use categories based on severity, recurrence and the presence of psychotic 
symptoms. Whereas ICD-11 includes mild depression in the diagnostic catalogue, DSM-5 no 
longer offers a diagnosis for symptoms with mild severity.  
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An estimated 10-15% of the world’s population is affected by depression at least once during 
their lifetime (Kessler & Bromet, 2013; Kessler et al., 2015). Prevalence rates in youth have 
been estimated to lie around 4% with ranges from 0.2% to 17% (Avenevoli, Swendsen, He, 
Burstein, & Merikangas, 2015; Costello, Egger, & Angold, 2005; Costello, Erkanli, & Angold, 
2006; Costello, Mustillo, Keeler, & Angold, 2004). Lifetime prevalence has even been esti-
mated to be as high as 32.5% (Angst et al., 2016) or 41.4% (Moffitt et al., 2010) depending on 
the study population investigated. When it comes to age distribution, median age of onset typ-
ically reported lies in the early to mid 20s (Kessler & Bromet, 2013) with very wide distribu-
tions (20-45) (Kessler et al., 2007). However, many patients already report symptoms during 
adolescence (Kessler et al., 2007; Wittchen et al., 2011) and earlier onset has been associated 
with poorer health outcomes such as more depressive episodes and more suicide attempts 
(Zisook et al., 2007). In community samples of children and adolescents, age of onset usually 
lies around 11 to 14 years of age (Merikangas & Avenevoli, 2003). In severe cases, depression 
can lead to suicide,  which in 2015 was the second leading cause of death amongst 15-29-years-
olds (World Health Organization, 2017). In youth, depression has been deemed the leading 
cause of disability-adjusted life years (DALY) and years lived with disability (YLD) (Erskine 
et al., 2015). In preadolescence, sex differences seem to play an inferior role compared to ad-
olescence (Merikangas & Avenevoli, 2003), where girls seem to be much more frequently af-
fected than boys (Avenevoli et al., 2015; Breslau et al., 2017; P. Cohen et al., 1993; Kessler & 
Walters, 1998; Wittchen, Nelson, & Lachner, 1998). Interestingly, sex differences seem to 
originate in childhood and then grow in magnitude with increasing age (Breslau et al., 2017; 
Smith, 2009). In terms of course of depression, Curry and colleagues (2011) reported that most 
adolescents recovered from a depressive episode within 63 months, however cumulative recur-
rence rate over 4 years was 38.1%. Dunn and Goodyer (2006) reported rather similar recurrence 
rates for youths in both clinical (44%) and community samples (52%). However, estimations 
might vary extensively, depending on the method used to define remission and recurrence 
(Kraus, Kadriu, Lanzenberger, Zarate, & Kasper, 2019).  
Despite the severity of this psychiatric disorder, strikingly, it is often neither recognized in  
adults (Lecrubier, 2007) nor in adolescents (Leaf et al., 1996; E. G. Scott, Luxmore, Alexander, 
Fenn, & Christopher, 2006), and only about a third of affected adolescents receive appropriate 
treatment (Costello, He, Sampson, Kessler, & Merikangas, 2014; Ghio, Gotelli, Marcenaro, 
Amore, & Natta, 2014) with similar numbers observed for adult patients (Lecrubier, 2007).  
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In conclusion, depression is a very common but also severe psychiatric disorder that in both 
youths and adults can have serious implications and often remains unrecognized and hence 
untreated.  
 
1.5.2 Depression and cognition 
In chapter 1.5.1 the emphasis was set on emotional symptoms of depression and their poten-
tially disastrous health outcomes. One particular cognitive symptom however, namely prob-
lems concentrating, can also have serious implications in daily life and affect personal and 
social development as well as subjective quality of life (Cambridge, Knight, Mills, & Baune, 
2018; Hammar & Årdal, 2009; Knight, Lyrtzis, & Baune, 2020). Especially in children and 
adolescents neurocognitive complaints can lead to further problems, for example not being able 
to attend school and hence not reach educational goals, which again can lead to serious social 
and educational impairments and hence strongly influence quality of life (Fletcher, 2008; 
Morey-Nase et al., 2019). Functional outcomes in depressed patients often seem to be mediated 
by these cognitive impairments rather than by emotional symptoms of depression (R. McIntyre, 
2014). Morey-Nase and colleagues (2019) reported that for affected adolescents, perceived 
cognitive impairment seemed to have a bidirectional influence on depression symptomatology 
and different aspects of quality of life. Additionally, study results have indicated that cognitive 
impairments might persist even after remission of other symptoms, which may lead to mainte-
nance of these adverse outcomes (Biringer et al., 2007; Bo Jacob Hasselbalch, Knorr, & 
Kessing, 2011; Semkovska et al., 2019). 
A reduced ability to concentrate is a key element in the diagnostic catalogue of depression and 
diagnosis often depends on the subjective perception and awareness of this impairment. Indeed 
perceived cognitive impairments are often reported by depressed adults (Iverson & Lam, 2013; 
R. S. McIntyre et al., 2015) and although studies in younger individuals are rather scarce, they 
seem to confirm these findings (Morey-Nase et al., 2019). However, especially in depression, 
self-reports of symptoms might often not validly reflect reality and could be either exaggerated 
due to negative self-perception (Lahr, Beblo, & Hartje, 2007; Sachs-Ericsson, Joiner, & Blazer, 
2008) or underestimated due to for example lack of motivation to cooperate. Furthermore, it 
remains unknown whether these cognitive complaints are reflected in diminished cognitive test 
performance. Lahr, Beblo, and Hartje (2007) and Srisurapanont, Suttajit, Eurviriyanukul, and 
Varnado (2017) for example reported large differences between subjective cognitive com-
plaints and cognitive test performance in adult patients. Evidence from further studies have 
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tended to underpin these results (R. S. McIntyre et al., 2013; Ott et al., 2016; Svendsen, 
Kessing, Munkholm, Vinberg, & Miskowiak, 2012). This could mean that patients with large 
self-reported cognitive complaints might still achieve average scores in neuropsychological 
test situations. Srisurapanont and colleagues (2017) found that subjective and objective cogni-
tive impairments depended on specific predictors. While depression severity and antidepres-
sant treatment were significant predictors of subjective complaints, age and education were 
significant predictors of objective cognitive test performance. It has further been debated 
whether subjective or objective cognitive impairments are more predictive of impaired every-
day functioning, with inconsistent results so far (Naismith, Longley, Scott, & Hickie, 2007; 
Potvin, Charbonneau, Juster, Purdon, & Tourjman, 2016). Together these findings again sug-
gest that self-reported cognitive impairments and cognitive test performance might not reflect 
the same concept and should be investigated separately (Potvin et al., 2016).  
There is, however, vast evidence supporting the notion of poorer cognitive test performance in 
adult depressed individuals throughout different cognitive domains (Knight & Baune, 2018; R. 
S. C. Lee, Hermens, Porter, & Redoblado-Hodge, 2012; Marazziti, Consoli, Picchetti, Carlini, 
& Faravelli, 2010; Rock, Roiser, Riedel, & Blackwell, 2014). Studies have also suggested  cor-
relations with indices of illness chronicity like, for example, for memory outcomes (Gorwood, 
Corruble, Falissard, & Goodwin, 2008). Severity of depression has quite consistently been neg-
atively associated with cognitive test performance (McDermott & Ebmeier, 2009). Yet again, 
some studies report results where different domains seem less affected or even undisturbed, 
like for example spatial selective attention (Ladouceur et al., 2012; Olvet, Klein, & Hajcak, 
2010). For children and adolescents, results seem even more heterogeneous. Maalouf and 
colleagues (2011), for example, reported impaired executive functioning in depressed adoles-
cent with tendencies towards negative associations between executive functioning and depres-
sion severity. Other cognitive functions like memory and attention however seemed undis-
turbed. Whereas Goodall and colleagues (2018) and Wagner, Müller, Helmreich, Huss, and 
Tadić, (2014) reported meta-analytic evidence in favor of deficits in cognitive test performance 
throughout different domains, Vilgis, Silk, and Vance (2015) found little support for any exec-
utive function deficits in children and adolescent according to their narrative review. One ex-
planation for the lack of evidence for impaired cognition in depressed youths might be the 
shorter depression duration compared to adults, as it has been found to be negatively associated 
with cognitive functioning (B. J. Hasselbalch, Knorr, Hasselbalch, Gade, & Kessing, 2013). 
This hypothesis has also been investigated on a neuroanatomical level, providing evidence for 
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inverse correlations between hippocampal grey matter and duration of depression (Arnone et 
al., 2013).  
Taken together, problems concentrating are a key diagnostic criterion for the diagnosis of de-
pression. These problems are reflected by studies reporting self-reported cognitive complaints 
in depressed youths as well as adults. Especially in young individuals, studies investigating 
cognitive test performance have, however, reported mixed results for different cognitive do-
mains. Illness duration might be inversely associated with test performance and hence serve as 
an explanation for the inconsistent findings concerning cognitive tests performance in youths. 
 
1.5.3 Depression and the brain 
Research on the pathophysiology of depression has investigated underlying neuronal networks 
that show functional or anatomical alterations in depressed compared to healthy individuals. 
Clark, Chamberlain and Sahakian (2009) described functional abnormalities in a neural circuit 
including multiple areas of the PFC, subcortical regions like the thalamus and temporal lobe 
structures like the hippocampus and the amygdala. In treatment-resistant depression, decreased 
functional connectivity was found between the hippocampus and limbic regions of the brain 
(Ge et al., 2019). Clark and colleagues (2009) further concluded that structural abnormalities 
were mostly found within the fronto-striatal circuitry, with volume reductions in the anterior 
cingulate cortex.  Studies investigating structural abnormalities of the hippocampus have con-
sistently shown depression to be associated with a reduction in the hippocampal volume 
(Campbell, Marriott, Nahmias, & MacQueen, 2004; Eker & Gonul, 2010; Schmaal et al., 2016; 
Videbech & Ravnkilde, 2004). Due to its key role in memory function, these anatomical 
changes have been at least partly made responsible for differences observed in memory test 
results achieved by depressed individuals compared to healthy controls (Austin, Mitchell, & 
Goodwin, 2001; Clark et al., 2009; Frodl et al., 2006). Smaller hippocampi in MDD patients 
have further been associated with earlier age of onset and recurrence of depression (Schmaal 
et al., 2016). In depressed adolescents, alterations in cortical gray matter have been reported, 
especially when symptoms were already present at a young age (Schmaal et al., 2017). These 
findings further stress the importance of early intervention. 
Chronic stress has been discussed as a prominent underlying factor, contributing to pathophys-
iological changes in the brain of depressed patients. Whereas the bodily stress response is a 
crucial mechanism in humans and animals, persistent stress can have detrimental effects on the 
human body including the brain (Conrad, 2008). Maladaptive reactions to chronic stress and 
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the resulting hyperactivity and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis 
in depressed individuals has been associated with impaired forebrain glucocorticoid receptor 
function which may be one underlying cause for the emergence of depressive symptoms  
(Boyle et al., 2005; Holsboer, 2013; Kunugi et al., 2006). Chronic stress and maladaptive re-
actions to it, have been shown to give rise to both structural and functional alterations in the 
human brain, which then again influence the HPA axis and the body’s ability to respond to 
stress (Ulrich-Lai & Herman, 2009), resulting in a vicious circle. Studies have further shown 
that chronic stress can lead to the recruitment of additional brain circuits which are then in-
volved in the immediate stress response (Ulrich-Lai & Herman, 2009). It has for example been 
suggested that chronic stress results in the hippocampus being less involved in the regulation 
of the HPA axis than without repeated stress exposure (Ulrich-Lai & Herman, 2009). When it 
comes to cognitive functioning in depression, structural and functional changes in the hippo-
campus have been deemed to originate from increased glucocorticoid levels (Conrad, 2008). 
Cortisol has been thought to act as a toxin, progressively contributing to the deterioration of 
hippocampal grey matter (Conrad, 2008). Further evidence has also suggested altered effects 
of cortisol on hippocampal function in depressed patients (Abercrombie et al., 2011). Together 
these alterations have been summarized in a theory called The Glucocorticoid Vulnerability 
Hypothesis which has been reviewed by Conrad (2008).  
Neurotrophins play a key role in the maintenance of normal brain functioning as they are in-
volved in neural growth and differentiation and many other plastic and pathological processes 
reviewed by Chao (2003). Low serum levels of certain neurotrophins like the brain-derived 
neurotrophic factor (BDNF) have been associated with depression (Molendijk et al., 2011). 
Chronic stress has been made responsible for the decrease in the expression of neurotrophic 
factors BDNF which in turn has been linked to atrophy in certain brain regions like the hippo-
campus or the PFC in depressed patients (Duman & Monteggia, 2006). In a review by Miranda, 
Morici, Zanoni, and Bekinschtein (2019) BDNF expression, its role in the pathological brain 
and memory functions are revisited. Figure 2 summarizes the alterations to the HPA axis and 










Simplistic model depicting the impact of chronic stress on structural and functional changes 
to the brain.  
 
 







Structural and functional 





Effects of chronic stress on selected brain areas, the HPA axis and cognitive functioning 
Brain area Effect on the brain Effect on HPA and cognition 
Hippocampus  Dendritic atrophy 
 Decreased glucocorticoid 
receptor expression 
 Decreased HPA feedback 
 Decreased memory 
Medial prefrontal 
cortex (mPFC) 
 Dendritic atrophy 
 Decreased glucocorticoid 
receptor expression 
 Decreased HPA feedback 
 Decreased memory extinc-
tion 
 Decreased reward 
Amygdala  Increased corticotropin-re-
leasing hormone expression 
and release 
 Increased dendritic branch-
ing 
 Increased stress excitability 
 Increased HPA autonomic 
excitability 
 Increased anxiety 
 Increased emotional 
memory 
 Decreased reward 
Thalamus  Increased stress excitability  Increased HPA excitability 
to novel stress 
 Decreased HPA excitability 
to familiar stress 
Locus coeruleus  Increased neurotransmitter 
release 
 Increased stress excitability 
 Increased HPA excitability 
to novel stress 
 
Hypothalamus  Increased stress responsive-
ness 
 Decreased glucocorticoid 
receptor expression 
 Increased excitability to 
novel stress 
Note. Adapted from Ulrich-Lai & Herman (2009) p. 404 
 
Although glucocorticoids have potent anti-inflammatory effects, the excessive release through 
the processes of HPA axis dysregulation described above, can lead to increased inflammation 
and vice versa (Horowitz, Zunszain, Anacker, Musaelyan, & Pariante, 2013; Tapp, Godbout, 
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& Kokiko-Cochran, 2019) and inflammatory processes have been discussed to play an im-
portant role in depression (Dantzer, O’Connor, Freund, Johnson, & Kelley, 2008; Y. K. Kim, 
Na, Myint, & Leonard, 2016; Leonard & Maes, 2012; Lotrich, 2015; Rosenblat, Cha, Mansur, 
& McIntyre, 2014). Evidence of increased inflammation in depressed patients has emerged, 
following the detection of increased levels of biomarkers of inflammation like interleukins (IL) 
6, IL-1- β, C-reactive protein (CRP) and tumour necrosis factor (TNF) α in depressed patients 
(Iob, Kirschbaum, & Steptoe, 2019; A. H. Miller & Raison, 2016). Inflammation has also been 
linked to altered neurotransmitter systems involved in for example motivation and anxiety 
which are important in relation to depression symptomatology (A. H. Miller & Raison, 2016). 
Correlations between increases in hippocampal volumes and decreases in inflammatory mark-
ers following electroconvulsive therapy in depressed patients have been reported (Belge et al., 
2020), although recent evidence negates any relationship between inflammatory markers and 
hippocampal volumes in depressed individuals (Tannous et al., 2020). 
Lastly, diminished dopaminergic transmission has been discussed as a further pathophysiolog-
ical factor in depression and underlying mechanisms have been reviewed by Belujon and Grace 
(2017) and Dunlop and Nemeroff (2007).  
Through complex interactions between the processes discussed in this chapter, functional and 
structural alterations related to the hippocampus and other brain regions that have been identi-
fied in depressed individuals, may be explained. These changes offer pathophysiological ex-
planations for both emotional as well as cognitive complaints, especially mnemonic functions, 
in depression.  
 
1.6 n-3 PUFAs and psychiatric benefits 
A large body of literature has investigated potential beneficial effects of n-3 PUFAs on psychi-
atric disorders. Psychiatric disorders investigated include bipolar disorder (Clayton et al., 
2009), psychotic disorder (Amminger, Schäfer, Schlögelhofer, Klier, & McGorry, 2015), At-
tention Deficit Hyperactivity Disorder (ADHD) (Chang et al., 2019) and depression (Mocking 
et al., 2016). In the following chapter, an overview over current research concerning n-3 PUFA 




1.6.1 n-3 PUFAs and depression 
As mentioned before, lower n-3 PUFA compared to n-6 PUFA intake over the last two centu-
ries has been associated with the rise of several diseases, including psychiatric diseases like 
depression (Simopoulos, 2011). Epidemiological studies formed the basis of this area of re-
search, as they reported inverse relationships between oily fish intake and the prevalence 
(Appleton et al., 2007; Murakami, Miyake, Sasaki, Tanaka, & Arakawa, 2010; Tanskanen, 
2001; Timonen, 2004) and incidence (Y. Li, Dai, Ekperi, Dehal, & Zhang, 2011; Sanchez-
Villegas et al., 2007) of depression. Meta-analyses have further confirmed negative associa-
tions between fish consumption and risk of depression (F. Li, Liu, & Zhang, 2015). 
Studies investigating the relationship between n-3 PUFAs and depression have on the one hand 
focused on differences of the n-3 PUFA status measured in blood and brain between depressed 
and non-depressed individuals and on the other hand, on the efficacy of supplementation with 
n-3 PUFAs on symptomatology. Observational studies in adults have reported lower EPA and 
DHA levels in the blood (Lin, Huang, & Su, 2010; Riemer, Maes, Christophe, & Rief, 2010) 
as well as in post-mortem orbitofrontal cortex (McNamara et al., 2007, 2013) in depressed 
individuals compared to healthy controls. Also, Conklin and colleagues (2007) found that 
higher n-3 PUFA intake was positively associated with a larger grey matter volume in the cor-
ticolimbic circuitry. These findings suggest that n-3 PUFA deficiency could have similar con-
sequences for brain development as have been proposed for depression pathophysiology. In 
youths, evidence seems heterogenic. In 13-25 years old individuals at ultra-high risk for psy-
chosis, Berger and colleagues (2017) found that a high n-6/n-3 ratio at baseline predicted mood 
disorders over a 7-year follow-up. Pottala and colleagues (2012) reported lower omega-3 indi-
ces in depressed individuals aged 13 to 18 years, compared to a healthy control group. Other 
studies have reported similar results, however only for DHA and not EPA (McNamara et al., 
2014). Van der Wurff and colleagues (2019), on the other hand, found no association of neither 
DHA, EPA or the omega-3 index with depression scores in a random sample of adolescents 
attending lower general secondary education. These conflicting results might be explained by 
the influence of other dietary factors. Adjustment for factors like energy intake might mask 
preliminary results of significant associations between n-3 PUFA status and depression symp-
toms, like Oddy and colleagues (2011) concluded. 
Several meta-analyses investigating supplementation effects of n-3 PUFA on depression in 
adults have confirmed beneficial effects, with a tendency towards stronger effects for EPA 
rather than DHA (Grosso, Pajak, et al., 2014; Hallahan et al., 2016; Liao et al., 2019; Martins, 
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2009; Mocking et al., 2016). Interestingly, symptom severity has been positively associated 
with treatment effects of n-3 PUFA in depressed individuals (Appleton et al., 2010). In children 
and adolescents, a meta-analysis summarizing the limited amount of evidence, did not confirm 
any beneficial effects of n-3 PUFA supplementation in the treatment of depression (Zhang, 
Liu, Kuang, Meng, & Zhou, 2019). However, conflicting evidence exists, supporting the notion 
of beneficial supplementation effects in youths (Fristad et al., 2019; McNamara et al., 2014; 
Nemets, 2006). 
Differential effects in n-3 PUFA supplementation trials could be explained by several factors 
like for example baseline blood levels, differences in trial formulations and individual absorp-
tion and utilization rates. As compared to RCTs on for example antidepressants, baseline levels 
of n-3 PUFA may vary considerably between individuals and are never zero. Hence, the level 
of n-3 PUFA deficiency might play a role in treatment efficacy, where lower levels might pre-
dict stronger benefits (Messamore, Almeida, Jandacek, & McNamara, 2017). Also, study for-
mulations vary significantly regarding fatty acid composition, and meta-analyses have sug-
gested that formulations with larger proportions of EPA rather than DHA might be more effec-
tive in the treatment of depression symptoms (Grosso, Pajak, et al., 2014; Hallahan et al., 2016; 
Liao et al., 2019). Furthermore, little is known about the actual absorption rate and utilization 
within the brain as well as the influence of the microbiome on PUFA metabolism.  
Taken together, studies have shown positive associations of oily fish intake, higher n-3 PUFA 
status and n-3 PUFA supplementation on depression symptoms. Meta-analytic evidence has 
suggested tendencies towards beneficial effects of EPA rather than DHA. Results in youths are 
rather heterogeneous. These discrepancies could have emerged from differences in baseline n-
3 PUFA status, differences in study formulations or inter-individual differences in absorption 
and utilization rates. 
 
1.6.2 Biochemical mechanisms of action 
Underlying mechanisms of beneficial effects of n-3 PUFAs on depression symptoms have 
largely been based on their anti-inflammatory properties (Rapaport et al., 2016), effects on 
monoamine transmission (Chalon, 2006) and effects on the HPA axis (Larrieu et al., 2014), 
which are all key factors in MDD psychopathology.  
Over the last few years, the monoamine hypothesis has been used dominantly to explain path-
ophysiology of depression. Consequently, pharmacological treatment with selective serotonin 
reuptake inhibitors (SSRI), based on the enhancement of serotonergic neurotransmission, have 
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been deemed the treatment of choice (NICE, 2015). However, a recent meta-analysis by scien-
tists associated with the Nordic Cochrane Centre in Denmark, concluded that there was not 
enough evidence to conclude that modern day antidepressants are more efficacious than pla-
cebo treatment (Munkholm, Paludan-Müller, & Boesen, 2019). These results have received 
great attention and have been controversially discussed by scientists and clinicians, due to their 
extensive implications for patients and practitioners. However, these results confirm previous 
findings of rather large non-response rates to antidepressant therapies (Rush et al., 2008). Sev-
eral types of antidepressants can furthermore have severe side effects like for example sexual 
dysfunction (Carvalho, Sharma, Brunoni, Vieta, & Fava, 2016; Outhoff, 2010), nausea 
(Carvalho et al., 2016), weight changes (Carvalho et al., 2016; Serretti & Porcelli, 2018), sleep 
disruption (Aszalós, 2006; Carvalho et al., 2016) and even increased suicidality especially in 
younger individuals (Brent, 2016; Sharma, Guski, Freund, & Gøtzsche, 2016). In Switzerland, 
no antidepressant medication has been approved for the treatment of pMDD and all prescrip-
tions are hence done off-label, which further emphasizes the need for alternatives. Conse-
quently, n-3 PUFAs have been suggested as an alternative or additional treatment, as they have 
been shown to affect monoamine transmission, especially in animal models (McNamara et al., 
2009; Zimmer et al., 2000). Membrane changes induced by the introduction of larger amounts 
of n-3 PUFAs, may influence several neurotransmitter systems including dopaminergic and 
serotonergic pathways, which are of great importance to the pathophysiology of depression.  In 
a rodent model, Chalon (2006) was able to demonstrate that a decrease in brain DHA following 
deficiency in n-3 PUFA consumption, was followed by a decrease in dopamine in the frontal 
cortex.  
Another factor possibly influencing the development or maintenance of depressive symptoms 
is linked to inflammatory processes (Leonard & Maes, 2012; Lotrich, 2015; Rosenblat et al., 
2014). Current research has broadened the knowledge on brain-inflammation-immune interac-
tions as risk and resilience factors for depressive disorders (for a review refer to Miller & 
Raison (2016)). Systemic inflammation has been linked to increased depressive symptoms 
(Beydoun et al., 2019), and n-3 PUFA supplementation has been shown to be able to reduce 
these inflammatory processes (Natto et al., 2019). Processes involved in this anti-inflammatory 
effect of n-3 PUFAs are for example the downregulation of n-6 PUFAs and the promotion of 
proresolvins, neuroprotectins as well as anti-inflammatory mediators (Freeman & Rapaport, 
2011; Müller, Myint, & Schwarz, 2009).  
Other pathways through which n-3 PUFAs might influence depression pathophysiology in-
clude the endocannabinoid system. Studies in rodents have reported depression-like behavior 
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following a n-3 PUFA deficient diet, potentially explained by the impairment of long-term 
depression (LTD) in certain brain regions, which is related to the endocannabinoid system 
(DeMar et al., 2006; Larrieu, Madore, Joffre, & Layé, 2012).   
In light of the uncertainty of beneficial effects of traditional antidepressants together with the 
severe side effects linked to them, alternative or supplementary treatments of depression are 
needed. The anti-inflammatory properties of n-3 PUFAs may counteract inflammatory pro-
cesses involved in depression pathophysiology (Grosso, Galvano, et al., 2014). Consequently, 
n-3 PUFAs have been suggested as a potential treatment option. 
 
1.6.3 n-3 PUFAs and cognitive effects related to depression 
In the previous chapters, n-3 PUFAs were introduced and their role in both depression and 
cognition has been discussed. The question remains as to what extent n-3 PUFAs might be used 
for the treatment of cognitive complaints in depression. This is of particular interest, as differ-
ent kinds of antidepressant medication have proven rather heterogeneously effective in the 
treatment of cognitive problems in depression (Bennabi, Haffen, & Van Waes, 2019; Biringer, 
Rongve, & Lund, 2009; Bortolato et al., 2016; Prado, Watt, & Crowe, 2018; Rosenblat, Kakar, 
& McIntyre, 2015; Shilyansky et al., 2016; Skandali et al., 2018; Zuckerman et al., 2018). 
Furthermore, they have been associated with severe side effects like increased suicidality in 
youths (Brent, 2016; Sharma et al., 2016). Especially in youths, adverse effects on the brain 
and cognitive functioning caused by depression could have long-lasting consequences concern-
ing educational attainment and consequently, quality of life. Treatment of cognitive complaints 
in pMDD could prove especially important concerning the fact that these have been suggested 
to persist even in the remitted stage (Biringer et al., 2007; Bo Jacob Hasselbalch et al., 2011; 
Semkovska et al., 2019).   
The hippocampus is very important for learning and memory (Bird & Burgess, 2008; Deng, 
Aimone, & Gage, 2010; Squire, 1992) and both structural and functional changes to the hippo-
campus have been reported in depressed individuals (discussed in chapter 1.5.3). In the hippo-
campus, DHA has been made responsible for neuronal development and synaptic function (Cao 
et al., 2009). Studies in healthy individuals have shown that n-3 PUFA intake (Conklin et al., 
2007) but also status (Pottala et al., 2014) are associated with larger hippocampal volumes. 
Related to cognitive functioning, animal studies have reported improved memory performance 
following increases in dietary DHA intake and hippocampal DHA levels (Labrousse et al., 
2012). DHA deficiency on the other hand has been associated with deficits in dopaminergic 
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and serotonergic neurotransmission (McNamara et al., 2009; Zimmer et al., 2000), involved in 
depression pathophysiology (Belujon & Grace, 2017; Dunlop & Nemeroff, 2007), as well as 
impaired learning and memory (Kuratko et al., 2013). Larrieu and colleagues (2014) reported 
that n-3 PUFA deficiency in rats leads to both disrupted glucocorticoid receptor mediated sig-
nalling and HPA hyperactivity, which in turn resulted in neuronal atrophy in the PFC. Further-
more, EPA but not DHA plasma levels have been associated with lower gray matter atrophy 
of the right hippocampal and parahippocampal area and of the right amygdala (Samieri et al., 
2012) in older subjects. Interestingly, the atrophy in the amygdala was again positively associ-
ated with the 4-year decline in semantic memory performances and depressive symptoms. In a 
recent study, Borsini, Stangl, Jeffries, Pariante and Thuret (2020) were able to provide the first 
direct evidence for EPA and DHA treatment of cortisol-induced reduction in human hippocam-
pal neurogenesis. These findings summarize the mechanisms suspected to influence functional 
and structural neurological changes related to n-3 PUFAs, depression and cognition, described 
in the preceding chapters. 
Despite the growing body of evidence suggesting beneficial effects of n-3 PUFAs on cognition 
and depression symptoms, supplementation studies in depressed individuals seldom report cog-
nitive outcomes  (Knochel et al., 2015). Rogers and colleagues (2008) found no benefits of n-
3 PUFA supplementation on cognitive symptoms in depressed individuals. Cognitive function-
ing of recovered (Niki Antypa, Smelt, Strengholt, & Van Der Does, 2012) and adults “at risk” 
for depression (Duffy et al., 2015) was equally unaffected  after n-3 PUFA supplementation. 
In youths with depression or bipolar disorder however, Vesco, Young, Arnold, and Fristad 
(2018) reported decreased parent-rated impairments in executive functioning after a 12-weeks 
supplementation with n-3 PUFAs.  
Although a vast body of literature has been able to link n-3 PUFAs to benefits related to de-
pression symptoms as well as cognitive functioning and underlying pathophysiological mech-
anisms have equally been shown to benefit from adequate n-3 PUFA intake, cognitive effects 
in depression have been insufficiently studied and current evidence remains inconclusive. Po-
tential protective effects of n-3 PUFAs in relation to cognition in depressed youths could prove 
especially relevant, considering ongoing brain development in this population, where preven-




1.7 Rationale study 2: n-3 PUFAs and cognitive test performance in depressed youths 
The following chapter gives a brief overview over the previously discussed findings on the 
association between n-3 PUFAs and cognition in the context of depression. Specific research 
questions for study 2 are presented in a second step. 
 
1.7.1 Summary 
Vast nutritional changes in relation to a decrease of n-3 PUFAs in favor of an increase in n-6 
PUFAs within the last century have been associated with the rise of different civilization dis-
eases including depression (Simopoulos, 2011a). Because n-3 PUFA are vital for normal brain 
development (J. Baumgartner, 2016; Bazinet & Layé, 2014; Innis, 2008; Koletzko et al., 2008; 
Lauritzen et al., 2016; Sun et al., 2018), potential positive associations between n-3 PUFA and 
cognitive functioning have been suggested. Positive associations between n-3 PUFA status and 
cognition have been found in both adults (Cook et al., 2019) and children (Montgomery et al., 
2013), however meta-analyses have reported heterogenous results of n-3 PUFA supplementa-
tion in youths (Bloch & Qawasmi, 2011; Cooper et al., 2015; Emery et al., 2020; Jiao et al., 
2014). Although problems concentrating are part of the diagnostic criteria for depression in 
both children as well as adults (American Psychiatric Association, 2013), deficits in cognitive 
test performance have more consistently been reported in adult patient groups (Knight & 
Baune, 2018; R. S. C. Lee et al., 2012; Marazziti et al., 2010; Rock et al., 2014). Although 
there is yet no clear understanding of to what degree depressed youths are affected by deficits 
concerning cognitive test performance, the potential negative impact such deficits might have 
on their personal and academic development are substantial. Also, it has been established that 
cognitive deficits might at least partially persist even after remission (Biringer et al., 2007; Bo 
Jacob Hasselbalch et al., 2011; Semkovska et al., 2019) and hence establishing preventive 
measures or adequate treatment is paramount. Because antidepressants have proven heteroge-
neously effective in the treatment of cognitive deficits in depression (Bennabi et al., 2019; 
Biringer et al., 2009; Bortolato et al., 2016; Prado et al., 2018; Rosenblat et al., 2015; 
Shilyansky et al., 2016; Skandali et al., 2018; Zuckerman et al., 2018) and potential side effects 
are unnegotiable, an easily accessible and natural treatment approach could prove important, 
especially in youths. Current findings have suggested that EPA might be more effective than 
DHA in the treatment of depression symptoms (Grosso, Pajak, et al., 2014; Hallahan et al., 
2016; Liao et al., 2019) and at the same time, beneficial supplementation effects concerning 
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cognitive functioning have been mostly reported for EPA rather than DHA (Chang et al., 2019; 
Emery et al., 2020). Despite the importance of an early intervention for cognitive complaints 
in depressed individuals, only few studies so far have investigated the role of n-3 PUFA in 
cognitive functioning in depressed populations.      
 
1.7.2 Research questions study 2 
Although a vast number of studies has already investigated the effects of n-3 PUFA related to 
cognition, to date, there has been no study investigating the relationship between n-3 PUFA 
status and cognition in depressed youths. The aim of study 2 was hence to fill this research gap 
and investigate associations between n-3 PUFA status and verbal memory performance in a 
large sample of depressed youths. Study 2 also aimed at investigating potential differences in 
the association between EPA versus DHA status and cognitive functioning. Based on research 
in depressed adult patient groups, where depression severity has been negatively associated 
with cognitive functioning (McDermott & Ebmeier, 2009) and also n-3 PUFA treatment effi-
cacy has been related to severity of depression (Appleton et al., 2010), another aim pursued in 
paper 2 was to investigate these assumptions in youths.  
Based on the literature discussed in previous chapters the following research questions were 
developed for study 2: 
1) Is the DHA and/or EPA status of depressed youths related to their verbal memory per-
formance? 
2) Are there association differences between DHA and EPA status concerning verbal 
memory performance in depressed youths? 
3) Is depression severity related to verbal memory performance in depressed youths? 
4) Does depression severity impact the association between DHA and/or EPA and verbal 
memory performance in youths? 
 
Highlighting associations between n-3 PUFA status and cognitive test performance in de-
pressed youths would form the basis for further investigations into supplementation effects in 
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Omega-3 fatty acids are vital for brain development. The aim of this meta-analysis was to 
broaden current knowledge of the effects of omega-3 supplementation on cognitive test perfor-
mance in youths. Randomized controlled trials (RCTs) meeting selection criteria were identi-
fied through two independent literature searches on PubMed, Cochrane Library, PsycARTI-
CLES and PsycINFO (last search June 2019). Twenty-nine out of 1126 studies assessing 4247 
participants met all selection criteria. A meta-analysis using random-effects model was per-
formed for eight different cognitive domains. This first analysis revealed no main effect of 
omega-3 fatty acid supplementation on domain-specific cognitive test performance in youths. 
Subgroup analyses identified beneficial effects of eicosapentaenoic acid (EPA)-rich but not 
docosahexaenoic acid (DHA)-rich formulations in the domains of long-term memory, working 
memory and problem solving and a tendency towards beneficial effects in clinical rather than 
non-clinical populations. Future research should investigate differential effects of EPA and 
DHA and consider their baseline levels, other nutritional components and interactions with 




Impaired cognitive development can severely interfere with everyday life, including school 
life, work life and social relationships, hence severely impacting quality of life. Due to its crit-
ical role in human life, a multitude of studies have attempted to establish factors potentially 
influencing cognitive development, for example genetics (Mollon et al., 2018); pre- and post-
natal factors, such as parental mental health (Mensah & Kiernan, 2010; Wen et al., 2017); or 
alcohol consumption (Shokri-Kojori, Tomasi, Wiers, Wang, & Volkow, 2017). 
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Nutrition is one of the most controversially discussed factors thought to influence cognitive 
development. Dramatic changes in dietary habits over the last two centuries are widely consid-
ered to be a major cause of several diseases including diabetes, cardiovascular diseases and 
cancer (Anderson & Ma, 2009; Simopoulos, 2011a). Consequently, nutrition has also been 
suggested to influence developmental processes, such as brain maturation during gestation and 
early childhood (Cusick & Georgieff, 2016). Within nutrition research, the past few years have 
seen a renewed interest in omega-3 (n-3) polyunsaturated fatty acids (PUFAs), due to the vast 
changes in dietary habits from a balanced omega-3 to omega-6 ratio to an excess in omega-6 
fatty acids in Western societies across the 20th century (Simopoulos, 2011a). Eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) are two of the main n-3 PUFAs (Layé et al., 
2018). The human body is not able to synthesize these fatty acids by itself and hence relies on 
the intake of n-3 PUFAs through nutrition (Bazinet & Layé, 2014; Simopoulos, 2011a; Weiser 
et al., 2016). Indeed, Montgomery, Burton, Sewell, Spreckelsen and Richardson (2013) found 
an association between low blood n-3 PUFAs and poorer reading abilities and working memory 
performance in children. Kalmijn et al. (2004) reported an inverse relationship of EPA and 
DHA consumption with the risk of impaired overall cognitive function and speed at middle 
age. Moreover, beneficial effects of maternal n-3 PUFA supplementation on child growth and 
development have been reported (Middleton et al., 2019), suggesting a positive effect on cog-
nitive performance in later life. Consequently, there have been various attempts to enhance 
cognition through n-3 PUFA supplementation in healthy children and adolescents (M. Johnson, 
Fransson, Östlund, Areskoug, & Gillberg, 2017; Makrides, Neumann, Simmer, & Gibson, 
2000; Osendarp et al., 2007; D. T. Scott et al., 1998; Van Der Merwe et al., 2013) and youths 
from clinical populations such as ADHD (Bloch & Qawasmi, 2011; Chang et al., 2018). Sim-
ilarly, treatment effects have been investigated in healthy adults (N Antypa, Van der Does, 
Smelt, & Rogers, 2009; Bauer et al., 2014) and for the treatment of Alzheimer’s disease 
(Canhada, Castro, Perry, & Luft, 2017; Mazereeuw, Lanctôt, Chau, Swardfager, & Herrmann, 
2012). Meta-analyses on the subject report rather heterogeneous results. Jiao et al. (2014) pro-
posed significant positive effects of n-3 PUFA supplementation on cognitive development in 
infants, yet failed to prove general beneficial effects in other populations and cognitive do-
mains. Findings by Chang et al. (2018) suggest positive effects of n-3 PUFA supplementation 
on cognitive measures associated with attention in youths with ADHD. Bloch and Qawasmi 
(2011) also found moderate positive treatment effects for ADHD symptoms, especially with 
higher doses of EPA, similarly to  Grosso, Pajak and colleagues (2014a), Hallahan and 
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colleagues (2016), Mocking and colleagues (2016) and Liao and colleagues (2019) who re-
ported beneficial effects of EPA on depression symptoms. Meta-analyses focusing on the pre-
vention of cognitive decline were only able to report marginal benefits in specific populations 
(Mazereeuw et al., 2012), or with specific doses (Abubakari, Naderali, & Naderali, 2014). A 
recent meta-analysis including both children and adults by Cooper, Tye, Kuntsi, Vassos and 
Asherson (2015), found no effect of n-3 PUFA supplementation on any cognitive domain, but 
reported some evidence that only n-3 PUFA deficient populations might benefit from supple-
mentation in terms of enhanced cognitive functioning. 
 
2.1.2 Biological mechanism 
PUFAs have diverse effects on various bodily systems. The bioactive roles of EPA and DHA 
and their bioactive mediators have been extensively reviewed (Dyall, 2015; Layé et al., 2018; 
Weiser et al., 2016). It is currently widely accepted that n-3 PUFA supplementation results in 
positive health effects, including benefits to the cardiovascular system (Lovegrove et al., 2004; 
Massaro et al., 2008; Psota et al., 2006), eye health (Merle et al., 2014), and they give rise to 
important anti-inflammatory and pro-resolving mediators, reducing inflammation (Bazinet & 
Layé, 2014; Layé et al., 2018; K. Li et al., 2014). To date, potentially unwanted effects (e.g. 
decreased blood clotting, decreased blood pressure, diarrhea and acid reflux) have been deemed 
to be harmless (Bradberry & Hilleman, 2013; Chen, Tofler, McEwen, Ward, & Morel-Kopp, 
2013; Clarke, Cullen-Dean, Regelink, Chan, & Rose, 1990; Khodarahm & Azadbakht, 2016; 
Morris, Sacks, & Rosner, 1993). Conversely, n-6 PUFAs, although also assuming a vital role 
in bodily functioning, are thought to affect health negatively, mainly due to their proinflamma-
tory and prothrombotic properties (Simopoulos, 2008). 
The main PUFAs found in the brain are arachidonic acid (AA), an n-6 PUFA, and docosahex-
aenoic acid (DHA), an n-3 PUFA (Bazinet & Layé, 2014; Weiser et al., 2016). Within the 
brain’s grey matter, DHA makes up a larger proportion than AA, whereas within white matter, 
AA is proportionally higher (Bazinet & Layé, 2014; Weiser et al., 2016). EPA, however, exists 
in a far lower concentration in the brain (Bazinet & Layé, 2014; Weiser et al., 2016). PUFAs 
are essential for the maturation of the brain during gestation (Bazinet & Layé, 2014; Innis, 
2008; Koletzko et al., 2008) and PUFA metabolism regulation is a fundamental process of 
many core elements of human pubertal brain development, such as myelination and synaptic 
formation as well as pruning (McNamara & Carlson, 2006; McNamara et al., 2015). Various 
reviews have summarized the biological role of PUFAs in the brain and their effect on cognitive 
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functions (Bazinet & Layé, 2014; Bourre, 2004; Janssen & Kiliaan, 2014; Weiser et al., 2016). 
PUFAs have been found to affect several cellular processes such as membrane fluidity, neu-
roinflammation, neurotransmitter release, myelination, signal transduction, synaptogenesis and 
neuronal growth (Dyall, 2015; Weiser et al., 2016). Animal studies have provided vast evidence 
for the importance of n-3 PUFAs in normal brain developmental processes such as neurogen-
esis (Coti Bertrand et al., 2006; Kawakita et al., 2006). Igarashi, Santos and Cohen-Cory (2015) 
found that tadpoles from n-3 PUFA deficient frogs had morphologically simpler tectal neurons 
with fewer dendrite branches and that this process was partially reversed when they were later 
fed n-3 PUFAs. Depending on where these cellular processes are taking place, n-3 PUFA de-
ficiency could affect for example memory and executive functioning. Bartl, Walitza and 
Grünblatt (2014) provided evidence for a protective effect of n-3 PUFAs on pheochromocy-
toma-12 dopaminergic cell viability in rats. Animal studies also support the association of n-3 
PUFA deficiency and impaired learning (Takeuchi, Fukumoto, & Harada, 2002). 
The differential effects of EPA and DHA for brain maturational processes are not well under-
stood. Differential effects of DHA and EPA on cell function and health have been extensively 
reviewed elsewhere (Dyall, 2015; Gorjão et al., 2009; Russell & Bürgin-Maunder, 2012) and 
have to be taken into account when reviewing the effects of PUFAs on cognition. 
Although the findings clearly indicate the crucial role of n-3 PUFAs in human brain biology, 
the aforementioned meta-analyses have failed to determine consistent beneficial effects of n-3 
PUFA supplementation on cognitive functioning throughout the lifespan. Owing to the well-
documented importance of n-3 PUFAs in brain maturation and the inconsistent findings relat-
ing to their effects on cognition in later life, one might postulate that the effects of EPA and 
DHA on cognition might change as the brain develops throughout life (Layé et al., 2018). To 
date, a lack of understanding persists of whether type and ratio of n-3 PUFA supplements, and 
dosage may contribute to conflicting study results, as has been proposed in relation to primary 
depression (Grosso, Pajak, et al., 2014; Hallahan et al., 2016; Liao et al., 2019; Mocking et al., 
2016; Sublette, Ellis, Geant, & Mann, 2011) and ADHD (Bloch & Qawasmi, 2011). As certain 
effects have been deemed unique to EPA and DHA, pooling them in meta-analyses seems 
highly problematic (Dyall, 2015). Furthermore, few researchers have addressed age as a vari-
able, possibly overlooking differential effects for different age groups. Additionally, there has 
been some disagreement on whether n-3 PUFAs only benefit individuals with deficits in certain 
cognitive domains, with little to no benefit to individuals with healthy cognition. Lastly, pre-
vious meta-analyses have failed to consider the impact of intervention products containing n-6 
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PUFAs along with n-3 PUFAs, making it impossible to differentiate between their separate 
effects on cognitive functioning. 
 
2.1.3 Objectives 
The aim of this meta-analysis was to broaden current knowledge of the effects of n-3 PUFA 
supplementation on domain-specific cognitive test performance in children, adolescents and 
young adults, whose brain maturational processes are still ongoing. We performed separate 
analyses for specific cognitive domains, in order to avoid random selection of study results for 
analysis and hence render our results more interpretable. Further, subgroup analyses aimed to 
examine possible differential effects of EPA-rich and DHA-rich formulations and the effects 
in non-clinical versus clinical populations. To our knowledge, this is the first meta-analysis to 
investigate domain-specific effects on cognitive test performance in youths, specifically ex-
cluding studies with n-6 PUFA and investigating the differential effects of EPA and DHA and 
effects in clinical versus non-clinical populations. Evidence supporting a beneficial effect of n-
3 PUFAs on cognition in youths could establish the recommendation for a natural and easily 
accessible nutritional supplement, without any major side effects. 
 
2.2 Methods 
2.2.1 Criteria for considering studies for meta-analysis 
This systematic review included published randomized controlled trials (RCTs), which inves-
tigated the effect of n-3 PUFAs in children and young adults aging from birth up to 25 years 
of age, as 25 is approximately believed to be the age when most of the brain is fully developed 
(Arain et al., 2013; S. B. Johnson et al., 2009; Sowell et al., 2003; Thompson et al., 2000). 
Studies on both healthy subjects and subjects with psychiatric disorders were included. We 
included all studies with intervention products containing EPA and/or DHA, including fish but 
no other food products (e.g. walnuts). Only studies assessing cognitive domains through stand-
ardized tests were included; all ratings-based studies were excluded. As ratings constitute a 
measure for externally observable dysfunctions in everyday behavior, rather than a measure of 
brain functioning, it seemed imperative to exclude questionnaire studies in order to be able to 
isolate treatment effects on cognitive functioning. Even though this approach might be consid-
ered more conservative, the advantage of an objective measure of cognitive functioning seemed 
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indispensable, as the association between performance measures and rating scales is known to 
be low (e.g. Krieger & Amador-Campos, 2018). Studies including subjects suffering from se-
vere mental dysfunctions, such as intellectual disability, studies in which infants were supple-
mented through maternal intake, and studies supplementing more AA in the experimental com-
pared to the control group (due to inconclusiveness on the source of the effect), were excluded 
from the analysis. Study inclusion parameters disregarded publication year and supplementa-
tion time. 
 
2.2.2 Outcome measures 
The primary outcome of this systematic review was cognitive functioning. However, cognition 
summarizes a set of diverse functions controlled by different (sometimes age-related) neural 
circuits (Samson & Barnes, 2013). Because cognitive functions differ greatly in the brain areas 
and networks involved as well as their role in everyday functioning and are assessed by funda-
mentally different cognitive tests, separating the study results into different cognitive domains 
seemed critical. Also, as there is yet no clear conclusion about potentially select biological 
effects of n-3 PUFAs on specific brain functions and networks, separate analyses for the dif-
ferent cognitive domains seemed even more important. In cases of studies reporting results for 
different cognitive tests, we incorporated all results into separate meta-analyses of the specific 
domains. By doing so, potential selective effects of n-3 PUFAs on different functional networks 
are considered. The separation process is described in further detail in the results section 2.3.1. 
 
2.2.3  Search methods 
An electronic search was conducted by SE and TA individually, which included the following 
online databases: PubMed, Cochrane Library, PsycARTICLES and PsycINFO. Keywords used 
in the search included children, adolescents, omega-3, cognition, and related synonyms. For a 
detailed statement of search (search string) see Appendix A. Other searched resources included 
recent systematic reviews and related articles, along with pertinent studies referenced therein. 




2.2.4 Data collection and analysis 
All deviations between the two individual searches were discussed and agreed upon through 
consensus. Data was managed using RevMan 5.3 (Nordic Cochrane Centre, 2014) and SPSS 
version 25.0. The change mean and standard deviations from individual cognitive tests were 
extracted whenever available. Where change scores were not reported, they were calculated 
using an imputation formula described in the following missing data section. For “develop-
ment”, post-treatment scores were utilized in the meta-analysis, as it was mainly measured and 
reported post-treatment only, and change and final values should not be mixed in a meta-anal-
ysis using standardized mean difference (SMD) as the outcome measure (Deeks, Higgins, & 
Altman, 2006). 
Risk of bias was assessed using the Cochrane risk of bias criteria (Higgins, Altman, & Sterne, 
2006). Here, selection bias, performance bias, detection bias, attrition bias, reporting bias and 
other biases are judged using the levels low, unclear and high risk, based on a set of fixed 
criteria. For a detailed description, see Appendix B. The bias analysis was performed by SE 
and IH independently and all disagreements were agreed upon through consensus. 
For the measure of treatment effect, SMD was used because although included studies all meas-
ured the same cognitive function within one meta-analysis, different tests to assess these func-
tions were used. Effect sizes were categorized as 0.2 representing a small, 0.5 a medium and 
0.8 a large effect size (J. Cohen, 1988). 
For all cross-over trials, results from the first phase, prior to the cross-over occurring, were 
incorporated in this meta-analysis. For all other studies with multiple follow-ups, the assess-
ments conducted directly after supplementation ceased were extracted, in order to minimize 
effect declines. 
For all multi-arms trials, the method of splitting placebo groups into approximately equally-
sized groups was applied, in order to avoid a unit-of-analysis error (Higgins, Deeks, & Altman, 
2006). This is something of a pitfall, because equal means are assumed when using this meth-
ods (Rücker, Cates, & Schwarzer, 2017). One of the major drawbacks to using the method is 
that groups turn out to be correlated. However, the loss of information when combining the 
intervention groups was considered even more problematic. 
All authors who did not report sufficient data (missing change scores, pre- and postscores or 
number of participants per group), were contacted via e-mail and asked to provide the missing 
data until one month after request. We received one reply including the required dataset. All 
other studies had to be excluded from the quantitative analysis. For the few studies reporting 
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only the number of participants for the placebo and intervention group combined, group sizes 
were assumed to be distributed similarly to the full data set reported after attrition. For some 
studies reporting only standard errors, standard deviations were computed using the calculator 
implemented in RevMan 5.3 (Nordic Cochrane Centre, 2014). 
Also, whenever no change scores but only pre- and posttreatment scores were reported, an 
imputation formula was utilized to calculate the missing within-subject change standard devi-
ation 𝑆𝐷𝑐ℎ𝑎𝑛𝑔𝑒  =  𝑆𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒2  +  𝑆𝐷𝑓𝑖𝑛𝑎𝑙 2 −  (2 ×  𝐶𝑜𝑟𝑟 ×  𝑆𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  ×  𝑆𝐷𝑓𝑖𝑛𝑎𝑙) was com-
puted for the experimental and control group separately (Higgins, Deeks, et al., 2006). The 
correlation coefficient used in this equation was derived from the “true” correlation coefficient 
found for the change standard deviations that were reported in some of the included studies. 
Our analysis of these studies resulted in a mean correlation of 0.649, with the lowest correlation 
being 0.419 and the highest being 0.940. Therefore, we used a correlation coefficient of 0.6 in 
the imputation. 
Study heterogeneity for each cognitive function was assessed using the Q statistic (a significant 
statistic indicating heterogeneity) and the percentage of variance due to heterogeneity was eval-
uated with the I2 statistic (Deeks et al., 2006). 
Reporting bias was evaluated using a funnel plot. A symmetrical appearance of this plot would 
indicate the absence of reporting bias. A funnel plot was only generated for cognitive domains, 
with at least ten studies, so that test power would be sufficient and real asymmetry could be 
distinguished from chance (Sterne, Egger, & Moher, 2006). 
We applied a random-effects model (DerSimonian & Laird, 1986) for all cognitive domains 
for the reason that some heterogeneity might be expected because the studies included slightly 
different populations and the protocol, along with the supplements themselves, differed be-
tween the studies. The true effect that was estimated might hence not be identical between the 
studies (Deeks et al., 2006). 
Subgroup analyses were performed considering possible differential effects of EPA and DHA. 
Hence, studies were placed in either the “more EPA” or “more DHA” group, depending on the 
supplementation used. Subgroup analyses were reported for all cognitive domains where at 
least three studies could be placed in either of the two groups. Additionally, subgroup analyses 
were computed for clinical versus non-clinical subjects. Studies were placed in the “non-clini-
cal” group if the participants included were not chosen due to specific health problems that 
were of interest to the investigators. Conversely, studies were placed in the “clinical” group, if 
they investigated the effect of n-3 PUFA in a population with a specific health problem. Again, 
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these analyses were performed for all cognitive domains with at least three studies in either 
group. Furthermore, results from studies supplementing less than 400 mg of daily DHA and 
EPA combined were excluded from the analysis to assess whether a minimum dose is needed 
in order for the supplementation to be effective. We chose a 400 mg cut-off following results 
reported by Bloch and Qawasmi (2011) who found EPA doses from around 400 mg and up to 
be the most effective. Dosage trends were also examined through comparing dose size in rela-
tion to the measured effect, in order to determine whether higher doses are more effective. 
Lastly, we investigated possible moderating variables by correlating them with the effect sizes 
found in each study. 
A sensitivity analysis for the imputation of within-subject change standard deviations was per-
formed using a correlation coefficient of 0.5, in order to assess the robustness of the results. 
The sensitivity analysis yielded a maximum effect size difference of 0.03, which was consid-
ered satisfactory, as most of the cognitive domains either exhibited no variance, or no more 
than 0.01–0.02. Another sensitivity analysis was performed for all studies indicating a substan-
tial amount of heterogeneity (I2 > 50 %) using random-effects model, by individually removing 
every study and checking for substantial effect size and heterogeneity changes. 
It was decided that the best procedure to investigate moderating variables was to look for any 
associations through correlations and then potentially perform further analyses, should any sig-
nificant correlations be identified. We chose to investigate whether the duration of supplemen-
tation or the year of publication might be associated with the effect size of the studies. 
 
2.3 Results 
2.3.1 Description of the studies 
The literature search yielded a total of 1078 records, along with 48 additional records that were 
identified through other sources (cross-referencing other meta-analyses). After exclusion of 
821 articles (see Figure 3), 36 were included in the qualitative analysis. Out of these, 7 had to 
be excluded from the quantitative analysis due to missing data (Birch et al., 2007; Bos et al., 
2015; Brew et al., 2015; Hirayama, Hamazaki, & Terasawa, 2004; Leutgeb, Köchel, Lang, 
Koch, & Schienle, 2015; Milte et al., 2012; Ryan & Nelson, 2008). In the end, 29 studies were 
included in the quantitative analysis (J. Baumgartner et al., 2012; Birch, Garfield, Hoffman, 
Uauy, & Birch, 2000; Carlson & Werkman, 1996; Cornu et al., 2018; Crippa et al., 2019; 
Demmelmair et al., 2019; Handeland et al., 2017; Harbild, Harsløf, Christensen, Kannass, & 
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Lauritzen, 2013; M. Johnson et al., 2017; Karr et al., 2012; Kean et al., 2017; Kennedy et al., 
2009; Kirby et al., 2010; Makrides et al., 2000; McNamara et al., 2010; Meldrum et al., 2012; 
Osendarp et al., 2007; Øyen et al., 2018; Parletta, Cooper, Gent, Petkov, & O’Dea, 2013; 
Portillo-Reyes, Perez-Garcia, Loya-Mendez, & Puente, 2014; Richardson, Burton, Sewell, 
Spreckelsen, & Montgomery, 2012; Richardson & Montgomery, 2005; D. T. Scott et al., 1998; 
Sinn, Bryan, & Wilson, 2008; Vaisman et al., 2008; Van Der Merwe et al., 2013; Voigt et al., 
2001; Werkman & Carlson, 1996; Widenhorn-Müller, Schwanda, Scholz, Spitzer, & Bode, 
2014). For a more detailed description of the inclusion/exclusion process see Figure 3. 
 
Figure 3 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow dia-




A summary of the studies’ characteristics is provided in Table 5. Overall, the 29 studies in-
cluded 4247 participants, ranging in age from birth to 20.43 years. These participants were 
treated with either the intervention product or the control product for four to 48 weeks. 13 
studies used more EPA than DHA in their interventions, and 17 studies used the inverse in their 
interventions. One study created two intervention groups, where one received more DHA and 
the other more EPA. Out of the 29 included studies, 13 assessed executive functions, 11 lan-
guage skills, four intelligence (IQ), nine cognitive development, 10 memory function, five 
problem solving and visuospatial cognition, seven processing speed and nine attention. From 
these, the following eight cognitive domains for the meta-analyses were established: Attention; 
general cognitive ability (IQ); memory (short-term, long-term, recognition); executive func-
tions (working memory, shifting/flexibility, inhibition); cognitive development, language (gen-
eral, reading, spelling); processing speed and problem solving, and visuospatial cognition. A 
detailed list of cognitive functions and related tests are provided in Appendix C. For further 
details on all included studies, refer to Table 6. 
 
Table 5 
Summary of baseline characteristics of included studies 
Characteristics Included studies 
Publication year range 1996 - 2019 
No. of participants 4247 
Age range of means Birth – 20.43 years 
Number of studies with non-clinical / clinical participants1 16 / 14 
EPA dose range per day2. 3 0-720 mg / day 
DHA dose range per day2, 3 0-1200 mg /day 
n-3 PUFA dose range per day (combined)2, 3 94.29 mg – 1200 mg 
Number of studies with more EPA / more DHA1 13 / 17 
Treatment duration range 4 – 48 weeks 
Note. All numbers refer to baseline characteristics.  
1 One study included twice because both apply 
2 Formula supplements were excluded from this statistic 
3 For studies that did not administer the supplement daily, the daily dose was calculated by 
dividing the weekly dose by seven 
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M = 8.82  
SD = 2.27 
 
E: 23%  
C: 6% 
E: 54  
C: 58 
≤ 45 kg: 140.4 
mg EPA, 109.2 
mg DHA  
> 45kg: 187.2 
mg EPA, 145.6 
mg DHA 






14 wk 1: COMPASS Cognitive 
Test Battery  
2: TOVA  
1: word and picture presen-
tation, immediate word re-
call, simple and choice re-
action time, numeric work-
ing memory, delayed word 










ME = 9.3 
SDE = 1.17 
MC = 9.08 
SDC = 0.99 
E: 34% 
C: 24% 
E: 30  
C: 25 
180 mg DHA 
and 270 mg 
EPA 
1.5 : 1 soybean 
oil cap-
sules 
3 mos. 1: WISC-IV 
2: ENI 
3: Letter cancellation 
4: Rey complex figures 
5: Word list  
6: Semantic fluency 
7: Matrix reasoning 
8: Letter–number se-
quencing 
9: Stroop color and word 
test  
10: TMT-A and TMT-B 
 
1: Symbol search and 
Block design 







poor iron and 
n-3 FA status 
 
ME = 8.9  
SDE = 1.3  
MC = 9.1  





420 mg DHA, 
80 mg EPA on 
4d/wk  




8.5 mos. 1: KABC-II   
2: HVLT 
1: Atlantis, Atlantis De-
layed, Hand movement 
test, Triangles test  















Healthy ME1 = 11.11 
SDE1 = 0.79 
ME2 = 10.70 
SDE2 = 0.79 
MC = 10.87 
SDC = 1.01 
E1: 32% 
E2: 50%  
C: 60% 
E1: 28  





1 : 50 Capsules 
with veg-
etable oil 
8 wk 1: Internet Battery  
2: Cognitive 
Drug 
Research Battery (CDR) 
1: Word and Picture 
Presentation, Arrow Reac-
tion Time and Flanker 
Test, Paired Associate 
Learning, Sentence Verifi-
cation, Delayed Word and 
Picture Recognition 
2: Picture Presentation, 
Word Presentation/Imme-
diate word recall, simple 
and choice reaction time, 
spatial and numeric work-
ing memory, delayed word 









ME = 8.8  
SDE = 1.0 
MC = 8.5 
SDC = 1.0 
 
IND: 
ME = 8.1  
SDE = 1.1 
MC = 8.1 














E: 94  
C: 88 
88 mg DHA 










12 mos. Factor scores for several 




Healthy ME = 19.9  
SDE = 1.83  
MC = 20.43  





480 mg DHA, 
720 mg EPA 
1.5 : 1 Coconut 
oil 
4 wk 1: RAVLT  
2: Stroop Color-Word 
Test  
3: TMT-A and B 
1: Memory score after 










E: 138  
C: 149 
at least 250 mg 
DHA and 60 
mg EPA 
 
0.24 : 1 Olive oil 6 mos. Bayley Scales of Infant 
Development III 






          
Birch (2000) 
USA 
Healthy M = 2.1 d  
SD = 1.0 
E: 59% 
C: 55% 










17 wk Bayley Scales of Infant 
Development 2nd edi-
tion 
MDI, cognitive composite 




Healthy ME = 2.6 d  
SDE = 1.9 
MC = 3.2 d 
SDC = 2.5 
E: 40% 
C: 46% 




from fish oil 



















0.35% DHA  











Healthy ME = 5.2  
SDE = 0.6 
MC = 5.2 
SDC = 0.6 
E: 53% 
C: 59% 
E: 105  
C: 113 
3/wk fatty fish, 
approx. 1081 












16 wk WPPSI-III 
 
Total raw score, verbal raw 
score, performance raw 





ADHD ME = 10.2 
SDE = 2.8 
MC = 9.7 
SDC = 2.5 
E: 24% 
C: 19% 
E: 80  
C: 82 
6–8 y: EPA 
336 mg, DHA 
84 mg; 9–11 y: 
EPA 504 mg, 
DHA 126 mg 
12–15 y: EPA 
672 mg and 
DHA 168 mg 
4 : 1 Olive oil 
capsules 
3 mos. 1: Alouette test 
2: KiTAP 








ME = 103.7 
mos. 
SDE = 10.0 
MC = 104.8 
mos. 
SDC = 10.1 
E: 47%  
C: 47% 
E: 180  
C: 182 
600 mg DHA  0 : 1 corn/soy-
bean oil 
16 wk 1: British Ability Scales 
(BAS II) 
1: Word reading achieve-
ment sub-test, Recall of 






Healthy ME = 9.17 
SDE = 0.57 
MC = 9.08 
SDC = 0.56 




DHA 400 mg, 
EPA 56 mg 
0.14 : 1 Olive oil 16 wk 1: WIAT-II 
2: WMTB-C 
3: TEA-Ch 
1: word reading, pseudo 
word reading, spelling 
2: digit recall, block recall, 
backward digit recall 




















































healthy ME1 = 14.6 
SDE1 = 0.3 
ME2 = 14.6 
SDE2 = 0.3 
MC = 14.6 












g DHA (one 
meal is 230g) 
or 7 capsules 
(each 158 mg 
EPA, 105 mg 
DHA, 13 mg 
DPA) (3/week) 
Meal:  












ADHD ME = 8.90 
SDE = 1.48 
MC = 8.92 





600 mg EPA, 
120 mg DHA 
5 : 1 Olive oil 16 wk 1: HAWIK-IV  
2: TAP/KiTAP 
1: Processing speed index 
score, Digit Span Forward, 






healthy ME = 92.3d 
SDE = 4.25 
MC = 93.2d 





200 mg DHA 
and 300 mg 
EPA 
1.5 : 1 Olive oil 6 mos. 1: Willatts’ Infant Plan-
ning Test 
2: Toddler attention as-
sessment 
1: Average total intention 
score 




Healthy boys ME1 = 9.2  
SDE1 = 1.0 
ME2 = 9.5 
SDE2 = 0.7 
MC = 8.8 






400 mg or 
1200 mg DHA 
mg 














ME1 = 9.17 
SDE1 = 1.27 
ME2 = 9.40 
SDE2 = 1.06 
MC = 9.31 









mg EPA, 95 
mg DHA 
FO: 153 mg 




1.64 : 1 
FO 
group: 
1.59 : 1 
rapeseed 
oil 




ADHD ME = 9.1 
SDE = 2.1 
MC = 95 









4 mos. 1: TOVA 
2: Children’s Color 
Trails Test 
1: Errors of omission, er-
rors of commission 
2: A and B 
Harbild 
(2013)  





and 697 mg 
EPA 
1.5 : 1 No sup-
plemen-
tation 





ADHD ME = 9.38  
SDE = 1.89 
MC = 9.47 
SDC = 1.83 
E: 27% 
C: 21% 
E: 37  
C: 28 
EPA 93 mg, 
DHA 29 mg, 
GLA 10 mg 




5: Stroop color-word test 
6: Inspection time 
1: Vocabulary, Block De-
sign, Digit-Symbol Cod-
ing, Digit Span Backward 
and IQ estimate 
2: total recall, delayed re-
call and recognition 
3: Creature Counting 




Healthy 3-13 E: 47% 
C: 46% 
E: 147  
C: 163 
EPA 558 mg, 
DHA 174 mg, 
GLA 60 mg 
per school day 
3.21 : 1 Palm oil 20 school 
weeks 
(crossover 
to fish after 
that) 











558 mg EPA, 
174 mg DHA, 
60 mg GLA 




Logos Test Reading, listening compre-



















M: 105.8 mos. 
SD: 16.3 
33% E: 55 
C: 57 
558 mg EPA, 
174 mg DHA, 
GLA 60 mg 







Reading age, Spelling age 
Crippa 
(2019) ITA 
ADHD ME = 11.06 
SDE = 1.85 
MC = 10.91 





500 mg DHA 0 : 1 Germ oil 6 mos 1: ANT 
2: Battery for the As-
sessment of Develop-
mental Reading and 
Spelling Disorder 
1: baseline speed, focused 
attention 4 letters, shifting 
attentional set – visual, sus-
tained attention 





Healthy MdnE = 4.9 
IQRE = 0.8 
MdnC = 5.0 









0.56 : 1 Meat 16 wk WPPSI-III (HAWIWA-
III) 
FIQ, VIQ, PIQ, PSQ 
Excluded studies due to missing data 
Bos (2015) ADHD ME = 10.3  
SDE = 2.0 
MC = 10.9 









1 : 1 marga-
rine 




Healthy M = 62.2 mos. 





600 mg EPA, 
200 mg DHA 
3 : 1 Waiting 
list 
8 wk WET (Wiener Entwick-
lungstest): 
1: Zahlen merken 
2: Muster legen 




healthy M = 2.1d  
















ily history of 
asthma) 
from the time 
breastfeeding 
ceased or at 6 
mos. 
47% E: 118 
C: 121 
135 mg of 
DHA and 
32 mg of EPA 
per capsule  







Note. Age means and standard deviations are given in years if not otherwise indicated. Where only age ranges are given, means and standard 
deviations were not reported in article. “E” refers to the experimental group and “C” refers to the control group. All characteristics for other 
irrelevant interventions and/or control groups (breast milk, other nutrients etc.) were omitted. GLA refers to gamma linolenic acid, FO = fish 
oil, MDI = mental development index, VIQ = verbal IQ, PIQ = performance IQ, FIQ = full scale IQ.
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Milte (2012) 
AUS 
ADHD ME1 = 8.77 
SDE1 = 1.76 
ME2 = 8.89 
SDE2 = 1.6 
MC = 9.13 





E2: 28  
C: 29 
1109 mg EPA 
and 108 mg 
DHA or 264 
EPA mg and 
1032 mg DHA 
10.27 : 1  
or 







4 mos. 1: TEA-ch 
2: WIAT-III 
3: Go/no-go task 
4: WISC-III 
 
1: Creature Counting, Sky 
Search, Score!, Sky Search 
DT 
2: Reading and Spelling 
subscale 





















2 mos. 1: Memorizing digits 
2: CPT 
1: visual and auditory 
Ryan (2008) 
USA 
Healthy ME = 52.0 
mos. 
SDE = 2.3 
MC = 51.4 
mos. 










4 mos. 1: Leiter-R  
2: PPVT  
3: Stroop Day-Night 
Test  
4: kCPT 
1: Attention Sustained 
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2.3.2 Risk of bias 
According to the Cochrane Risk of Bias Criteria (Appendix A), four studies were rated low 
across all bias risks (Cornu et al., 2018; McNamara et al., 2010; Richardson et al., 2012; Van 
Der Merwe et al., 2013). “Selective reporting” was the criterion most frequently rated un-
clear, whereas “incomplete outcome data” and “blinding of participants and personnel” were 
the criteria most frequently rated high. Appendix D. Fig. 1 provides a more detailed summary 
on the proportion of suspected biases for the included studies. 
 
2.3.3 Main analysis results 
The meta-analyses revealed no main effect of n-3 PUFA supplementation for any of the cog-
nitive domains. The number of studies included in one meta-analysis ranged from three 
(spelling) to 14 (inhibition) and SMDs ranged from −0.07 (95 % CI: −0.25, 0.11) for language 
to 0.13 (95 % CI: −0.05, 0.32) for long-term memory (recall). Most analyses resulted in sat-
isfactory heterogeneity, except for the analyses on problem solving and visuospatial cogni-





Main treatment effect for all cognitive domains. 
Domain n studiesa Effects of intervention Heterogeneity 
  SMD 95% CI p I2 p 
Long-term memory (recall) 6 0.13 -0.05, 0.32 .16 9% 0.65 
Working memory 7 0.12 -0.05, 0.29 .16 33% 0.18 
Shifting/Flexibility 7 0.12 -0.08, 0.32 .25 38% 0.14 
Problem solving and 
visuospatial cognition 
5 0.12 -0.10, 0.34 .27 51% 0.08 
Development 9 0.11 -0.10, 0.23 .08 2% 0.42 
Long-term memory (recog-
nition) 
5 0.11 -0.12, 0.35 .35 22% 0.28 
Processing speed 7 0.09 -0.06, 0.24 .25 0% 0.97 
Short-term memory 12 0.08 -0.02, 0.17 .14 0% 0.92 
Reading 7 0.07 -0.09, 0.23 .40 51% 0.06 
Spelling 3 0.05 -0.12, 0.21 .58 24% 0.27 
Attention 13 0.00 -0.12, 0.12 .98 0% 0.54 
IQ 5 0.00 -0.14, 0.14 .97 0% 0.45 
Inhibition 14 0.00 -0.18, 0.19 .98 37% 0.08 
Language 7 -0.07 -0.25, 0.11 .44 28% 0.21 
aResults for different treatment groups were counted as separate studies 
 
2.3.4 EPA-rich versus DHA-rich formulations 
To address the issue of differential effects of EPA and DHA, a subgroup analysis was per-
formed by categorizing the studies according to whether EPA or DHA content was higher in 
the supplementation product. The subgroup analysis resulted in small effects for the EPA 
group in the cognitive domains of long-term memory (recall) (SMD of 0.25 (95 % CI: −0.08, 
0.58)) (Figure 4), working memory (SMD of 0.36 (95 % CI: 0.09, 0.63)) (Figure 5) and 
problem solving (SMD of 0.21 (95 % CI: −0.21, 0.64)) (Figure 6) with satisfactory hetero-
geneities of I2 = 24 %, p = 0.27 and I2 = 0 %, p = 0.39 for long-term memory (recall) and 
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working memory respectively. The meta-analysis on problem solving however, was signifi-
cantly heterogeneous (I2 = 71 %, p = 0.03). 
 
Figure 4 
Main treatment effect of n-3 PUFA supplementation on long-term memory (recall) and sub-
group analysis for the studies supplementing either more DHA or more EPA. 
 
Note. The horizontal lines represent 95 % CIs, the green square reflects the statistical 
weight of the study, and its position reflects the SMD for the respective study. The dia-
mond data markers represent overall SMD for subgroup analysis and main treatment ef-





Main treatment effect of n-3 PUFA supplementation on working memory and subgroup 
analysis for the studies supplementing either more DHA or more EPA. 
 
Note. The horizontal lines represent 95 % CIs, the green square reflects the statistical 
weight of the study, and its position reflects the SMD for the respective study. The dia-
mond data markers represent overall SMD for subgroup analysis and main treatment ef-





Main treatment effect of n-3 PUFA supplementation on problem solving and visuospatial 
cognition and subgroup analysis for the studies supplementing either more DHA or more 
EPA. 
 
Note. The horizontal lines represent 95 % CIs, the green square reflects the statistical 
weight of the study, and its position reflects the SMD for the respective study. The dia-
mond data markers represent overall SMD for subgroup analysis and main treatment ef-
fect and 95 % CI’s. SMD is standardized mean difference, CI is confidence interval. 
 
2.3.5 Clinical versus non-clinical populations 
Another subgroup analysis was performed for studies with non-clinical participants com-
pared to studies including participants possessing a cognitive deficit or another general health 
problem. Conversely, small effects were found for the clinical subgroup in the domains of 
working memory (SMD of 0.23 (95 % CI: 0.02, 0.45)) (Figure 7), shifting and flexibility 
(SMD of 0.22 (95 % CI: −0.04, 0.48)) (Figure 8), and problem solving and visuospatial cog-
nition (SMD of 0.22 (95 % CI: −0.22, 0.65)) (Figure 9). The analyses on working memory 
and shifting and flexibility were acceptably heterogeneous (I2 = 28 %, p = 0.24, I2 = 36 %, p 
= 0.18), whereas the analysis on problem solving and visuospatial cognition resulted in a 
significant percentage of heterogeneity (I2 = 71 %, p = 0.03). Surprisingly, the analysis re-
sulted in a small effect for the non-clinical subgroup in the domain of long-term memory 
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(recall) (SMD of 0.22 (95 % CI: −0.15, 0.58)) (Figure 10) with satisfactory heterogeneity (I2 
= 0 %, p = 0.42). 
 
Figure 7 
Main treatment effect of n-3 PUFA supplementation on working memory and subgroup 
analysis for studies supplementing either non-clinical or clinical study populations. 
 
Note. The horizontal lines represent 95 % CIs, the green square reflects the statistical 
weight of the study, and its position reflects the SMD for the respective study. The dia-
mond data markers represent overall SMD for subgroup analysis and main treatment ef-





Main treatment effect of n-3 PUFA supplementation on shifting and flexibility and sub-
group analysis for studies supplementing either non-clinical or clinical study populations. 
 
Note. The horizontal lines represent 95 % CIs, the green square reflects the statistical 
weight of the study, and its position reflects the SMD for the respective study. The dia-
mond data markers represent overall SMD for subgroup analysis and main treatment ef-





Main treatment effect of n-3 PUFA supplementation on problem solving and visuospatial 
cognition and subgroup analysis for studies supplementing either non-clinical or clinical 
study populations. 
 
Note. The horizontal lines represent 95 % CIs, the green square reflects the statistical 
weight of the study, and its position reflects the SMD for the respective study. The dia-
mond data markers represent overall SMD for subgroup analysis and main treatment ef-





Main treatment effect of n-3 PUFA supplementation on long-term memory (recall) and sub-
group analysis for studies supplementing either non-clinical or clinical study populations. 
 
Note. The horizontal lines represent 95 % CIs, the green square reflects the statistical 
weight of the study, and its position reflects the SMD for the respective study. The dia-
mond data markers represent overall SMD for subgroup analysis and main treatment ef-
fect and 95 % CI’s. SMD is standardized mean difference, CI is confidence interval. 
 
2.3.6 Dose effects 
Post exclusion of studies with a daily dose smaller than 400 mg (EPA and DHA combined), 
the analysis now revealed a small effect size in the domains of both recall and recognition 
long-term memory with satisfactory heterogeneity (recognition: SMD of 0.24 (95 % CI: 
−0.12, 0.59), I2 = 0 %, p = 0.40, recall: SMD of 0.27 (95 % CI: −0.04, 0.58), I2 = 0 %, p = 
0.56)). Owing to this evidence supporting a dose effect, possible dose trends were further 
investigated. In order to do so, dose trends for the cognitive domains most frequently occur-
ring across the included studies (short-term memory, attention and inhibition), were visual-
ized. EPA and DHA doses were plotted, along with the effect sizes for each of the respective 
studies. As presented in Appendix D. Fig. 2, Appendix D. Fig. 3 and Appendix D. Fig. 4, no 
evident dose size trends presented. Furthermore, we performed a correlation analysis for 
EPA, DHA and n-3 PUFA daily dose with the mean effect size found for each study. Because 
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the data was not normally distributed, we performed a Spearman’s rank correlation. The anal-
ysis yielded no significant correlation for neither of the daily dose sizes (rs = 0.322, p = .089, 
rs = 0.030, p = .878, rs = 0.281, p = .140). 
 
2.3.7 Further analysis of an effect on general cognitive functioning 
Although splitting the results into different cognitive domains proved crucial in order to avoid 
random selection of study results, computing an analysis for general cognitive improvement 
according to all included studies and domains seemed important. We hence performed a sec-
ondary analysis using the best effect reported by each study (Appendix D. Fig. 5). No main 
effect and no effect in the “more DHA” group presented. However, we again found a small 
effect for the analysis of the group where more EPA rather than DHA was administered. A 
detailed overview of the domains and tests included in this analysis and the corresponding 
SMDs is given in Appendix D. Table 1. Although, for methodological reasons, these results 
should be interpreted with caution, they support the previously reported differential effects 
of EPA and DHA, as the analysis might be considered “the largest possible” effect of the two 
substances. 
 
2.3.8 Sensitivity analysis and asymmetry evaluation 
Substantial heterogeneity (>50 %) for main treatment effects was only found for the cognitive 
domains of problem solving and visuospatial cognition and reading. In order to identify the 
driver of this heterogeneity, a sensitivity analysis was performed using a random effects 
model. Heterogeneity dropped from I2 = 51 %, p = 0.08 to I2 = 0 %, p = 0.62, when data 
from  Portillo-Reyes et al. (2014) was removed from the analysis for problem solving and 
visuospatial cognition. Also, the SMD dropped from 0.12 (95 % CI: −0.10, 0.34) to 0.04 (95 
% CI: −0.11, 0.19), with only four studies left in the meta-analysis. For the domain reading, 
heterogeneity dropped from I2 = 51 %, p = 0.06 to I2 = 17 %, p = 0.30, when data from  Crippa 
et al. (2019) was removed. The SMD rose from 0.07 (95 % CI: −0.09, 0.23) to 0.09 (95 % 
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CI: 0.03, 0.21). We were able to confirm that the specific study data contributed to a signifi-
cant amount to the heterogeneity in this analysis. However, analysis on the amended datasets 
did not alter the conclusion about the lack of effect found for these domains. 
Asymmetry was assessed using a funnel plot for all domains with more than ten study results 
in order to look for small study effects. The funnel plot for the domain short-term memory 
(Appendix D. Fig. 6) and attention (Appendix D. Fig. 7) suggest symmetry, hence providing 
no evidence for small study effects. The funnel plot for inhibition (Appendix D. Fig. 8) how-
ever, seems to suggest some asymmetry. Altogether, the results indicate that biases should 
be considered when interpreting the results of this meta-analysis. 
 
2.3.9 Moderating variables 
In order to investigate possible moderating variables, we tested for significant correlations 
between year of publication (M = 2009.79, SD = 6.447), duration of supplementation (M = 
19.06 weeks, SD = 12.70) and the mean SMD reported for each study over all cognitive 
domains. As both Shapiro-Wilk and Kolmogorov-Smirnov test confirmed that normal distri-
bution of the data could not be assumed, we performed Spearman’s rank correlations. Neither 
supplementation duration nor year of publication were significantly correlated with mean 
effect size per study (rs = −0.251, p = .153, rs = −0.144, p = .416). 
 
2.4 Discussion 
In the field of cognitive research, nutrition has been generating considerable interest in terms 
of its effect on cognitive functioning. Within nutrition research, a growing body of literature 
has examined possible effects of n-3 PUFA supplementation on cognitive functioning, pre-
dominantly due to their key role in the maturation of the brain during gestation (Innis, 2008; 
Koletzko et al., 2008). As a result of the biological properties of n-3 PUFAs, including their 
key roles for anti-inflammatory and pro-resolving mediators (Bazinet & Layé, 2014), their 
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modulatory role in brain development and synaptic plasticity (Layé et al., 2018), their ability 
to change membrane fluidity (Dyall, 2015) and neurotransmission (Weiser et al., 2016), the 
role of n-3 PUFAs in promoting cognitive functioning has received considerable critical at-
tention (Luchtman & Song, 2013; Moriguchi, Greiner, & Salem, 2000). Several meta-anal-
yses have attempted to reach a conclusion regarding the cognitive effects of n-3 PUFAs 
(Abubakari et al., 2014; Bloch & Qawasmi, 2011; Chang et al., 2018; Cooper et al., 2015; 
Jiao et al., 2014; Mazereeuw et al., 2012), resulting in considerable disagreement. A key 
problem with much of the literature are the considerable differences between the subjects and 
intervention products included in the analyses. The aim of the present meta-analysis was to 
reach a more specific conclusion by addressing shortcomings of previous meta-analyses. 
More specifically, we excluded studies that administered more AA in the intervention com-
pared to the control group. We also investigated potential differential effects of EPA and 
DHA on various cognitive domains in children, adolescents and young adults. In addition, 
we conducted subgroup analyses to determine whether dose size, the cognitive domain tested 
or the degree of health of study participants (clinical vs. non-clinical) would yield variable 
results. 
 
2.4.1 Summary of main results 
Our analysis combining studies with EPA-rich and DHA-rich n-3 PUFA formulations re-
vealed no main effect of n-3 PUFA supplementation on any cognitive domain. Our subgroup-
analysis investigating differential effects of EPA and DHA, identified beneficial effects for 
EPA-rich formulations in the domains of long-term memory (recall), working memory and 
problem solving, with high heterogeneity for the latter. However, the computed effects of the 
meta-analytic data were rather small. DHA-rich formulations had no superior effect over 
EPA-rich formulations in any cognitive domain. In working memory, shifting and flexibility, 
and problem solving, clinical populations rather than non-clinical populations benefitted 
from the intervention, indicating a greater effectiveness of the intervention. Non-clinical par-
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ticipants benefitted more than clinical participants in the domain of long-term memory (re-
call). Removing all data from low dose studies resulted in small effects for long term 
memory. We were not able to confirm any general dosage effect or trend. Also, no significant 
correlations were found for daily dose and mean effect size. While including only the results 
for the domain that yielded the best treatment effects from each study resulted in small but 
beneficial treatment effects for the EPA group, neither effects for DHA-rich formulations, 
nor for the combined analysis of EPA- and DHA-rich formulations were observed. This fur-
ther confirmed our previously described domain-specific results, that indicated a tendency 
towards a treatment effect of EPA-rich but not DHA-rich formulations. When investigating 
moderating variables, we found that neither treatment duration nor year of publication were 
correlated with mean effect size. The sensitivity analysis illustrated that the results reported 
by Portillo-Reyes et al. (2014) contributed significantly to the heterogeneity found in the 
analysis on problem solving, and the results reported by Crippa et al. (2019) contributed to 
the heterogeneity in the domain of reading. However, removing the data from the analysis 
did not change the conclusion about the lack of a main effect. 
 
2.4.2 Completeness of evidence 
A major strength of the current study lies in the broad body of literature that was systemati-
cally reviewed with a comprehensive and replicable search strategy. As we encountered only 
very few disagreements between the two individual literature searches performed and be-
cause the studies identified in our study are in line with the ones identified in other meta-
analyses, bias in terms of studies that were not identified seems unlikely. However, the ex-
clusion of seven studies due to missing data constitutes a serious drawback. 
The protocol heterogeneity observed in studies on n-3 PUFAs and cognition seems to be a 
key problem with much of the literature on this subject. Because the studies used very differ-
ent study protocols with large differences in dosage, intervention duration, cognitive tests 
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and age of participants, finding a consensus on overall treatment effects on cognitive func-
tioning proves challenging. The heterogeneity of study protocols could have a great impact 
on the statistical evaluation of the treatment effect. However, we succeeded in minimizing 
this problem by including only test results obtained with standardized cognitive tests rather 
than questionnaires and most importantly, by clearly separating the results into different cog-
nitive domains to be able to report specific treatment effects. The separation of results into 
different cognitive domains constitutes a major advantage of this meta-analysis, as it rendered 
the results interpretable, avoiding the mixture and/or random selection of study results from 
different cognitive functions. This resulted in a more complete overview of selective effects 
on different domains, hence also providing results for potentially selective effects in different 
brain areas. Even more, we were also able to report specific results for clinical and non-
clinical youths as well as account for the different PUFA formulations used throughout the 
different trials (DHA-rich versus EPA-rich formulations). However, this meta-analysis in-
vestigated the cognitive effects of n-3 PUFA supplementation in youths only and the conclu-
sions drawn are hence limited to this specific age group. Although we reported results for 
clinical and non-clinical populations separately, study populations were still quite heteroge-
neous. The tendency towards an effect in the clinical group adverts to the possibility that 
supplementation effects on cognition might only be expected in individuals with poor nutri-
tional status or poorer cognitive functioning, as suggested by Chang et al. (2019). Future 
studies should investigate to what degree nutritional status and baseline cognitive perfor-
mance contribute to supplementation effects in all study populations investigated. 
Based on our findings, we believe that studies investigating cognitive effects of n-3 PUFAs 
should not pool EPA-rich and DHA-rich formulations in the same meta-analysis. The present 
meta-analysis provides the framework for further investigations on differential effects of 




2.4.3 Quality of evidence 
All studies included were RCTs with significant methodological quality. We have obtained 
comprehensive results by selecting only those RCTs that did not administer AA in order to 
separate n-3 from n-6 PUFA supplementation effects. By including a selective study popula-
tion, we were able to accurately report treatment effects while brain maturation is still ongo-
ing. We succeeded in eliminating any pre-existing group differences, using change scores 
instead of only post-treatment scores for most cognitive domains. We also successfully per-
formed a sensitivity analysis, identifying two studies that had great impact on heterogeneity 
and the associated effects sizes. Additionally, we were able to rule out moderating effects by 
year of publication and treatment duration by confirming no correlation between these factors 
and the mean effect sizes. 
However, a number of potential shortcomings need to be considered. Although this meta-
analysis included 29 studies with 4247 participants, it was limited by the few studies that 
reported results for a specific cognitive domain, especially in the subgroup analyses. This 
resulted in statistically sensitive results, highly subject to change should further studies be 
added. This limitation was confirmed by the finding of one study contributing significantly 
to the heterogeneity and effect size of one specific cognitive domain. Also, the large confi-
dence intervals supported the conclusion of highly sensitive results. 
Furthermore, our risk of bias analysis revealed some considerable flaws in study designs. 
These could potentially have influenced study results and hence also the results found in this 
meta-analysis. Risk of bias was nevertheless considered moderate. 
Another pitfall lies in the nature of the subgroup analysis performed. Although we established 
groups where more EPA rather than DHA and vice versa were administered, results gener-
ated by this analysis only provide information about the efficacy differences of formulations 
with different EPA/DHA ratios. Formulations in one group might hence supplement more 
DHA than EPA and be placed in the DHA group, but still supplement a larger dose of EPA 
than another study placed in the EPA analysis. 
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A general limitation lies in the fact that putative moderating variables such as pre- and post-
treatment n-3 PUFA blood plasma concentrations were frequently not considered in the in-
cluded studies or only post hoc and hence could not be included in the meta-analysis. Alt-
hough participants were randomly allocated to either treatment or control group, it remains 
unclear whether baseline PUFA levels and compliance might have influenced our study re-
sults. Further experimental investigation should therefore determine the effect of pre-treat-
ment levels of n-3 PUFAs, similarly to trials that have investigated how these predict depres-
sion outcomes (Carney et al., 2016). Future studies on the current topic should also evaluate 
possible interactions with other substances and nutrients such as anti-oxidant vitamins 
(Assmann, Adjibade, Hercberg, Galan, & Kesse-Guyot, 2018) and B vitamins (Jernerén et 
al., 2019), blood plasma concentration of n-3 PUFAs or more specifically the ApoEε4 allele, 
as suggested by studies on cognitive decline (Samieri et al., 2011). A related and serious 
limitation is still the lack of understanding about the actual absorption and utilization of sup-
plemented n-3 PUFAs as well as the influence of the microbiome on PUFA metabolism. 
Although blood serum levels are a useful measure for intake compliance, it is yet very poorly 
understood to what extent grey matter or white matter levels change following serum aug-
mentation. It seems to be of great importance, whether the current nutritional status might 
further influence uptake and utilization of n-3 PUFAs in the human body. More specific stud-
ies on n-3 PUFA absorption and moderating factors hence would be invaluable. 
 
2.4.4 Agreements and disagreements with other meta-analyses 
In contrast to the meta-analysis conducted by Jiao et al. (2014) we were not able to replicate 
an overall beneficial effect of n-3 PUFA on cognitive development. This discrepancy may be 
related to the fact that Jiao et al. (2014) only included studies on the mental development 
index (MDI). Also, three out of six of their study results within this domain originated from 




Like Cooper et al. (2015) we failed to reveal a main beneficial effect of n-3 PUFA supple-
mentation. Conversely, in line with meta-analyses on depression (Grosso, Pajak, et al., 2014; 
Hallahan et al., 2016; Liao et al., 2019; Mocking et al., 2016; Sublette, Ellis, et al., 2011), we 
were able to establish a tendency towards stronger effects of EPA-rich over DHA-rich for-
mulations and stronger effects for clinical than non-clinical populations. These findings are 
also in line with the results reported by  Bloch and Qawasmi (2011) who found moderate 
effects of n-3 PUFA supplementation on ADHD symptoms especially with higher doses of 
EPA. 
 
2.5  Author’s conclusions 
Our meta-analysis of pooled EPA- and DHA-rich n-3 PUFA supplementation was not able 
to demonstrate an overall effect of n-3 PUFA supplementation on domain-specific cognitive 
test performance in youths. However, some cognitive domains, in particular long-term 
memory (recall), working memory and problem solving may benefit from EPA-rich n-3 
PUFA formulations. In contrast to EPA-rich formulations, no beneficial effect of DHA-rich 
formulations could be found, even when only best study effects were considered. We believe 
that our meta-analysis provides support that it is not justified to combine EPA-rich and DHA-
rich formulations in the same meta-analysis. It may in fact well be, that combining the two 
formulations masks the beneficial neuropsychological effects of EPA-rich formulations. 
Nevertheless, to this date, we cannot make clear recommendations about the use of n-3 
PUFAs for cognitive enhancement or treatment of cognitive deficits. 
Further research should investigate the effects of EPA-rich and DHA-rich n-3 PUFA supple-
mentation separately in order to be able to draw conclusions about differential effects. Most 
importantly, moderating effects of obesity, inflammatory status, other nutritional compo-
nents, pre- and post- blood levels of n-3, n-6 and n-9 PUFAs and their interactions with gene 




2.6 Appendix – Supplementary material 
Appendix A. 
Search string: (child OR adolescent OR infant) AND (omega-3 OR PUFA OR EPA OR 
DHA OR n-3 fatty acid) AND (cognition OR cognitive function OR memory OR attention 





Risk of bias criteria 
RANDOM SEQUENCE GENERATION 
Selection bias (biased allocation to interventions) due to inadequate generation of a 
randomised sequence. 
Criteria for a judgement of ‘Low risk’ of 
bias. 
The investigators describe a random com-
ponent in the sequence generation process 
such as: 
- Referring to a random number ta-
ble; 
- Using a computer random number 
generator; 
- Coin tossing; 
- Shuffling cards or envelopes; 
- Throwing dice; 
- Drawing of lots; 
- Minimization*. 
 *Minimization may be implemented with-
out a random element, and this is consid-
ered to be equivalent to being random. 
Criteria for the judgement of ‘High risk’ of 
bias. 
The investigators describe a non-random 
component in the sequence generation pro-
cess. Usually, the description would in-
volve some systematic, non-random ap-
proach, for example: 
- Sequence generated by odd or even 
date of birth; 
- Sequence generated by some rule 
based on date (or day) of admission; 
- Sequence generated by some rule 
based on hospital or clinic record 
number. 
Other non-random approaches happen 
much less frequently than the systematic 
approaches mentioned above and tend to be 
obvious.  They usually involve judgement 
or some method of non-random categoriza-
tion of participants, for example: 




- Allocation by preference of the par-
ticipant; 
- Allocation based on the results of a 
laboratory test or a series of tests; 
- Allocation by availability of the in-
tervention. 
Criteria for the judgement of ‘Unclear risk’ 
of bias. 
Insufficient information about the sequence 
generation process to permit judgement of 
‘Low risk’ or ‘High risk’. 
ALLOCATION CONCEALMENT  
Selection bias (biased allocation to interventions) due to inadequate concealment of 
allocations prior to assignment. 
Criteria for a judgement of ‘Low risk’ of 
bias. 
Participants and investigators enrolling par-
ticipants could not foresee assignment be-
cause one of the following, or an equivalent 
method, was used to conceal allocation: 
- Central allocation (including tele-
phone, web-based and pharmacy-
controlled randomization); 
- Sequentially numbered drug con-
tainers of identical appearance; 
- Sequentially numbered, opaque, 
sealed envelopes. 
Criteria for the judgement of ‘High risk’ of 
bias. 
 
Participants or investigators enrolling par-
ticipants could possibly foresee assign-
ments and thus introduce selection bias, 
such as allocation based on: 
- Using an open random allocation 
schedule (e.g. a list of random num-
bers); 
- Assignment envelopes were used 
without appropriate safeguards (e.g. 
if envelopes were unsealed or 
non-opaque or not sequentially 
numbered); 
- Alternation or rotation; 
- Date of birth; 
- Case record number; 
- Any other explicitly unconcealed 
procedure. 
Criteria for the judgement of ‘Unclear risk’ 
of bias. 
Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’. This is 
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usually the case if the method of conceal-
ment is not described or not described in 
sufficient detail to allow a definite judge-
ment – for example if the use of assignment 
envelopes is described, but it remains un-
clear whether envelopes were sequentially 
numbered, opaque and sealed. 
BLINDING OF PARTICIPANTS AND PERSONNEL 
Performance bias due to knowledge of the allocated interventions by participants 
and personnel during the study. 
Criteria for a judgement of ‘Low risk’ of 
bias. 
Any one of the following: 
- No blinding or incomplete blinding, 
but the review authors judge that 
the outcome is not likely to be in-
fluenced by lack of blinding; 
- Blinding of participants and key 
study personnel ensured, and un-
likely that the blinding could have 
been broken. 
Criteria for the judgement of ‘High risk’ of 
bias. 
Any one of the following: 
- No blinding or incomplete blinding, 
and the outcome is likely to be in-
fluenced by lack of blinding; 
- Blinding of key study participants 
and personnel attempted, but likely 
that the blinding could have been 
broken, and the outcome is likely to 
be influenced by lack of blinding. 
Criteria for the judgement of ‘Unclear risk’ 
of bias. 
Any one of the following: 
- Insufficient information to permit 
judgement of ‘Low risk’ or ‘High 
risk’; 
- The study did not address this out-
come. 
BLINDING OF OUTCOME ASSESSMENT 
Detection bias due to knowledge of the allocated interventions by outcome assessors. 
Criteria for a judgement of ‘Low risk’ of 
bias. 
Any one of the following: 
- No blinding of outcome assessment, 
but the review authors judge that 
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the outcome measurement is not 
likely to be influenced by lack of 
blinding; 
- Blinding of outcome assessment en-
sured, and unlikely that the blinding 
could have been broken. 
 
Criteria for the judgement of ‘High risk’ of 
bias. 
Any one of the following: 
- No blinding of outcome assessment, 
and the outcome measurement is 
likely to be influenced by lack of 
blinding; 
- Blinding of outcome assessment, 
but likely that the blinding could 
have been broken, and the outcome 
measurement is likely to be influ-
enced by lack of blinding. 
Criteria for the judgement of  ‘Unclear 
risk’ of bias. 
- Insufficient information to permit 
judgement of ‘Low risk’ or ‘High 
risk’; 
- The study did not address this out-
come. 
INCOMPLETE OUTCOME DATA  
Attrition bias due to amount, nature or handling of incomplete outcome data. 
Criteria for a judgement of ‘Low risk’ of 
bias. 
Any one of the following: 
- No missing outcome data; 
- Reasons for missing outcome data 
unlikely to be related to true out-
come (for survival data, censoring 
unlikely to be introducing bias); 
- Missing outcome data balanced in 
numbers across intervention groups, 
with similar reasons for missing 
data across groups; 
- For dichotomous outcome data, the 
proportion of missing outcomes 
compared with observed event risk 
not enough to have a clinically rele-
vant impact on the intervention ef-
fect estimate; 
- For continuous outcome data, plau-
sible effect size (difference in 
means or standardized difference in 
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means) among missing outcomes 
not enough to have a clinically rele-
vant impact on observed effect size; 
- Missing data have been imputed us-
ing appropriate methods. 
Criteria for the judgement of ‘High risk’ of 
bias. 
Any one of the following: 
- Reason for missing outcome data 
likely to be related to true outcome, 
with either imbalance in numbers or 
reasons for missing data across in-
tervention groups; 
- For dichotomous outcome data, the 
proportion of missing outcomes 
compared with observed event risk 
enough to induce clinically relevant 
bias in intervention effect estimate; 
- For continuous outcome data, plau-
sible effect size (difference in 
means or standardized difference in 
means) among missing outcomes 
enough to induce clinically relevant 
bias in observed effect size; 
- ‘As-treated’ analysis done with sub-
stantial departure of the intervention 
received from that assigned at ran-
domization; 
- Potentially inappropriate applica-
tion of simple imputation. 
Criteria for the judgement of ‘Unclear risk’ 
of bias. 
Any one of the following: 
- Insufficient reporting of attrition/ex-
clusions to permit judgement of 
‘Low risk’ or ‘High risk’ (e.g. num-
ber randomized not stated, no rea-
sons for missing data provided); 
- The study did not address this out-
come. 
SELECTIVE REPORTING  
Reporting bias due to selective outcome reporting. 
Criteria for a judgement of ‘Low risk’ of 
bias. 
Any of the following: 
- The study protocol is available and 
all of the study’s pre-specified (pri-
mary and secondary) outcomes that 
are of interest in the review have 
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been reported in the pre-specified 
way; 
- The study protocol is not available, 
but it is clear that the published re-
ports include all expected outcomes, 
including those that were pre-speci-
fied (convincing text of this nature 
may be uncommon). 
Criteria for the judgement of ‘High risk’ of 
bias. 
Any one of the following: 
- Not all of the study’s pre-specified 
primary outcomes have been re-
ported; 
- One or more primary outcomes is 
reported using measurements, anal-
ysis methods or subsets of the data 
(e.g. subscales) that were not pre-
specified; 
- One or more reported primary out-
comes were not pre-specified (un-
less clear justification for their re-
porting is provided, such as an un-
expected adverse effect); 
- One or more outcomes of interest in 
the review are reported incom-
pletely so that they cannot be en-
tered in a meta-analysis; 
- The study report fails to include re-
sults for a key outcome that would 
be expected to have been reported 
for such a study. 
Criteria for the judgement of ‘Unclear risk’ 
of bias. 
Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’. It is 
likely that the majority of studies will fall 
into this category. 
OTHER BIAS  
Bias due to problems not covered elsewhere in the table. 
Criteria for a judgement of ‘Low risk’ of 
bias. 
The study appears to be free of other 
sources of bias. 
Criteria for the judgement of ‘High risk’ of 
bias. 
There is at least one important risk of bias. 
For example, the study: 
- Had a potential source of bias re-




- Has been claimed to have been 
fraudulent; or 
- Had some other problem. 
Criteria for the judgement of ‘Unclear risk’ 
of bias. 
There may be a risk of bias, but there is ei-
ther: 
- Insufficient information to assess 
whether an important risk of bias 
exists; or 
- Insufficient rationale or evidence 
that an identified problem will in-
troduce bias. 
Note. Adapted from the Cochrane Collaboration Risk of Bias Tool. See Higgings & 





Cognitive tests and domains included in quantitative analysis 
 
IQ: 
- WISC-III (Osendarp et al., 2007; Sinn et al., 2008) 
- WPPSI-III: Total raw score (Demmelmair et al., 2019; Øyen et al., 2018) 
Attention: 
- KiTAP/TAP: Distractibility: Omission errors (Cornu et al., 2018) 
- D2 test of attention: TN-E total performance (Handeland et al., 2017) 
- Visual attention factor score (Osendarp et al., 2007) 
- Letter cancellation (Portillo-Reyes et al., 2014) 
- TOVA: omission errors (Vaisman et al., 2008; Voigt et al., 2001),  (Kean et al., 
2017) (non-diagnosed subsample, target infrequent, QTR 1)) 
- Cognitive Drug Research Battery (CDR): Digit Vigilance: Accuracy (%) (Kennedy 
et al., 2009) 
- ANT: focused attention 4 letters – misses (Crippa et al., 2019) 
Executive Functions: 
Shifting/Flexibility: 
- KiTAP/TAP: Flexibility: errors (Cornu et al., 2018) 
- TMT-B: completion time: (Karr et al., 2012; Portillo-Reyes et al., 2014) 
- TEA-ch: Creature Counting: Trials correct (Sinn et al., 2008), Trials correct age-
scaled (Kirby et al., 2010) 
- Children’s Color Trails Test 2 (Voigt et al., 2001) 
- ANT: shifting attentional set – visual: number of errors flexibility (Crippa et al., 
2019) 
Inhibition: 
- KiTAP/TAP: Go/No-go: commission errors (Cornu et al., 2018) 
- Stroop Color and Word Test: Interference T-score (Karr et al., 2012), Color-word 
score (Portillo-Reyes et al., 2014), Stroop score (Sinn et al., 2008) 
- Matching Familiar Figures Task (MFFT): number of errors (Kirby et al., 2010) 
- CPT-IP: commission errors (McNamara et al., 2010) 
- TOVA: commission errors (Kean et al., 2017; Vaisman et al., 2008; Voigt et al., 
2001) 
- Internet Battery: Arrow Flanker Test : % error (Kennedy et al., 2009) 
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- ANT: shifting attentional set – visual: number of errors inhibition (Crippa et al., 
2019) 
Working Memory: 
- Working Memory Test Battery for Children (WMTB-C): Backward digit recall 
(Kirby et al., 2010) 
- WISC-IV: Letter-number sequencing (Portillo-Reyes et al., 2014) 
- British Ability Scales: Recall of digits backwards (Richardson et al., 2012) 
- WISC-III: Digit backwards (Sinn et al., 2008) 
- Cognitive Drug Research Battery: Numeric Working Memory: Accuracy (% > 
chance) (Kennedy et al., 2009) 
- HAWIK-IV: Digits backwards (Widenhorn-Müller et al., 2014) 
Memory 
Short-Term Memory (recall): 
- HVLT: recall (J. Baumgartner et al., 2012) 
- WISC-III: Digit forward (Sinn et al., 2008) 
- RAVLT: Total recall (Karr et al., 2012) 
- Working Memory Test Battery for Children (WMTB-C): Forward digit recall 
(Kirby et al., 2010) 
- Verbal learning factor score (Osendarp et al., 2007) 
- ENI: verbal immediate recall (Portillo-Reyes et al., 2014) 
- British Ability Scales: Recall of Digits Forward (Richardson et al., 2012) 
- Cognitive Drug Research Battery (CDR): Immediate word recall (% correct), post-
breakfast (Kennedy et al., 2009) 
- HAWIK-IV: Digit forward (Widenhorn-Müller et al., 2014) 
- Logos Test: Verbal short-term memory (M. Johnson et al., 2017) 
Long-Term Memory (recall): 
- KABC-II: Atlantis delayed (J. Baumgartner et al., 2012) 
- RAVLT: Delayed recall (Karr et al., 2012; Sinn et al., 2008) 
- ENI: Free recall (Portillo-Reyes et al., 2014) 
- Cognitive Drug Research Battery (CDR): Delayed word recall accuracy: % correct 
(Kennedy et al., 2009) 
Long-Term Memory (recognition): 
- HVLT: Delayed recognition (J. Baumgartner et al., 2012) 
- ENI: Verbal recognition (Portillo-Reyes et al., 2014) 
- RAVLT: Recognition (Sinn et al., 2008) 
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- Internet Battery: Delayed word recognition (% error), post-breakfast (Kennedy et 
al., 2009) 
Processing speed: 
- TMT-A: completion time (Karr et al., 2012; Portillo-Reyes et al., 2014) 
- WISC-III: Digit- Symbol Coding (Sinn et al., 2008) 
- Children’s Color Trails Test 1 (Voigt et al., 2001) 
- WPPSI-III: Processing speed raw score (Demmelmair et al., 2019; Øyen et al., 
2018) 
- ANT: baseline speed (Crippa et al., 2019) 
Problem solving and visuospatial cognition: 
- KABC-II: Triangles test (J. Baumgartner et al., 2012) 
- WISC-IV: Block design (Portillo-Reyes et al., 2014) 
- WAIS-III/WISC-III: Block design (Sinn et al., 2008) 
- WPPSI-III: Performance (PIQ) raw score (Demmelmair et al., 2019; Øyen et al., 
2018) 
Language 
General language skills: 
- ENI: Comprehension instruction (Portillo-Reyes et al., 2014) 
- WISC-III: vocabulary subscale (Sinn et al., 2008) 
- WPPSI-III: Verbal raw score (VIQ) (Demmelmair et al., 2019; Øyen et al., 2018) 
- Internet Battery: Sentence verification: % error (Kennedy et al., 2009) 
- Logos Test: Vocabulary (number correct) (M. Johnson et al., 2017) 
Reading: 
- L’Alouette Test (Cornu et al., 2018) 
- WIAT-II Word reading subscale (Kirby et al., 2010) 
- WRAT4: Standardized reading score (Parletta et al., 2013) 
- NAPLAN: Reading score (Brew et al., 2015) 
- Logos Test: Reading comprehension (M. Johnson et al., 2017) 
- Wechsler Objective Reading Dimensions (WORD): reading age (Richardson & 
Montgomery, 2005) 
- Battery for the Assessment of Developmental Reading and Spelling Disorders: read-
ing accuracy (Crippa et al., 2019) 
Spelling: 
- WIAT-II: spelling subscale (Richardson & Montgomery, 2005) 
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- WRAT4: Standardized spelling score (Parletta et al., 2013) 
- Wechsler Objective Reading Dimensions (WORD): spelling age (Richardson & 
Montgomery, 2005) 
Development: 
- Bayley Scales of Infant Development, 2nd edition: MDI (Birch et al., 2000) 
- Bayley Scales of Infant and Toddler Development (3rd edition; BSID-III): Cogni-
tive standard score (Meldrum et al., 2012) 
- Draw-A-Person (Parletta et al., 2013) 
- Bayley Scales of Infant Development: MDI (Makrides et al., 2000; D. T. Scott et 
al., 1998) 
- Willatts’ Infant Planning Test: Average total intention score (Van Der Merwe et al., 
2013) 
- Fagan Test of Infant Intelligence: Novelty preference (%) (Carlson & Werkman, 
1996; Werkman & Carlson, 1996) 




Appendix D. – Figures 
Appendix D. Figure 1 
Summary of potential biases across all included studies. 
 
 
Appendix D. Figure 2 
EPA and DHA minimum daily dose size and the corresponding effect sizes found for the 
studies reporting results for inhibition. 
 
Note. Negative effect sizes and zero effect sizes were omitted from the figure. Negative 
axis values were added for visualization purposes (bubbles overlapping axes). 
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Appendix D. Figure 3 
EPA and DHA minimum daily dose size and the corresponding effect sizes found for the 
studies reporting results for attention. 
 
Note. Negative effect sizes and zero effect sizes were omitted from the figure. Negative 
axis values were added for visualization purposes (bubbles overlapping axes). 
 
Appendix D. Figure 4 
EPA and DHA minimum daily dose size and the corresponding effect sizes found for the 
studies reporting results for short-term memory. 
 
Note. Negative effect sizes and zero effect sizes were omitted from the figure. Negative 
axis values were added for visualization purposes (bubbles overlapping axes). 
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Appendix D. Figure 5 





Appendix D. Figure 6 
Funnel plot for short-term memory suggesting symmetry. 
 
Note. Bubbles represent the studies reporting results for short-term memory. SMD is 
standardized mean difference. 
 
Appendix D. Figure 7 
Funnel plot for attention suggesting symmetry. 
 
Note. Bubbles represent the studies reporting results for short-term memory. SMD is 




Appendix D. Figure 8 
Funnel plot for inhibition suggesting some asymmetry. 
 
Note. Bubbles represent the studies reporting results for short-term memory. SMD is 




Appendix D. – Tables 
Appendix D. Table 1 
Summary of the largest treatment effects found for each study.  
   Effect of interven-
tion 
Study Domain Test SMD 95% CI 
Subgroup: DHA 
Mc Namara 2010 
– 400 mg DHA 
Inhibition CPT-IP: commission errors 0.66 -0.45, 1.77 
Crippa 2019 Attention focused attention 4 letters – 
misses 
0.57 -0.01, 1.10 
Birch 2000 Development Bayley Scales of Infant De-
velopment, 2nd edition: 
MDI 
0.49 -0.16, 1.15 
Makrides 2000 Development Bayley Scales of Infant De-
velopment: MDI 








(PIQ) raw score 
0.19 -0.09, 0.48 
Voigt 2001 Shifting/Flex-
ibility 
Children’s Color Trails Test 
2 
0.18 -0.35, 0.72 
Handeland 2017 - 
Fish 
Attention D2 test of attention: TN-E  
total performance 
0.13 -0.15, 0.41 
Kirby 2010 Short-term 
memory 
Working Memory Test Bat-
tery for Children (WMTB-
C): Forward digit recall 
 
0.11 -0.10, 0.32 
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Appendix D.  
Table 1 continued 
    
McNamara 2010 
– 1200 mg  
Inhibition CPT-IP: commission errors 0.11 -0.92, 1.15 
Richardson 2012 Working 
Memory 
British Ability Scales: Re-
call of digits backwards 
0.10 -0.11, 0.30 
Kennedy 2009 – 
1000 mg DHA 
Working 
Memory 
Cognitive Drug Research 
Battery: Numeric Working 
Memory: Accuracy (% > 
chance) 
0.09 -0.53, 0.71 
Kennedy 2009 – 
400 mg DHA 
Working 
Memory 
Cognitive Drug Research 
Battery: Numeric Working 
Memory: Accuracy (% > 
chance) 
0.08 -0.56, 0.73 
Baumgartner 2012 Long-Term 
Memory (re-
call) 
KABC-II: Atlantis delayed 
 
0.07 -0.24, 0.38 
Meldrum 2012 Development Bayley Scales of Infant and 
Toddler Development (3rd 
edition; BSID-III): Cogni-
tive standard score 
0.05 -0.18, 0.28 
Osendarp 2007 – 
AUS  
IQ WISC-III 0.02 -0.31, 0.36 
Werkman 1996 Development Fagan Test of Infant Intelli-
gence: Novelty preference 
(%) 
0.00 -0.52, 0.52 
Scott 1998 Development Bayley Scales of Infant De-
velopment: MDI 
 




Appendix D.  
Table 1 continued 
    
Osendarp 2007 – 
IND  
Attention Visual attention factor score -0.09 -0.45, 0.27 
Carlson 1996 Development Fagan Test of Infant Intelli-
gence: Novelty preference 
(%) 
-0.63 -1.41, 0.15 
 n studiesa Effects of intervention Heterogeneity 
  SMD 95% CI p I2 p 
Overall sub-
group 
19 0.10 0.01, 
0.18 








WISC-IV: Block design 0.83 0.24, 1.42 
Vaisman 2008 – 
PL-n-3 







0.65 0.14, 1.17 
Sinn 2008 Shifting/Flex-
ibility 
TEA-ch: Creature Counting: 
Trials correct 
0.62 0.24, 1.01 
Karr 2012 Long-term 
memory 
RAVLT: Delayed recall 0.56 -0.07, 1.18 
Vaisman 2008 – 
FO 
Inhibition TOVA: commission errors 0.47 -0.30, 1.24 
Johnson 2017 Reading Logos Test: Reading com-
prehension 
0.40 0.04, 0.76 
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Appendix D.  
Table 1 continued 
    
Harbild 2013 Development Single object free play task: 
Time on task 
0.36 -0.14, 0.87 
Richardson 2005 Spelling WIAT-II: spelling subscale 0.32 -0.06, 0.69 
Parletta 2013 Development Draw-A-Person 0.20 -0.02, 0.43 
Cornu 2018 Reading L’Alouette Test 0.17 -0.16, 0.51 
Van der Merwe 
2013 
Development Willatts’ Infant Planning 
Test: Average total intention 
score 







speed raw score 
0.01 -0.25, 0.28 
Handeland 2017 – 
Supplement 
Attention D2 test of attention: TN-E 
total performance 
-0.04 -0.32, 0.24 
Kean 2017 – non 
diagnosed 
Inhibition TOVA: commission errors -0.05 -0.91, 0.80 
 n studiesa Effects of intervention Heterogeneity 
  SMD 95% 
CI 
p I2 p   
Overall sub-
group 
15 0.28 0.15, 
0.41 
< 0.0001 37% 0.07   
TOTAL 34 0.16 0.09, 
0.24 
< 0.0001 14% 0.24   
Note. SMD  0.20 are marked in bold. aResults for different treatment groups were 
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3 Study 2: Verbal memory performance in depressed children and adolescents: As-
sociations with EPA but not DHA and depression severity 
Abstract 
 
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been described as positively associ-
ated with cognitive functioning. Current meta-analyses have identified eicosapentaenoic acid 
(EPA) as potentially more effective than docosahexaenoic acid (DHA). An especially vul-
nerable subgroup that might benefit from these beneficial effects are depressed youths. In 
this study, we examined associations between red blood cell (RBC) DHA and EPA levels 
and depression severity and verbal memory performance in a sample of 107 moderately (n = 
63) and severely (n = 44) depressed youths. The findings showed that youths with high RBC 
EPA levels had steeper learning curves compared to those with moderate or low RBC EPA 
levels (Pillai’s Trace = 0.195, p = .027, ηp2 = .097). No associations between RBC DHA 
levels or depression severity and verbal memory performance were observed. Our results 
further confirm previous findings indicating a more important role of EPA compared to DHA 
in relation to cognitive functioning. Future research should further investigate the differential 
role of EPA and DHA concerning cognitive functioning in depressed youths. Evidence sup-
porting beneficial supplementation effects could potentially establish a recommendation for 
a natural and easily accessible intervention for cognitive improvement or remission. 
 
3.1 Introduction 
According to the World Health Organization (WHO), approximately 4.4% of the world’s 
population suffer from depression (World Health Organization, 2017), with a lifetime prev-
alence rate of approximately 10%–15%  (Kessler & Bromet, 2013; Kessler et al., 2015). Alt-
hough the median age of onset lies at around 25 (Kessler & Bromet, 2013), the first symptoms 
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and onset of depression often occur as early as during childhood or adolescence (Kessler et 
al., 2007), and earlier onset is associated with poorer health outcomes, such as more depres-
sive episodes, more suicide attempts, and poorer functional outcomes (Zisook et al., 2007). 
For adolescents, the one-year prevalence rates are estimated to lie around 5% with a large 
range of approximately 0.2%–17% (Avenevoli et al., 2015; Costello et al., 2005, 2006, 2004). 
Depression is a very severe mental disorder and can lead to suicide, which, in 2015, was the 
second leading cause of death amongst 15–29-year-olds (World Health Organization, 2017). 
In youths, depression has been deemed the leading causes of disability-adjusted life years 
(DALY) and years lived with disability (YLL) (Erskine et al., 2015). Altogether, these find-
ings highlight the burden that this disease poses on today’s youth and the devastating associ-
ated consequences.  
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 
(American Psychiatric Association, 2013) defines the diagnostic criteria for major depressive 
disorder (MDD), which include depressed mood, fatigue, and diminished pleasure, as well 
as cognitive problems such as difficulties concentrating. To meet the diagnostic criteria for 
MDD, at least five symptoms must have been present for most of the time during the same 
two-week period. Symptoms must include either depressed mood or loss of interest or pleas-
ure. In children and adolescents, key symptoms also include irritable mood. 
Clinical research to date has primarily focused on the emotional symptoms of depression, 
while problems with cognition can equally impact everyday functioning and subjective qual-
ity of life (Cambridge et al., 2018; Hammar & Årdal, 2009; Knight et al., 2020). Moreover, 
cognitive deficits have been associated with poorer antidepressant treatment outcome 
(Bruder et al., 2014; Etkin et al., 2015). Cognitive impairments could be especially problem-
atic when children and adolescents are affected. At this critical stage in life, problems with 
concentration and cognition could lead to long-lasting consequences concerning personal life 
and educational attainment (Fletcher, 2008; Morey-Nase et al., 2019). Meta-analyses inves-
tigating cognitive deficits in depressed adults have reported moderate impairments in several 
cognitive domains compared to healthy controls (Ahern & Semkovska, 2017; R. S. C. Lee et 
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al., 2012; Lim et al., 2013; Porter, Robinson, Malhi, & Gallagher, 2015; Rock et al., 2014; 
Snyder, 2013; Wagner, Doering, Helmreich, Lieb, & Tadić, 2012). Evidence from several 
studies suggests that these cognitive problems remain at least partially present even in the 
remitted stage (Biringer et al., 2007; Bo Jacob Hasselbalch et al., 2011; Semkovska et al., 
2019). Although cognitive complaints are equally part of the diagnostic criteria in youths, 
evidence for impaired cognitive test performance in this subgroup of depressed individuals 
seems much more heterogeneous. Some meta-analyses have found similar deficits to anal-
yses with adult patients (Brooks, Iverson, Sherman, & Roberge, 2010; Goodall et al., 2018; 
Wagner et al., 2014). A qualitative review by Vilgis, Silk, & Vance (2015), however, con-
cluded that while some studies reported cognitive deficits in depressed children and adoles-
cents, the majority did not find any impairments. Günther, Holtkamp, Jolles, Herpertz-
Dahlmann and Konrad (2004) reported heterogenous results with undisturbed attention, 
whereas memory impairment was associated with depressive disorders.  
In their review, McDermott and Ebmeier (2009) reported negative associations between de-
pression severity and cognitive functioning in adults; however, this effect seemed domain-
specific. In youths, thus far only tendencies towards a similar association have been reported 
(Maalouf et al., 2011), highlighting the need for further investigation into this subject. In the 
past few years, cognitive remission has become an important goal for MDD treatment; how-
ever, treatment options concerning cognitive symptoms are scarce. Evidence for positive 
cognitive effects of antidepressant medication has proven rather heterogeneous (Bennabi et 
al., 2019; Biringer et al., 2009; Bortolato et al., 2016; Prado et al., 2018; Rosenblat et al., 
2015; Shilyansky et al., 2016; Skandali et al., 2018; Zuckerman et al., 2018).  
Since the industrial revolution, nutritional patterns in Western societies have shifted towards 
foods containing more omega-6 (n-6) compared to omega-3 (n-3) polyunsaturated fatty acids 
(PUFAs) (Simopoulos, 2011a). These changes have been held responsible for the rise in dif-
ferent civilization diseases such as cardiovascular diseases, but also psychiatric diseases such 
as depression (Simopoulos, 2011a). n-3 PUFA deficiency has been associated with depres-
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sion (Edwards, Peet, Shay, & Horrobin, 1998; F. Li et al., 2015; Lin et al., 2010) and eicosa-
pentaenoic acid (EPA) status has been negatively associated with depression severity 
(Adams, Lawson, Sanigorski, & Sinclair, 1996). Meta-analytic evidence has further sug-
gested beneficial effects of n-3 PUFA supplementation on depression symptoms (Grosso, 
Pajak, et al., 2014; Hallahan et al., 2016; Liao et al., 2019; Mocking et al., 2016; Sublette, 
Ellis, et al., 2011), especially with high doses of EPA (Grosso, Pajak, et al., 2014; Sublette, 
Ellis, et al., 2011). Interestingly, symptom severity might moderate this beneficial effect, as 
some studies have reported stronger effects in more severely depressed patients (Appleton et 
al., 2010). However, other meta-analyses in both adults (Bloch & Hannestad, 2012) and chil-
dren and adolescents (Zhang et al., 2019) have revealed no beneficial effect of n-3 PUFAs 
for the treatment of depressive disorder. In youths, however, only four randomized controlled 
trials (RCTs) thus far have been included (Zhang et al., 2019). The anti-inflammatory prop-
erties of n-3 PUFAs have mostly been made responsible for their beneficial effects in relation 
to depression (Rapaport et al., 2016). Proinflammatory cytokines have been shown to play a 
role in depression (Young, Bruno, & Pomara, 2014), and hence n-3 PUFAs have been dis-
cussed to counteract these inflammatory processes (Bazinet & Layé, 2014).  
n-3 PUFAs are vital for normal brain development (J. Baumgartner, 2016; Bazinet & Layé, 
2014; Koletzko et al., 2008; Lauritzen et al., 2016). Consequently, the past few years have 
seen a renewed interest in the investigation of n-3 PUFAs in relation to cognition. Several 
studies in youths have reported positive associations between reported dietary n-3 PUFA 
intake and cognitive performance (Darcey, McQuaid, Fishbein, & VanMeter, 2019; Lassek 
& Gaulin, 2011). In a study by Montgomery, Burton, Sewell, Spreckelsen and Richardson 
(2013), low blood n-3 PUFA status was associated with poorer reading abilities and working 
memory performance in children. Similarly, Wurff and colleagues (2016) reported better per-
formance on an attention task for adolescents with higher n-3 PUFA status. Meta-analyses 
on n-3 PUFA supplementation have reported mixed results, depending on the study popula-
tion investigated (Abubakari et al., 2014; Bloch & Qawasmi, 2011; Chang et al., 2018; 
Cooper et al., 2015; Emery et al., 2020; Jiao et al., 2014; Karr, Alexander, & Winningham, 
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2011; Mazereeuw et al., 2012). It remains unclear whether the specific type of n-3 PUFA 
ingested might have significantly contributed to these heterogenous study results, as some 
meta-analyses have suggested beneficial effects of EPA rather than docosahexaenoic acid 
(DHA) (Chang et al., 2019; Emery et al., 2020).  
The question remains as to how n-3 PUFAs might affect cognition in depressed individuals, 
as supplementation studies in depressed populations are very scarce (Knochel et al., 2015). 
The results reported by Rogers and colleagues (2008) showed no benefit of n-3 PUFA sup-
plementation on cognition in adult individuals with mild to moderate depression. In youths, 
however, Vesco, Young, Arnold and Fristad (2018) reported decreased parent-rated impair-
ments in executive functioning after 12-week supplementation with n-3 PUFAs. To the best 
of our knowledge, there is yet no study investigating associations between EPA and DHA 
statuses and cognitive performance in depressed children and adolescents. 
The aim of the current study was to address the previously mentioned research deficits and 
to investigate verbal memory performance in depressed children and adolescents in relation 
to EPA and DHA statuses as well as depression severity. The aforementioned research find-
ings suggest that (1) EPA but not DHA is positively associated with cognitive functioning, 
(2) depression severity is negatively associated with cognitive functioning, and (3) depres-
sion severity might moderate the association between EPA and depression symptoms. We 
hence hypothesized that patients with a high EPA status would outperform patients with a 
low EPA status in verbal memory tasks and that this would be especially evident in severely 
depressed compared to moderately depressed individuals. Furthermore, we hypothesized that 
moderately depressed patients would outperform severely depressed patients. 
If EPA but not DHA were to be identified as being associated with cognitive functioning in 
depressed children and adolescents, this would prove important, especially for this specific 
population, as EPA compared to DHA has also been considered to be more effective in the 
treatment of depression symptoms(Grosso, Pajak, et al., 2014; Sublette, Ellis, et al., 2011). 
Consequently, future RCTs could investigate EPA supplementation as an intervention in 
these individuals, targeting both emotional as well as cognitive symptoms at the same time. 
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3.2 Materials and Methods  
The findings reported in this present study were generated from data collected by the “The 
Omega-3-pMDD trial”, a multi-center placebo-controlled trial aiming to investigate the effi-
cacy of omega-3 fatty acid supplementation in moderately to severely depressed children and 
adolescents aged 8–17 years. Two hundred and twenty patients across Switzerland will be 
recruited in order to investigate both the psychopathological and cognitive effects of nine 
months of n-3 PUFA supplementation. In the present study, we report cross-sectional find-
ings from data collected prior to randomization to a treatment arm, with the exception of 
intellectual ability that was assessed six weeks post-randomization. Funding was received 
from the Swiss National Foundation and the private foundations that are listed later in the 
funding section. No industry funding was received. The clinical trial was registered on 
www.ClinicalTrials.gov, protocol no. NCT03167307. The clinical trial’s design paper has 
already been published (Häberling, Berger, Schmeck, Held, & Walitza, 2019). The study was 
approved by the local ethics committee and was conducted in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and later amendments. All parents 
(or legal guardians) provided written informed consent and written or oral assent was ob-
tained from the participating children before entering the study. 
 
3.2.1 Participants 
Participants were recruited from seven different in- and outpatient services across Switzer-
land. For inclusion, the patients had to meet the diagnostic criteria for MDD according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (American Psychiatric 
Association, 2000) and had to have reported symptoms of at least moderate severity defined 
by a Children’s Depression Rating Scale (Poznanski & Mokros, 1996) total score of  ≥ 40 
(Guo, Nilsson, Heiligenstein, Wilson, & Emslie, 2006). Patients who met the DSM-IV diag-
nostic criteria for an eating disorder within the last six months or the diagnostic criteria for a 
lifetime diagnosis of schizophrenia, bipolar affective disorder, or substance dependency were 
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excluded from the trial. Mental retardation, pervasive development disorder, or pre-existing 
neurological or medical conditions that are likely to be responsible for depression symptoms 
constituted further exclusion criteria. Antidepressant treatment was allowed at study entry to 
avoid selection bias toward less severely depressed patients. Lastly, patients regularly sup-
plementing n-3 PUFAs within the last six months (dosage limit set at 600 mg/day) or patients 
unable to follow the study procedures (e.g., due to a language barrier) were also excluded. 
During the screening visit, inclusion and exclusion criteria were assessed using the Kiddie 
Schedule for Affective Disorders and Schizophrenia (K-SADS-PL) (Kaufman et al., 1997) 
and Children’s Depression Rating Scale revised (CDRS-R) (Poznanski & Mokros, 1996). 
Patients meeting all inclusion and no exclusion criteria were then included in the lead-in 
phase of the trial (7–14 days). During the lead-in phase, all participants received a placebo in 
a single blinded fashion and psychopathological, cognitive, and bloodwork baseline data 
were collected. Assessment of the inclusion and exclusion criteria was repeated at the end of 
this phase, after which patients were randomized to a treatment arm in a double-blind fashion. 
At the time of analysis, the sample consisted of 107 patients that met all of the inclusion and 
no exclusion criteria at screening and had analyzed PUFA blood sample data. The current 
article investigated this subsample in a cross-sectional manner using single cognitive and 




Sociodemographic information and information on treatment history were obtained using the 
patients’ medical records, as well as patient and parent interviews. Information on the course 
of illness was collected via patients’ self-reports and parents’ reports. The patients’ medical 
records were consulted for confirmation of these reports. Patients or parents provided further 





Severity of depression (CDRS-R) 
The CDRS-R is a semi-structured clinical interview assessing severity of depression using 
17 depression symptoms (Poznanski & Mokros, 1996). Patients and parents provide infor-
mation on 14 of these symptoms which are then rated on a 7- or 5-point Likert scale, depend-
ing on the specific symptom. The interviewer then integrates this information and provides a 
final score for each symptom. Three further nonverbal symptoms are rated by the interviewer 
only (depressed facial affect, hypoactivity and listless speech). The final scores for each re-
ported symptom, as well as the ratings on nonverbal symptoms are added up to obtain a final 
score for depression severity. Scores of 30–39 can be interpreted as mild, 40–59 as moderate, 
and ≥60 as severe symptoms of depression (Guo et al., 2006). Validation studies on CDRS-
R have reported good validity and reliability for depressed children and adolescents (Mayes, 
Bernstein, Haley, Kennard, & Emslie, 2010).  
 
EPA and DHA Statuses 
Venous blood samples were collected. For determination of erythrocyte fatty acid composi-
tion, blood was drawn into EDTA tubes, centrifuged, and then the plasma and buffy coat 
taken off; the erythrocytes were then frozen at −80 °C until analysis. The fatty acid compo-
sition of the erythrocytes was analyzed by gas chromatography at Omegametrix GmbH using 
previously described methods (Harris et al., 2013). EPA and DHA statuses are given as a 
percentage of total fatty acids measured in RBCs.  
 
Outcome Variables 
Cognitive Tests - Memory  
Verbal memory: VLMT 
We used a validated German version (Verbaler Lern- und Merkfähigkeitstest (VLMT) 
(Helmstaedter & Durwen, 1990)) of the Auditory Verbal Learning Test (AVLT) (Schmidt, 
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1996a), in which a list of 15 semantically independent words is presented auditorily to an 
individual and he or she is asked to remember and reproduce as many words as possible. This 
process is repeated five times. Then, a second list of 15 words (= interference list (I)) is 
presented and the individual is asked to remember and reproduce as many words as possible 
from the second list. In the next step, the individual is asked to reproduce the words from the 
first list. After 20–30 min, he or she is once again asked to reproduce the first list of words. 
In the last step, the individual is asked to recognize the words from a list of 50 semantically 
or phonetically related and unrelated words. The test measures declarative verbal memory 
capacity. Short-term verbal memory is characterized by the number of words correctly repro-
duced by the individual in each of the five rounds (T1, T2, T3, T4, and T5). The long-term 
memory parameters are T7, which is the number of words from the first list recalled after 
20–30 min, and T5–T7, which is the difference between the number of words recalled at T5 
and T7. The interference score is I, which represents the number of correctly reproduced 
words from the interference list, T6, which is the number of words from the first list recalled 
after interference, and T5–6, which is the difference between the number of words repro-
duced from the first list before and after interference. Lastly, recognition (W) is the number 
of words correctly identified as belonging to the first list, and W–F is the correctly identified 
words minus the words wrongly attributed to the first list. 
 
Numeric memory: WISC-IV digit span 
The digit span subtest from the Wechsler Intelligence Scale for Children - Fourth Edition 
(WISC-IV) (Wechsler, 2003) consists of two parts, namely, forward and backward. In the 
first part, the individual has to reproduce sequences of digits of increasing length. In the 
second part, the individual is instructed to repeat a sequence of digits in reverse order. The 







IQ: Reynolds Intellectual Assessment Scales and Screening (RIAS) 
The RIAS is an intelligence test for individuals between 3 and 99 years of age, mostly used 
for research purposes (Hagmann-von Arx & Grob, 2014). It includes two subtests, the results 
of which are added to form a verbal intelligence index (VIX) and two subtests to form the 
nonverbal intelligence index (NIX). These are then integrated into the global intelligence 
index (GIX). Reliability of the RIAS is high (Cronbach 𝛼 = 0.95 for the global index) (Gygi, 
Hagmann-von Arx, Schweizer, & Grob, 2017; Krist, Kunter, Nückles, Pinquart, & Seidel, 
2016). 
 
C-reactive protein (CRP)  
High-sensitive CRP was measured in the plasma in an accredited medical laboratory using a 
commercial assay with a coefficient of variation of 1.3% at 3.6 mg/L, to be used as a marker 
for low-grade inflammation and as a stratification parameter for randomization. Values above 
10 were excluded from analysis, as they could have indicated infection. 
 
Body-mass-index (BMI) 
The BMI was calculated using weight (kg)/height (cm)2. BMI was not obtained in some cases 
because of missing measurement tools and devices.  
 
3.2.3 Statistical analysis 
Statistical Package for the Social Sciences (SPSS) software version 26 was used for all sta-
tistical analyses. Descriptive statistics are given in order to describe the study sample char-
acteristics. Moderately and severely depressed patient groups were distinguished using a clin-
ical cut-off of the CDRS-R total score (40–59 = moderate; ≥60 = severe) (Guo et al., 2006). 
Three approximately equally sized groups were formed according to the data distribution of 
EPA and DHA statuses, because patient’s n-3 PUFA statuses were all low when referring to 
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currently proposed ideal levels (von Schacky, 2019a). Hence, the formation of three groups 
would allow for the investigation of especially low status and rather normal values. Differ-
ences between moderately and severely depressed patients and differences between EPA and 
DHA status groups for the investigation of potential confounding variables were analyzed 
using chi-square tests, independent t-tests, and one-way ANOVAs, depending on the scale 
level of the variable investigated. Non-parametric Mann–Whitney U or Kruskal–Wallis tests 
were only used for strongly skewed data (>1, <(−1)), as in large sample sizes parametric tests 
should be robust against the violation of normality assumption (Lumley, Diehr, Emerson, & 
Chen, 2002). 
In order to investigate differences in memory scores depending on depression severity (mod-
erate vs. severe) and EPA and DHA statuses (low, intermediate, and high), multivariate anal-
yses of covariance (MANCOVAs) were computed to evaluate the VLMT short-term, long-
term, and interference parameters separately. Multivariate outliers were checked using Ma-
halanobis’ distances. Bonferroni correction was applied for the interpretation of between-
subjects effects and pairwise comparisons. For digit span parameters, univariate analyses of 
covariance (ANCOVAs) were used for the forward and backward parameters separately. 
Conservative results using Pillai’s Trace instead of Wilk’s Lambda were reported (Ateş, 
Kaymaz, Kale, & Tekindal, 2019). Pillai’s Trace values range from 0 to 1 with increasing 
values indicating a stronger contribution of the independent variable to the model. For all 
MANCOVAs, normal distribution within groups was investigated using Shapiro–Wilk tests 
and Q-Q plots where n ≤ 25. Box’s tests were used to evaluate the homogeneity of variance–
covariance matrices. Levene’s tests were used to assess the equality of error variances, alt-
hough the results should be robust against violation if none of the standard deviations are 
more than four times as large as the corresponding smallest standard deviation (Howell, 
2012). The homogeneity of regression slopes was assessed for all covariates. Significance 





At the time of analysis, the subsample of patients that met all inclusion and no exclusion 
criteria and where blood samples were available consisted of 107 patients. For one patient, 
the WISC digit span scores were missing due to the fact that the test had not been done with 
this individual. RIAS scores for seven patients were missing, because IQ testing was done 
six weeks post-randomization and these patients had not yet reached week six of the study. 
 
3.3.1 Descriptive statistics 
Patients achieved average mean normative scores for both the VLMT total learning parame-
ter (ΣT-15) (T-score, M = 49.15, SD = 9.21) as well as the WISC digit span score (scaled 
score metric, M = 9.57, SD = 2.43). However, a significant proportion of patients achieved 
below average scores, with 24 patients (22.42%) with T-scores < 40 for the VLMT; moreo-
ver, 24 patients (22.64%) achieved scaled metric scores < 8 for the digit span test. There was 
one outlier for long-term memory scores, with a Mahalanobis’ distance of 25.72 (critical 
value = 13.82); however, it was decided not to exclude this participant because all other 
memory parameters were within normal range. Only 5.8% achieved recognition normative 
scores below average and 67% recognized all 15 words from the list. The skewness of the 
recognition data was -2.32 (SE = 0.23) and kurtosis was 6.51 (SE = 0.47). A total of 46.2 % 
of the participants reached maximum recognition scores even when subtracting interference 
or false positive mistakes (skewness -1.691 (SE = 0.25) and kurtosis 2.96 (SE = 0.47)). Hence, 
it was decided to investigate depression severity and EPA/DHA group differences concerning 
recognition scores using nonparametric Kruskal-Wallis tests and Mann-Whitney U test in-
stead of MANCOVAs. 
Severity group formation resulted in a group of 63 moderately depressed patients and a group 
of 44 severely depressed patients. The sociodemographic information, IQ, physiological pa-
rameters and psychopathology data are summarized in Table 8 for both severity groups. Se-
verely depressed patients were over proportionally female compared to moderately depressed 
STUDY 2 
 110 
patients; hence, gender was later entered as a covariate for ANCOVA and MANCOVA anal-
yses. No other group differences except CDRS-R score differences presented between sever-
ity groups. Importantly, no differences concerning antidepressant use were found.
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Table 8.  














Age 107 15.50 (1.89) 8.67 18.00 15.25 (2.09) 15.85 (1.51) -1.630 .106 
 Sex: %female 107 67%   57% 82% 7.166 .007** 
Physiological pa-
rameters 
BMI 99 22.35 (4.87) 14.00 39.80 21.86 (4.35) 23.06 (5.52) 1285.0 .454 
 CRP 105 0.79 (1.26) 0 6.6 0.65 (0.81) 0.99 (1.69) 1220.0 .410 
IQ          
RIAS VIX 100 101.73 (9.93) 79 129 102.58 (10.18) 100.51(9.61) 1.019 .102 
 NIX 100 106.33 (8.93) 70 123 107.71 (8.61) 104.34 (9.12) 1.879 .310 
 GIX 100 104.52 (9.35) 76 128 105.78 (9.32) 102.68 (9.21) 1.651 .102 
Depression severity          
CDRS-R Total score 107 57.73 (7.76) 42 79 52.37 (4.18) 65.41 (4.54) - 15.331 <.001*** 
 aSevere % 44 41.1%   - - - - 
Course of illness          
Mean duration of de-
pression (months) 
Months 104 14.71 (11.69) 1 84 13.45 (9.76) 16.43 (13.84) 1503.0 .228 
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Table 8 continued          
Total number of epi-
sodes 
 105 1.46 (0.95) 1 8 1.44 (1.10) 1.48 (0.70) 1490.0 .230 
Recurrent depression Yes 104 31%   26% 38% 1.775 .183 
Use of antidepres-
sant medication 
Yes 102 37%   35% 40% 0.317 .573 
Note. **p < .01, ***p < .001. CRP, C-reactive protein, BMI, body mass index, VIX, verbal intelligence index, NIX, nonverbal intelligence index, 
GIX, global intelligence index, RIAS, Reynolds Intellectual Assessment Scales and Screening, CDRS-R, Children’s Depression Rating Scale re-
vised. aCDRS-R severity scores: 40-59 = moderate,  60 = severe
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EPA group formation resulted in three groups (n1 = 34, n2 = 39, n3 = 34) with group means 
of M1 = 0.34 (SD = 0.05), M2 = 0.46 (SD = 0.04), M3 = 0.66 (SD = 0.11). No gender (𝜒2 = 
0.172, p = .918), age (F(2,104) = 0.816, p = .445), IQ (F(2,97) = 2.317, p = .104), BMI (H(2) 
= 2.950, p = .229), CRP (H(2) = 2.771, p = .250) or differences concerning antidepressant 
use (𝜒2 = 0.866, p = 0.649) presented between the three groups. DHA group formation re-
sulted in three groups (n1 = 36, n2 = 35, n3 = 36) with group means of M1 = 2.89 (SD = 0.22), 
M2 = 3.48 (SD = 0.20), M3 = 4.54 (SD = 0.61). Moreover, between these groups, no gender 
(𝜒2 = 0.468, p = .791), age (F(2,104) = 0.774, p = .464), IQ (F(2,97) = 0.924, p = .401), (H(2) 
= 0.987, p = 0.611), CRP (H(2) = 0.539, p = .764) or differences concerning antidepressant 
use (𝜒2 = 0.527, p = .768) were found. 
As shown in Table 9, severely depressed patients had higher DHA and total omega-3 status 
compared to moderately depressed patients. No significant differences concerning EPA sta-
tus were observed. 
 
Table 9 
Fatty acid status for moderately and severely depressed patients 





Fatty acid M (SD) M (SD) M (SD)    
EPA 0.49 (0.15) 0.47 (0.14) 0.51 (0.16) -1.515 .133 
DHA 3.63 (0.79) 3.50 (0.71) 3.82 (0.87) -2.077 .040* 
All n-6 34.37 (1.32) 34.45 (1.26) 34.32 (1.40) 0.512 .609 
All n-3 6.45 (1.0) 6.26 (0.93) 6.71 (1.06) -2.318 .022* 
AA/EPA 35.10 (11.27) 36.08 (11.21) 33.74 (11.60) 1.045 .298 
Note. *p < .05. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; n-6, omega-6; 




3.3.2 Main analysis – EPA status and depression severity in relation to memory 
The MANCOVA results for short-term memory VLMT parameters resulted in a significant 
main effect for EPA status (F(10,194) = 2.094, p = .027) but not for depression severity 
(F(5,96) = 0.622, p = .684). The between-subjects effects of EPA status were significant for 
the second trial (T2) (F(2,100) = 6.096, p = .003) and reached borderline significance for T3 
(F(2,100) = 4.825, p = .010) after Bonferroni correction of significance level (p < .01). Pair-
wise comparisons showed that patients with a high EPA status (M = 10.96, SE = 0.37) out-
performed patients with a moderate (M = 9.42, SE = 0.35, p = .009) or low (M = 9.32, SE = 
0.40, p = .010) EPA status in T2. The same results presented for T3, where patients with a 
high EPA status (M = 12.23, SE = 0.35) outperformed patients with a moderate (M = 10.97, 
SE = 0.33, p = .027) or low EPA status (M = 10.86, SE = 0.37, p = .023). The VLMT short-
term memory score profiles for the three EPA status groups are shown in Figure 11. The 
results indicate that patients with a high EPA status had steeper learning curves compared to 
those with a moderate or low EPA status. No main effect of either EPA status or depression 
severity presented for interference, long-term memory parameters, and the parameters of the 
digit span test. All results are summarized Table 10. Independent samples Kruskal-Wallis 
test showed no effect of EPA status for either the uncorrected (H(2) = 0.893, p = .640) or the 
corrected recognition parameter (H(2) = 2.239, p = .326); there was also no significant effect 
of depression severity (U = 1370.500, p = .901, U = 1274.000, p = .580). Further analyses 
concerning potential confounding group differences revealed no significant IQ differences 




MANCOVA and ANCOVA results for VLMT and digit span parameters. EPA status and depression severity entered as factors and gender as a co-
variate. 
 MANCOVA 
EPA status (EPA) 
Depression severity (S) 
Interaction Severity*EPA status (I) 




EPA: F(10,194) = 2.094, p = .027*, ηp² = .097 
S: F(5,96) = 0.622, p = .684, ηp² = .031 
I: F(10,194) = 0.910, p = .525, ηp² = .045 
G: F(5,96) = 1.287, p = .276, ηp² = .063 
 Moderate 
depression 









Pairwise  p 
 
EPA S I G 
T1 score      













Moderate EPA 7.00 (0.35) 6.29 (0.46) 
High EPA 7.11 (0.40) 7.06 (0.42) 
T2 score      












EPA: h > m 
EPA: h > l 
p = .009** 
p = .010* Moderate EPA 10.14 (0.56) 8.71 (0.46) 
High EPA 10.67 (0.26) 11.25 (0.44) 
T3 score      













EPA: h > m 
EPA: h > l 
p = .027* 
p = .023* Moderate EPA 11.27 (0.52) 10.71 (0.45) 
High EPA 11.94 (0.38) 12.50 (0.52) 
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Table 10  
continued 
     
T4 score      













 Moderate EPA 12.32 (0.50) 11.88 (0.70) 
High EPA 13.00 (0.33) 13.06 (0.42) 
T5 score      













Moderate EPA 12.32 (0.50) 12.18 (0.58) 
High EPA 12.50 (0.41) 12.75 (0.37) 
VLMT interfer-
ence parameters 
EPA: F(6,198) = 1.426, p = .206, ηp² = .041 
S: F(3,98) = 1.056, p = .372, ηp² = .031 
I: F(6,198) = 0.102, p = .996, ηp² = .003 
G: F(3,98) = 0.869, p = .460, ηp² = .026 
I      













Moderate EPA 6.41 (0.44) 5.71 (0.58) 
High EPA 7.33 (0.71) 6.63 (0.52) 
T6      













Moderate EPA 11.36 (0.56) 10.94 (0.70) 
High EPA 12.28 (0.43) 12.44 (0.48) 
T5-6      













Moderate EPA 0.95 (0.24) 1.24 (0.36) 




EPA: F(4,200) = 0.604, p = .660, ηp² = .012 
S: F(2,99) = 0.055, p = .946, ηp² = .001 
I: F(4,200) = 0.093, p = .984, ηp² = .002 




Table 10  
continued 
      
T7       













Moderate EPA 11.55 (0.67) 11.18 (0.69) 
High EPA 12.00 (0.46) 12.44 (0.58) 
T5-7       













Moderate EPA 0.77 (0.44) 1.00 (0.39) 
High EPA 0.50 (0.31) 0.31 (0.44) 
Digits forward      













Moderate EPA 8.45 (0.37) 8.29 (0.49) 
High EPA 8.89 (0.40) 8.88 (0.52) 
Digits backwards     













Moderate EPA 8.41 (0.47) 7.88 (0.36) 
High EPA 8.33 (0.43) 8.31 (0.27) 
Note: ηp2= .01 (small), .06 (medium), .14 (large). l, low EPA; m, moderate EPA; h, high EPA. Group sizes (n): Moderately depressed with a low 
EPA status = 23; moderately depressed with a moderate EPA status = 22; moderately depressed with a high EPA status = 18; severely depressed 
with a low EPA status = 11; severely depressed with a moderate EPA status = 17; severely depressed with a high EPA status = 16. Multivariate 
effects, pairwise comparisons: °borderline significant *p < 0.05, **p < 0.01. Between-subjects effects: °borderline significant, *p < .010 (short-
term memory), *p < .017 (interference), *p < .025 (long-term memory) after Bonferroni correction of significance level. Significant effects are 




VLMT learning curve in relation to EPA status. 
 
Note. N = 107. *p < 0.05, **p < 0.01 
 
3.3.3 Main analysis – DHA status and depression severity in relation to memory 
The same analyses were run using DHA instead of EPA status as a factor. A significant in-
teraction effect for long-term memory parameters was found (F(4,200) = 3.069, p = .018). 
However, in contrast to the EPA analyses where no IQ differences were found between the 
groups, further analyses revealed significant IQ differences between moderately and severely 
depressed patients in the moderate DHA status group. Moderately depressed patients had 
significantly higher GIX scores (M = 106.05, SD = 8.56) compared to severely depressed 
patients in the moderate DHA status group (M = 97.62, SD = 10.57; t(31) = 2.537, p = .016). 
Hence, the MANCOVA and ANCOVA analyses were rerun entering IQ as a second covari-
ate. A significant main effect for DHA status was found for digits forward scores (F(2,91) = 
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3.342, p = .040). However, pairwise comparisons were no longer significant after Bonferroni 
correction for multiple comparisons. No significant main effect for depression severity pre-
sented for any memory parameter. A borderline significant interaction effect presented for 
interference parameters of the VLMT F(6,182) = 2.219, p = .052). Between-subjects effects 
revealed a significant effect for the T6 parameter F(2,92) = 4.337, p = .016) where severely 
depressed patients with a high DHA status (M = 12.56, SE = 0.50) outperformed severely 
depressed patients with a moderate DHA status (M = 10.50, SE = 0.61, p = .036). Moreover, 
in the moderate DHA status group, moderately depressed patients (M = 12.34, SE = 0.47) 
outperformed severely depressed patients (M = 10.50, SE = .061, p = .021). IQ proved a 
significant covariate for nearly all parameters. All MANCOVA and ANCOVA results are 
summarized in Table 11. Independent samples Kruskal-Wallis test showed no effect of DHA 
status for either the uncorrected (H(2) = 0.522, p = .770) or the corrected recognition param-




MANCOVA and ANCOVA results for VLMT and digit span parameters. 
 MANCOVA 
DHA status (DHA) 
Depression severity (S) 
Interaction Severity*DHA status (I) 




DHA: F(10,178) = 1.323, p = .221, ηp² = .069 
S: F(5,88) = 0.524, p = .758, ηp² = .029 
I: F(10,178) = 0.686, p = .736, ηp² = .037 
G: F(5,88) = 1.218, p = .308, ηp² = .065 
IQ: F(5,88) = 6.113, p < .001***, ηp² = .258 
 Moderate 
depression  










DHA S I G IQ 
T1 score      
















Moderate DHA 7.25 (1.68) 7.00 (1.41) 
High DHA 6.94 (1.61) 6.78 (1.90) 
T2 score      
















Moderate DHA 10.85 (2.87) 9.10 (2.13) 
High DHA 10.25 (1.18) 10.28 (2.63) 
T3 score      

















Moderate DHA 11.70 (2.06) 10.38 (2.06) 
High DHA 11.75 (2.05) 11.94 (1.86) 
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Table 11  
continued 
     
T4 score      
















 Moderate DHA 13.15 (1.73) 11.54 (3.05) 
High DHA 12.63 (1.09) 13.06 (1.51) 
T5 score      
















Moderate DHA 13.05 (1.79) 11.77 (1.88) 




DHA: F(6,182) = 0.933, p = .472, ηp² = .039 
S: F(3,90) = 0.716, p = .545, ηp² = .023 
I: F(6,182) = 2.219, p = .052°, ηp² = .066 
G: F(3,90) = 0.480, p = .697, ηp² = .016 
IQ: F(3,90) = 8.593, p = < .001***, ηp² = .223 
I        
















Moderate DHA 6.60 (1.76) 5.92 (2.63) 
High DHA 6.25 (2.46) 6.39 (1.91) 
T6          















I: s/h > s/m 
I: m/m > s/m 
p = .036* 
p = .021* Moderate DHA 12.45 (2.21) 10.00 (2.35) 
High DHA 12.06 (1.95) 12.61 (1.29) 
T5-6        




















Moderate DHA 0.60 (1.60) 1.77 (1.64) 
High DHA 0.38 (1.41) 0.28 (1.32) 
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DHA: F(4,184) = 0.599, p = .664, ηp² = .013 
S: F(2,91) = 0.181, p = .835, ηp² = .004 
I: F(4,184) = 1.805, p = .130, ηp² = .038 
G: F(2,91) = 0.488, p = .615, ηp² = .011 
IQ: F(2,91) = 11.721, p < .001***, ηp² = .205 
T7        
















Moderate DHA 12.25 (2.95) 10.62 (2.18) 
High DHA 11.69 (2.02) 13.00 (1.33) 
T5-7        
















Moderate DHA 0.80 (2.12) 1.15 (1.46) 
High DHA 0.75 (1.44) -0.11 (1.41) 
Digits forward 
















Moderate DHA 8.45 (1.50) 7.85 (1.41) 
High DHA 8.69 (1.66) 8.28 (2.08) 
Digits backwards 













 < .001* 
.164 
NS NS 
Moderate DHA 8.15 (1.81) 7.62 (1.26) 
High DHA 8.19 (1.64) 7.89 (1.61) 
Note: GIX, global intelligence index. ηp2= .01 (small), .06 (medium), .14 (large). l, low DHA status; m, moderate DHA status; h, high DHA status; 
m/l, moderately depressed with a low DHA status; m/m, moderately depressed with a moderate DHA status; m/h moderately depressed with a high 
DHA status; s/l, severely depressed with a low DHA status; s/m = severely depressed with a moderate DHA status; s/h = severely depressed with a 
high DHA status. Group sizes (n): m/l = 23; m/m = 20; m/h = 16; s/l n=10; s/m = 13; s/h = 18. Multivariate effects, pairwise comparisons: °border-
line significant *p < 0.05, ***p < .001. Between-subjects effects: °borderline significant, *p < .010 (short-term memory), *p < .017 (interference), 





The current study investigated RBC EPA and DHA levels, as well as depression severity in 
relation to memory performance in a sample of 107 moderately to severely depressed youths. 
Contrary to previous findings that reported inverse associations between oily fish intake and 
depression severity (Bountziouka et al., 2009), in our sample severely depressed patients had 
significantly higher DHA and total omega-3 statuses compared to moderately depressed pa-
tients. Whereas negative associations between EPA status and depression severity have been 
reported (Adams et al., 1996), we found no significant differences concerning EPA status 
between moderately and depressed patients. 
In our study, we examined potential cognitive deficits in depressed children and adolescents 
which have been inconsistently found in previous studies (Brooks et al., 2010; Goodall et al., 
2018; Günther et al., 2004; Vilgis et al., 2015; Wagner et al., 2014) in contrast to research 
conducted in adult patient groups, where deficits seem more consistent (Ahern & Semkovska, 
2017; R. S. C. Lee et al., 2012; Lim et al., 2013; Porter et al., 2015; Rock et al., 2014; Snyder, 
2013; Wagner et al., 2012). Although most patients achieved average normative scores for 
both the VLMT and the digit span test, over 20% of the patients (compared to an expected 
15.9% in a healthy population) achieved below average normative scores. These results in-
dicate a tendency towards impaired verbal memory in depressed youths. 
We further aimed at investigating potential negative associations between depression severity 
and cognitive functioning in depressed youths that so far have mostly been reported in adult 
patient groups (McClintock, Husain, Greer, & Cullum, 2010; McDermott & Ebmeier, 2009), 
with similar tendencies from research conducted in children and adolescents (Maalouf et al., 
2011). Contrary to our hypothesis, in our sample we did not find any significant differences 
in verbal memory performance between moderately and severely depressed patients. Hence, 
we could not confirm any negative associations between depression severity and cognitive 
functions previously reported in adult patient groups (McClintock et al., 2010; McDermott 
& Ebmeier, 2009). 
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Most importantly, we were interested in memory performance in relation to EPA and DHA 
status, because mostly EPA supplementation has been associated with beneficial cognitive 
effects in youths (Chang et al., 2019; Emery et al., 2020), and beneficial cognitive effects 
would prove especially important in this vulnerable population. Our results indicated that 
patients with a high EPA status had steeper learning curves across the short-term memory 
trials of a verbal list learning test, compared to patients with a moderate or low EPA status. 
Compared to patients with a moderate or low EPA status, those with a high EPA status, 
seemed to remember more words faster, although they achieved equal scores in the first trial 
and again in the last two trials. This finding only partly confirmed our hypothesis that patients 
with a high EPA status would outperform patients with a low EPA status in verbal memory 
tests, because differences were only observed for the second and third trials and not overall. 
Moreover, these differences were only found for short-term memory parameters, whereas no 
significant effect for EPA status presented for any other VLMT parameter or the digit span 
test. However, we were able to confirm our hypothesis concerning DHA by finding no sig-
nificant effect of DHA on any verbal memory parameter. Both results are in line with previ-
ous findings from meta-analyses on supplementation effects of EPA and DHA that suggested 
beneficial effects of EPA but not DHA on cognitive functioning (Chang et al., 2019; Emery 
et al., 2020) and effects in clinical rather than healthy populations (Emery et al., 2020). In 
contrast to our hypothesis, we were not able to confirm any superior effects of a high EPA 
status in severely compared to moderately depressed patients.   
A number of limitations should be kept in mind when interpreting the reported results. First, 
no healthy control group was investigated; hence, no comparison between depressed and 
healthy children and adolescents could be made. Nevertheless, our data suggested that a 
somewhat larger proportion of participants than expected in a healthy population achieved 
below average normative scores in both tests. Importantly, the current study was based on a 
cross-sectional design. It is hence limited by the impossibility to draw conclusions about any 
causal relationships. Another methodological limitation lies in the small and unequally sized 
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subgroups formed by the two factors of depression severity and DHA and EPA status. More-
over, for several analyses the Levene’s tests proved significant. However, rather conservative 
statistical methods for correction were applied throughout the analyses, minimizing the prob-
ability of a type-I error. 
Our results further contribute to previous findings that reported some impairment considering 
cognitive functions (Vilgis et al., 2015) and especially memory performance (Günther et al., 
2004) in depressed youths. Future studies should investigate differences between healthy and 
depressed individuals concerning memory performance in order to be able to further confirm 
these findings and make recommendations for cognitive assessments in this population. Sur-
prisingly, the analyses of our sample revealed higher DHA and total omega-3 status in se-
verely compared to moderately depressed patients. One explanation for this finding might lie 
in altered nutritional patterns in severely compared to moderately depressed youths. Moreo-
ver, considering the population investigated, low n-3 PUFA levels were expected to begin 
with, and hence, small ranges were presented. Wider ranges might therefore have produced 
different results. This explanation is, of course, only speculative. Although the reported anal-
yses with EPA and DHA only contributed associations between RBC levels and verbal 
memory rather than effects of supplementation, they further corroborate evidence from meta-
analyses that confirmed the beneficial supplementation effects of EPA but not DHA. Thus, 
our findings suggest that an increased dietary intake of EPA might prove beneficial for cog-
nitive improvement or even remission in depressed youths. Based on our findings, future 
RCTs should investigate the effects of EPA compared to DHA supplementation in depressed 
children and adolescents to potentially establish a recommendation for a natural and easily 
accessible intervention for cognitive improvement or remission in depressed youths. Neu-
roimaging studies have tried to explain differences in supplementation effectivity between 
DHA and EPA. Bauer and colleagues (2014), for example, reported a reduction in functional 
activation in the left anterior cingulate cortex and shorter reaction times in the Stroop color-
word task, following EPA rather than DHA supplementation, which, they argued, might rep-
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resent stronger neural efficiency in EPA-supplemented compared to DHA-supplemented in-
dividuals. Biologically, however, the supplementation advantages of EPA over DHA have 
yet to be explained, considering EPA is found in much smaller concentrations within the 
brain compared to DHA (Bazinet & Layé, 2014; Weiser et al., 2016). As there is also a lack 
of understanding about the actual absorption and utilization of both EPA and DHA, it would 
be paramount to investigate the moderating effects of, for example, the microbiome, as dif-





4 General Discussion 
The general discussion of the present dissertation starts with the summary and integration of 
the most important findings. In a next step, strengths and limitations of the conducted studies 
are discussed, and implications and future directions are delineated. The dissertation ends with 
some concluding thoughts. 
 
4.1 Summary and integration of findings 
In this thesis, the role of n-3 PUFAs concerning cognitive test performance in children and 
adolescents was investigated using two independent scientific studies.  
While some maternal supplementation studies have shown promising results concerning ben-
efits of maternal n-3 PUFA supplementation on child growth and development during preg-
nancy, meta-analytic results are still equivocal (Gould et al., 2013; Lehner et al., 2020; 
Middleton et al., 2019). Most robust evidence exists for beneficial effects on visual acuity 
(European Food Safety Authority, 2009). Because brain development continues until the age 
of about 25, youths constitute a vulnerable subgroup for adverse effects of n-3 PUFA defi-
ciency and cognitive complaints could have detrimental effects on educational attainment in 
youths. Due to the developmental course of the brain, the young brain might, however, simul-
taneously be most susceptible to protective effects and change, which in turn makes potential 
beneficial effects of n-3 PUFAs most probable in this population. Meta-analyses to date have, 
however, reported heterogeneous results (Bloch & Qawasmi, 2011; Chang et al., 2018; Cooper 
et al., 2015; Jiao et al., 2014). The first study aimed at systematically reviewing previous find-
ings concerning n-3 PUFA supplementation in youths reported by previous studies, tackling 
both heterogeneities as well as methodological and conceptual deficits of previous meta-anal-
yses, which will be discussed in depth in the next chapter. The meta-analysis on the effects of 
n-3 PUFA supplementation on cognitive test performance in youths revealed several important 
findings. In this study, it was established that overall, there seems to be little evidence for a 
general beneficial effect of n-3 PUFA supplementation on cognitive test performance in youths. 
These results confirm the findings previously reported by Cooper and colleagues (2015). Some 
disagreement arises in comparison with the findings reported by Jiao and colleagues (2014) 
who found significant supplementation effects in infants concerning the mental development 
index (MDI). These differences could at least partially be explained by the lower number of 
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studies included in their MDI analysis, together with the fact that three of the included results 
were based on results reported by the same study. Small beneficial effects of EPA but not DHA 
were revealed in our meta-analysis. As no other meta-analysis so far has investigated efficacy 
differences between EPA and DHA, this constitutes a novel and important finding. The results, 
however, go in line with some preliminary findings for example reported by Bloch and 
Qawasmi (2011) where EPA dosage was positively associated with increased efficacy in treat-
ing ADHD symptoms and Cooper and colleagues (2015) who found that small treatment ef-
fects emerged for working memory in studies that supplemented with an adequate amount of 
EPA. In our study, tendencies towards effects in clinical rather than healthy populations were 
revealed, which confirms some previous findings where patients with ADHD seemed to benefit 
from supplementation (Bloch & Qawasmi, 2011; Chang et al., 2018). These findings are of 
great importance considering the debilitating effects of cognitive deficits, especially in young 
clinical populations (Fletcher, 2008; Morey-Nase et al., 2019). Altogether, there seemed to be 
no clear evidence for a specific domain that would benefit most from supplementation. Dosage 
was unrelated to study effect size which again confirms results from some previous meta-anal-
yses (Chang et al., 2018; Cooper et al., 2015; Jiao et al., 2014) while contradicting others (Bloch 
& Qawasmi, 2011).  
In adults, meta-analyses have reported promising results concerning effects of n-3 PUFA sup-
plementation on depression symptomatology, hinting at potentially stronger effects of EPA 
rather than DHA (Grosso, Pajak, et al., 2014; Hallahan et al., 2016; Liao et al., 2019; Martins, 
2009; Mocking et al., 2016). In children, this has yet not been confirmed (Zhang et al., 2019). 
Also, studies on cognitive effects within depressed subgroups are scarce (Knochel et al., 2015). 
Although previously reported results in depressed (Rogers et al., 2008), recovered (Niki Antypa 
et al., 2012) and adults “at risk” (Duffy et al., 2015) have provided little evidence for an asso-
ciation between n-3 PUFAs and cognitive functioning in depression, in youths, Vesco, Young, 
Arnold, and Fristad (2018) revealed decreased parent-rated impairments in executive function-
ing after a 12-weeks supplementation with n-3 PUFAs. Also, the results reported by Borsini 
and colleagues (2020), where EPA and DHA were associated with the prevention of glucocor-
ticoid-induced reduction in human hippocampal neurogenesis, strongly suggest that n-3 
PUFAs might be associated with cognitive outcomes in depression. No studies to date have 
investigated associations between n-3 PUFAs and verbal memory performance in depressed 
youths. The goal of the second study was to investigate potential associations between n-3 
PUFA status, especially DHA and EPA status, and cognitive test performance in depressed 
youths, potentially paving the way for further investigation into a natural and easily accessible 
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treatment option for cognitive remission in this specific population. Based on findings from 
study 1 and previous studies that reported beneficial effects of especially EPA compared to 
DHA on both depression symptomatology (Grosso, Pajak, et al., 2014; Hallahan et al., 2016; 
Liao et al., 2019) as well as general cognitive test performance (Chang et al., 2019), study 2 
investigated potential differences in association between EPA versus DHA status and cognitive 
test performance in depressed youths. Based on previously discussed methodological concerns 
about using subjective rating scales, high quality cognitive outcome assessment measures were 
used. Furthermore, domain-specific cognitive assessments were used for the evaluation of ver-
bal memory performance only. 
In our study sample, only minor cognitive deficits presented, which confirms previous findings 
that youths might be less severely affected by cognitive deficits (Goodall et al., 2018; Maalouf 
et al., 2011; Vilgis et al., 2015; Wagner et al., 2014) compared to adults (Knight & Baune, 
2018; R. S. C. Lee et al., 2012; Marazziti et al., 2010; Rock et al., 2014). Findings further 
indicated that EPA status was positively associated with verbal memory performance, whereas 
DHA status was not. Depressed youths with a high EPA status had steeper learning curves 
concerning short-term memory parameters of a verbal learning task compared to those with a 
moderate or a low EPA status. These results both confirm our findings from study 1 as  well as 
results reported for depression symptomatology in general (Grosso, Pajak, et al., 2014; 
Hallahan et al., 2016; Liao et al., 2019) and results reported for cognitive test performance in 
youths with ADHD (Chang et al., 2019). These results, supporting a potential positive associ-
ation between EPA and verbal memory performance in youths, form a crucial basis for further 
investigation into potential beneficial supplementation effects in this vulnerable population. 
Preventing or diminishing cognitive complaints would prove most relevant because these cog-
nitive deficits have been shown to persist even in  the remitted stage (Biringer et al., 2007; Bo 
Jacob Hasselbalch et al., 2011; Semkovska et al., 2019), which would further prolong their 
debilitating effects. Contrary to studies in depressed adults that had shown negative associa-
tions between depression severity and cognitive test performance (McDermott & Ebmeier, 
2009) and where severity had also proven a moderating factor in the association between n-3 
PUFA supplementation efficacy in the treatment of depression symptoms (Appleton et al., 
2010), in the population investigated, depression severity was unrelated to verbal memory per-
formance.  
Taken together, our results support a positive association between EPA but not DHA status as 
well as supplementation and cognitive test performance in children, with tendencies towards 
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stronger associations in clinical rather than healthy population. A specific association between 
EPA status and verbal memory performance in depressed youths was established.  
 
4.2 Strengths and limitations of the conducted research 
Both studies were based on previous research and have conceptual as well as methodological 
strengths that should be pointed out. However, although especially study 1 was conceptualized 
in order to address pitfalls of previous meta-analyses, a number of limitations also need to be 
considered when interpreting the study results. 
 
4.2.1 Strengths  
The meta-analysis conducted was conceptualized and prepared based on limitations from pre-
vious meta-analyses. Those limitations were successfully tackled by the following key factors.  
Meta-analyses have reported age-specific results using an artificial (e.g. legally defined) cut-
off of, for example, 18 years of age for adulthood (Cooper et al., 2015). Instead, in our meta-
analysis, we used a cut-off based on the developmental course of the brain. The lack of thor-
ough and hence sometimes inaccurate classification of cognitive tests used within cognitive 
domains (Jiao et al., 2014) constitutes a further pitfall of previous meta-analyses which we 
tackled by thoroughly screening cognitive assessment measures within the included studies. 
Albeit providing no support for differential efficacy between certain cognitive domain, report-
ing domain- specific effects constituted a further strength. The separation rendered the results 
interpretable and avoided random selection of outcomes from each included study. Also, it 
accounted for potentially select effects of underlying neuroanatomical- and functional circuits 
involved in those cognitive functions. Vast differences in study formulations concerning n-3 
PUFA dosage exist, which we analyzed using correlations between dosage and effect size. 
Results from studies using formulations with both n-3 and n-6 PUFAs have previously been 
pooled within one analysis (Bloch & Qawasmi, 2011; Chang et al., 2018; Cooper et al., 2015), 
which we prevented by excluding all studies with n-6 PUFAs in their study formulations. This 
constituted a very conservative but at the same time crucial measure in order to selectively 
assess n-3 PUFA supplementation effects. We were hence able to pinpoint effects attributable 
to only n-3 PUFAs with no bias from n-6 PUFAs. Many previous studies have not reported any 
comparisons between effects in healthy and clinical populations (Bloch & Qawasmi, 2011; 
Chang et al., 2018; Jiao et al., 2014). In our study, however, we performed subgroup analyses 
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based on clinical and healthy population subgroups which further allowed for differentiation 
of supplementation effects. Often, meta-analyses have not investigated efficacy differences be-
tween EPA and DHA supplementation (Chang et al., 2018; Jiao et al., 2014) although concen-
tration differences within the brain are vast (Bazinet & Layé, 2014; McNamara & Carlson, 
2006; Weiser et al., 2016). In our meta-analysis, subgroup analyses were run for subgroups 
with EPA-rich versus DHA-rich study formulations. Implementing these subgroup analyses 
enabled us to highlight their differential potential in relation to cognitive functioning. Hetero-
geneities also exist concerning the cognitive measures used, as some studies have reported 
results based on subjective rating scales (Abdullah et al., 2019; Bloch & Qawasmi, 2011) as 
opposed to objective measures of cognitive test performance (Chang et al., 2018; Cooper et al., 
2015; Jiao et al., 2014). In our study, only studies reporting results on cognitive test perfor-
mance were included, due to bias concerns discussed in the introductory section. As has been 
established in previous chapters, subjective and objective cognitive outcomes represent differ-
ent entities and should hence not be mixed within a single meta-analysis. A further strength 
lies in the actual nature of this study, as with this meta-analysis a broad body of literature was 
systematically reviewed with a comprehensive and replicable search strategy. Also, all studies 
selected for analysis were RCTs and methodological quality was thoroughly assessed. Another 
important methodological success was reached by using change scores of cognitive test perfor-
mance instead of only post-treatment scores in order to eliminate any pre-existing group dif-
ferences. Lastly, potential effects of treatment duration and year of publication were success-
fully eliminated by confirming no association between these factors and the effect sizes re-
ported of the respective studies. The goal of the meta-analysis was to reach a more specific 
conclusion about potential beneficial effects of n-3 PUFA supplementation on cognitive test 
performance in youths while especially targeting potential efficacy differences between EPA 
and DHA and effects in clinical versus healthy populations. At the time of analysis, there had 
yet been no meta-analysis investigating the separate and domain-specific effects of EPA and 
DHA supplementation on cognitive test performance in both clinical and healthy youths. 
For the second study, further pivotal strengths should be highlighted. One of the major 
strengths constitutes the objective and validated measurement of verbal memory performance. 
Using the VLMT (Helmstaedter & Durwen, 1990) and the digit span test (Wechsler, 2003) 
enabled us to report results for cognitive test performance that were objectively measured with 
a validated test and could be interpreted using normative data. The same applies to the meas-
urement of blood n-3 PUFA status. Instead of using subjective nutritional measures like for 
example dietary questionnaires which have proven largely unreliable (Harris & Klurfeld, 
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2011), an objective, standardized and widely accepted measure for n-3 PUFA blood status was 
used (Harris et al., 2013). Following the recommendation established in study 1, n-3 PUFA 
status was not investigated as a whole. EPA and DHA status associations with verbal memory 
performance were separately assessed, allowing for differentiation between these two types of 
n-3 PUFAs. Most importantly, this study was conducted in order to begin to fill a large research 
deficit in the field of both n-3 PUFAs and depression in youths but also n-3 PUFAs and cogni-
tion in depression. To our knowledge, this was the first study ever conducted investigating n-3 
PUFA status in relation to cognitive test performance in depressed youths. General methodo-
logical strengths lie in the use of a substantial sample of depressed children and adolescents. 
Furthermore, diagnosis of MDD was assessed using standardized clinical interviews. As a 
whole, the sample was recruited and assessed as part of an RCT based on a high-quality design 
supported by the Swiss National Science Foundation.  
 
4.2.2 Limitations  
Although many strengths were highlighted in the previous section, a number of limitations of 
the conducted studies should also be addressed.  
For the meta-analysis, the exclusion of seven studies due to missing data constitutes a serious 
drawback. Despite the effort of contacting the corresponding authors of these studies, only 
some of the missing data could be obtained, hence resulting in the exclusion of these studies. 
Although the exclusion of studies also supplementing n-6 PUFAs in their study formulations 
represents a crucial measure in order to be able to isolate n-3 PUFA effects, this led to the 
exclusion of a total of 25 studies, which greatly limited the statistical power of the reported 
results. Moreover, some of the excluded studies only supplemented a very small amount of n-
6 PUFAs, but because there is no clear evidence suggesting a minimum dosage for any bodily 
effects, those studies were nevertheless excluded. While questionnaire outcomes were ex-
cluded based on the important notion that subjective and objective measure of cognitive func-
tions should not be mixed within a single analysis, the results are limited to cognitive test per-
formance, while effects on subjective cognitive functioning would be equally probable and 
interesting to assess. The results reported in our meta-analyses are hence also only marginally 
comparable with studies using self-rating questionnaires as study outcomes, for example in 
ADHD (Abdullah et al., 2019; Bloch & Qawasmi, 2011) and pediatric mood disorders (Vesco 
et al., 2018). Furthermore, effects on subjective cognitive complaints might even prove more 
relevant as these tend to be highly related to factors like education performance (Baars et al., 
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2015). One of the most important drawbacks lies in the vast protocol heterogeneity of the in-
cluded RCTs. This heterogeneity was mostly attributable to differences in n-3 PUFA dosage, 
intervention duration, cognitive tests and age of participants, reducing comparability of these 
studies. However, using random effects model, we were statistically able to reduce bias at-
tributable to study heterogeneity. Even though we performed subgroup analyses for clinical 
and healthy study populations, especially the clinical subgroup population seamed very heter-
ogeneous. Because of the limited number of studies within the subgroups of the clinical group, 
like ADHD, very low birth weight infants, malnourished and marginally nourished youths, 
youths with poor iron status, no separate analyses for all those groups could be run. This pitfall 
could only have been addressed if more studies could have been included in the meta-analysis, 
although the study heterogeneity problem was somewhat corrected for using a random-effects 
model. However, no separate conclusions about effects within the specific subgroups could be 
made. In general, the number of studies included in the analyses (and especially subgroup anal-
yses) was very low, which made results statistically very sensitive to the addition of further 
data. Two studies were identified that seemed to have had great impact on heterogeneity and 
the associated effects sizes reported. We were however able to resolve this bias by successfully 
performing a sensitivity analysis. The removal of these studies did not impact the results and 
hence the conclusion of the meta-analysis. An additional drawback associated to the subgroup 
analyses was that EPA and DHA group formation was only based on the criterion of whether 
study formulations contained more EPA or more DHA. Hence, in most studies, the influence 
of the other type of n-3 PUFA could not be excluded. This limitation corresponds to a similar 
issue found in the meta-analysis by Cooper and colleagues (2015) who reported small treatment 
effects in studies which supplemented adequate EPA, however without any reference to the 
amount of DHA supplemented. Bloch and Qawasmi (2011) equally reported a positive associ-
ation between higher doses of EPA and efficacy in treating ADHD symptoms, without being 
able to exclude effects of simultaneous DHA supplementation. Another pitfall lies in the out-
come measure heterogeneity. Despite the categorization of outcome measures and the separa-
tion of results into different cognitive domains, scales used within one analysis differed greatly. 
Even though we thoroughly screened all cognitive assessment scales and placed them within 
cognitive domains, an issue extensively discussed in the introductory section still constituted a 
major limitation. This issue concerns the distinctions between the assessment of different cog-
nitive domains, as definitions often overlap, and cognitive tasks often engage several cognitive 
domains simultaneously. Nevertheless, we were at least partially able to tackle this issue using 
standardized mean difference as an outcome measure. Our risk of bias analysis further revealed 
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several methodological flaws of included studies which might have substantially influenced 
study results. Only four studies were rated low across all bias risks (Cornu et al., 2018; 
McNamara et al., 2010; Richardson et al., 2012; Van Der Merwe et al., 2013) and “incomplete 
outcome data” and “blinding of participants and personnel” were the criteria most frequently 
rated high. These criteria are essential markers of study and design quality, hence high bias 
ratings strongly affect conclusions that can be drawn following the reported results. Lastly, 
many putative moderating or confounding variables such as pre- and posttreatment n-3 PUFA 
blood plasma concentrations could not be considered. 
The most obvious limitation of the second study lies in its cross-sectional design. Because the 
omega-3 pMDD trial is still ongoing, consequently only baseline data could be analyzed for 
the second study. Hence, study 2 was limited by the impossibility to draw conclusions about 
causal relationships. Although n-3 PUFA status associations with cognitive test performance 
hint at potential supplementation effects, clear evidence can only be obtained using RCTs. This 
study hence only provides associative evidence for a relationship between n-3 PUFAs and ver-
bal memory performance in youths. Another major drawback lies in the absence of a healthy 
control group.  Not being able to compare the findings in depressed youths with findings in 
healthy children and adolescents largely diminished the generalizability of our study results. 
Therefore, we were not able to draw any conclusions about the general level of RBC n-3 
PUFAs or cognitive performance in this study population. Another quite general limitation lies 
in the limited study sample. Although cognitive data would have been available for over 180 
patients, only 107 blood samples had been analyzed at time of analysis, limiting the statistical 
robustness of the reported results. While the objective tasks used for verbal memory perfor-
mance constitutes a strength of the study, it also limits the reported results to cognitive test 
performance. Memory complaints subjectively perceived in everyday life were not included in 
the analysis, whereas these potentially represent a more relevant outcome associated with an 
individual’s everyday functioning. As problems concentrating constitute a main diagnostic cri-
terion for pMDD (American Psychiatric Association, 2013), potentially evaluating these using 
self-report questionnaires would prove more accurate for the purpose of describing the cogni-
tive deficits associated with pMDD. This might be associated with an issue discussed in the 
introductory section, where cognitive complaints might not be adequately captured in objective 
and hence artificial testing situations. This assumption has so far been supported by findings in 
depressed youths who reported cognitive deficits (Morey-Nase et al., 2019), whereas results 
on reduced cognitive performance are heterogeneous (Goodall et al., 2018; Maalouf et al., 
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2011; Vilgis et al., 2015; Wagner et al., 2014). Whether subjective or objective cognitive im-
pairments are more predictive of impaired everyday functioning is, however, still unclear 
(Naismith et al., 2007; Potvin et al., 2016). Furthermore, the issue of bias through negative self-
perception would also have to be considered (Lahr et al., 2007). Although many confounding 
differences between the n-3 PUFA and severity groups were checked for (e.g. IQ and duration 
of depression), bias through potentially unidentified group differences cannot be fully ex-
cluded. Lastly, because significant group differences were only found for short-term memory 
verbal list learning parameters and no other memory parameter, only very limited evidence for 
any relationship between EPA status and verbal memory performance was given. Although the 
learning curves in those with high EPA status were steeper, there were no differences concern-
ing the number of words remembered in the last trial. This hence poses some questions con-
cerning any relevance in everyday life and functioning. 
 
4.3 Important contributions 
The results reported in the two studies conducted as part of this dissertation suggest some piv-
otal implications which will be discussed in the following chapter. Future directions are pro-
posed in the second part of this section.  
 
4.3.1 Potential implications 
Considering the results reported in study 1 and the limitations discussed, we can make no clear 
recommendations for n-3 PUFA supplementation in youths in order to improve cognitive test 
performance. However, the small effects found for EPA-rich formulations and the tendency 
towards stronger effects in clinical compared to healthy populations, suggests that EPA-rich 
formulations might prove useful as supportive measures in holistic treatments of cognitive 
complaints in vulnerable or clinical populations. This potential implication was also supported 
by the results from study 2, where EPA status was associated with verbal memory performance 
in a young depressed population with minor deficits concerning verbal memory. Positive cog-
nitive effects of n-3 PUFA supplementation, especially in depressed youths could prove essen-
tial, as treatment with antidepressant medication has proven heterogeneously effective 
(Bennabi et al., 2019; Biringer et al., 2009; Bortolato et al., 2016; Prado et al., 2018; Rosenblat 
et al., 2015; Shilyansky et al., 2016; Skandali et al., 2018; Zuckerman et al., 2018). Also, anti-
depressants are associated with a wide range of side effects like for example sexual dysfunction 
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(Carvalho et al., 2016; Outhoff, 2010), nausea (Carvalho et al., 2016), weight changes 
(Carvalho et al., 2016; Serretti & Porcelli, 2018), sleep disruption (Aszalós, 2006; Carvalho et 
al., 2016) and even increased suicidality, especially in younger individuals (Brent, 2016; 
Sharma et al., 2016). In Switzerland, no antidepressant medication has yet been approved for 
the treatment of depressive symptoms in youths, necessitating off-label prescriptions. These 
issues further emphasize the need for alternatives. Should future research succeed in disentan-
gling the previously discussed effects of potential moderating factors and come to a more def-
inite conclusion, this natural and easily accessible supplement could be used without concern 
about any major potential side effects. 
Further potential implications arise from the results reported in study 2. The results indicate 
that depression severity might not be associated with verbal memory performance. These re-
sults go in line with isolated results in youths (Maalouf et al., 2011) and results reported in 
adult populations (McDermott & Ebmeier, 2009), where executive functions rather than se-
mantic memory were associated with depression severity. Consequently, any associations 
found with subjective cognitive measures might either be attributable to the artificial testing 
environment of objective tests or might hint at a bias from negative self-perception (Lahr et al., 
2007; Sachs-Ericsson et al., 2008). Although no healthy control group was included as a com-
parison for verbal memory performance, the results showed only slight impairments in this 
sample of depressed youths. As has been previously discussed, this might be explained by the 
shorter duration of the disease compared to adult patients, because cumulative duration of de-
pressive episodes has been associated with diminished cognitive functioning (B. J. Hasselbalch 
et al., 2013) and smaller hippocampal grey matter (Arnone et al., 2013). This further highlights 
the importance of early intervention in depressed individuals. Because n-3 PUFA are vital for 
neurodevelopment (J. Baumgartner, 2016; Bazinet & Layé, 2014; Innis, 2008; Koletzko et al., 
2008; Lauritzen et al., 2016; Sun et al., 2018) and  potential neuroprotective effects of espe-
cially EPA related to grey matter atrophy of the hippocampal and parahippocampal area have 
been reported (Samieri et al., 2012), our results further contribute to the assumption that n-3 
PUFAs might prove important in the prevention or reduction of cognitive complaints in de-
pressed youths. When treated at an early stage, potential debilitating effects on cognitive func-
tioning that might result from longer illness duration might be prevented and hence negative 
effects on long-term educational and personal attainment could potentially be reduced. The 
potential neuroprotective effects of n-3 PUFAs in depression were recently even further sup-
ported by the already previously mentioned findings reported by Borsini and colleagues (2020), 
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who were able to confirm that both DHA and EPA prevented glucocorticoid-induced reduction 
in human hippocampal neurogenesis and increase in apoptosis. 
 
4.3.2 Future directions 
A general recommendation that we were able to establish from both study 1 and 2 is that EPA 
and DHA effects should be investigated separately and that individual factors such as nutri-
tional status and baseline cognitive functioning level should be considered. Most importantly, 
future research should investigate ideal supplementation doses of EPA and DHA and poten-
tially ideal ratios of n-3 PUFAs and n-6 PUFAs, due to their competitive role within the mem-
brane (Carrié et al., 2000; Neuringer et al., 1986; Simopoulos, 2008). A recently published 
meta-analysis by van der Wurff (2020) already established improved cognition in typically 
developing children when the omega-3 index rose to >6% and in studies with daily supplemen-
tation dose of ≥450 mg DHA + EPA. However, evidence for ideal n-3/n-6 PUFA ratios in 
relation to cognitive test performance in youths is still lacking. Also, because little is known 
about the actual absorption and utilization of n-3 PUFAs the impact of for example the indi-
vidual microbiome should be investigated. This has to date mainly been done concerning the 
role of n-3 PUFAs and the microbiome in relation to neurodegenerative disorders (Hort et al., 
2020). Many potential interactions with other substances and nutrients like for example anti-
oxidant vitamins (Assmann et al., 2018) and B vitamins (Jernerén et al., 2019) were neither 
addressed in study 1 nor study 2 and could prove important. Most importantly, moderating 
factors like for example obesity, inflammatory status, pre- and post- blood levels of n-3 and n-
6 PUFAs and interactions with gene variations like the ApoEε4 allele (where associations with 
cognitive decline have been reported (Samieri et al., 2011)) could prove important and should 
hence be considered in the evaluation of potential beneficial effects of supplementation. Iden-
tifying specific individual predictors of response together with the identification of specific 
subgroups that benefit most of n-3 PUFA supplementation would significantly specify and 
thereby improve recommendations for supplementation. Future studies should assess potential 
associations between n-3 PUFA status or supplementation and subjective cognitive functioning 
which was neither addressed in study 1 nor study 2. The artificial testing environment for ob-
jective cognitive testing could have masked potential beneficial effects on cognitive function-
ing in everyday life, better captured and evaluated through subjective outcome measures. Be-
cause especially studies on ADHD (Bloch & Qawasmi, 2011) but also studies in depressed 
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youths (Vesco et al., 2018) have reported beneficial cognitive effects of n-3 PUFA supplemen-
tation assessed using self-rating questionnaire, investigating differential outcomes depending 
on the cognitive measure applied could prove valuable. The results reported in study 2 pave 
the way for future RCTs investigating the effects of n-3 PUFA supplementation on cognitive 
test performance in depressed youths. Our results contributed evidence towards an association 
between EPA status and verbal memory performance in depressed youths. As we were once 
again able to support the already previously discussed recommendation of separately assessing 
effects of EPA and DHA, future studies should now further investigate the relationship between 
EPA and DHA status and cognitive test performance in other cognitive domains. Although 
study 1 provided no evidence for a certain cognitive domain that would benefit the most from 




Previous research has established the vital role of n-3 PUFAs in neurodevelopment (J. 
Baumgartner, 2016; J. Baumgartner et al., 2012; Bazinet & Layé, 2014; Koletzko et al., 2008) 
and suggested that n-3 PUFA supplementation during gestation might positively impact neu-
rodevelopmental outcomes (Middleton et al., 2019). Consequently, research on potential cog-
nitive effects of supplementation after birth have gained interest within several research fields. 
In youths, where brain development is still ongoing, and especially in depressed youths, where 
cognitive complaints constitute a main symptom (American Psychiatric Association, 2013), 
beneficial cognitive effects of n-3 PUFAs could prove essential. This should be especially em-
phasized considering the heterogeneous efficacy reported for antidepressant treatment 
(Bennabi et al., 2019; Biringer et al., 2009; Bortolato et al., 2016; Prado et al., 2018; Rosenblat 
et al., 2015; Shilyansky et al., 2016; Skandali et al., 2018; Zuckerman et al., 2018) and the 
associated severe side effects like for example increased suicidality especially in younger in-
dividuals (Brent, 2016; Sharma et al., 2016). Because, especially in depressed youths, cognitive 
complaints can have debilitating effects and negatively impact educational attainment and eve-
ryday functioning (Fletcher, 2008; Morey-Nase et al., 2019), preventing or reducing such com-
plaints could prove essential.  
The present dissertation dealt with the role of n-3 PUFAs in cognitive functioning in youths. 
With the use of a meta-analysis, previous findings on the effects of n-3 PUFA supplementation 
on cognitive test performance in youths was investigated, specifically tackling limitations of 
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previous meta-analyses. By cross-sectionally investigating associations between RBC DHA 
and EPA levels and verbal memory performance in a sample of depressed youths, the second 
study aimed at establishing potential associations between specific n-3 PUFAs and a specific 
cognitive domain. Taken together, our results suggest that EPA but not DHA might prove ben-
eficial in the promotion of cognitive functioning in youths and that clinical rather than typically 
developing youths might benefit. These results could prove especially valuable in relation to 
pMDD, considering that not only cognitive effects of EPA supplementation but also effects on 
emotional symptoms might be expected (Grosso, Pajak, et al., 2014; Hallahan et al., 2016; Liao 
et al., 2019; Martins, 2009; Mocking et al., 2016). However, optimal dosage and potentially 
optimal ratios between n-3 and n-6 PUFAs are in need of further investigation. Also, little is 
known about exact mechanisms of action, especially in relation to EPA. Research on the role 
of moderating factors is also seriously lacking. The discussed results presented in this disser-
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